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Irritable bowel syndrome (IBS) is among the most frequently occurring functional 
bowel disorders and is characterized by recurrent abdominal pain or discomfort 
accompanied by altered bowel habits1. Its prevalence ranges from 6% in the Nether-
lands2 to 22% in other Western countries3. Approximately two-third of patients is fe-
male and symptom onset generally occurs below the age of 35. IBS has considerable 
economic impact, accounting for total annual direct costs of £ 45.6 million on aver-
age in the United Kingdom4. In the Netherlands, health care utilization and absence 
from work in IBS patients is approximately twice that of the general population5. 
DIAGNOSIS
In 1978, Manning was the first to introduce diagnostic criteria for IBS after an era in 
which diagnosis was made by exclusion of organic disease6. The Manning criteria 
required onset of abdominal pain associated with more frequent and looser bowel 
movements, pain relieved with defecation, visible abdominal bloating, and subjec-
tive sensation of incomplete evacuation and mucous stools more than 25% of the 
time. In 1992, an international committee of specialists known as the Rome Working 
Team refined the Manning criteria and formulated the Rome I criteria for IBS. These 
were re-evaluated in 1998 (Rome II criteria, applied in this thesis; Table 1)1 and 
recently in 2006 (Rome III criteria)7,8. According to Rome III criteria, irritable bowel 
syndrome is defined as recurrent abdominal pain or discomfort at least 3 days per 
month in the last 3 months, associated with 2 or more of the following: 1) improve-
ment with defecation and/or 2) onset associated with a change in frequency of stool 
and/or 3) onset associated with a change in form (appearance) of stool8. Additional 
symptoms that support the diagnosis but are not part of these criteria include abnor-
mal stool frequency (≤ 3 times per week or ≥ 3 times per day), abnormal stool form 
(hard/lumpy stool or loose/watery stool), defecation straining, urgency, sensation 
of incomplete bowel movement, passage of mucus, and bloating. In daily practice, 
subgroups are recognized according to predominant bowel habit, i.e. IBS with diar-
rhoea (IBS-D), IBS with constipation (IBS-C), alternating or mixed IBS (IBS-A, both 
hard/lumpy and loose stools) and unsubtyped IBS (insufficient abnormality of stool 
consistency to meet criteria for IBS-D, IBS-C or IBS-A). From a clinical point of view, 
the Rome criteria help physicians to make a more firm diagnosis of IBS. In research, 





Despite the growing body of literature, the pathophysiology of IBS remains poorly 
understood. Currently, IBS is viewed as a multifactorial condition in which clini-
cal expression results from interplay between physiological and neuropsychological 
factors9,10. These factors are integrated in the brain-gut axis, a conceptual frame-
work which has recently emerged in an attempt to improve our understanding of 
the etiology, pathogenesis and clinical expression of IBS. They include autonomic 
dysfunction11,12, altered processing of afferent sensory information13,14, disturbed 
intestinal motility15,16, enhanced visceral sensitivity17,18, inflammatory processes19,20, 
altered immune activity21,22, and psychological disturbances23,24. Dysfunction at differ-
ent levels of the brain-gut axis may be responsible for these alterations.
Autonomic dysfunction
Several studies have demonstrated some form of autonomic dysregulation in 
IBS11,12,25,26, but the nature of autonomic dysfunction remains elusive and results have 
been far from congruent. For instance, spectral analysis of heart rate variability has 
suggested increased sympathetic activity in IBS patients25, both during waking and 
sleep26. These data are supported by findings showing hypertensive episodes dur-
ing sigmoidal balloon distension in both IBS and health, pointing to upregulated 
Table 1. Rome II criteria for irritable bowel syndrome
Diagnostic criteria
At least 12 weeks, which need to be consecutive, in the preceding 12 months of abdominal discomfort or pain that has 




Relieved with defecation; and/or
Onset associated with a change in frequency of stool; and/or
Onset associated with a change in form (appearance) of stool










Fewer than three bowel movements a week
More than three bowel movements a week
Hard or lumpy stools
Loose (mushy) or watery stools
Straining during a bowel movement
Urgency (having to rush to have a bowel movement)
Feeling of incomplete bowel movement
Passing mucus (white material) during a bowel movement
Abdominal fullness, bloating or swelling
Diarrhoea-predominant
1 or more of 2, 4, or 6 and none of 1, 3, or 5
Constipation-predominant
1 or more of 1, 3, or 5 and none of 2, 4, or 6
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sympathetic tone27. In contrast, it has also been shown that rectal balloon distension 
depresses blood pressure in IBS patients (but not in controls)11, suggesting down-
regulated sympathetic activity during visceral stimulation.
Autonomic control of gastrointestinal motor and sensory functioning is complex. 
In short, it is governed by the dorsal vagal complex28, an integrated central structure 
comprising the motor nucleus of the vagus from which autonomic outflow to the 
colon arises, and the nucleus tracti solitarii (NTS) which integrates viscerosensory 
input from the gut and other organs29. Physiological information from the gut proxi-
mal to the splenic flexure is carried by cranial nerve afferents that terminate in the 
NTS, while noxious viscerosensory information is transmitted by sympathetic spinal 
fibers. From the NTS, interneurons project to the ventrolateral medulla (VLM), which 
controls sympathetic outflow, and to higher centers. Sensory information originat-
ing distal from the splenic flexure (descending colon and rectum) is exclusively 
conveyed by spinal afferent fibers that terminate in the thalamus, but collaterals also 
reach the NTS and VLM30,31. This key role of the NTS suggests that the altered auto-
nomic outflow observed in IBS may result from either a normal or abnormal reflex 
response to disturbed afferent viscerosensory information from the gut. 
Altered intestinal motility
Both small intestinal and colonic motility are altered in IBS32,33. Intraluminal small 
intestinal pressure recordings have revealed shorter intervals between fasting migrat-
ing myoelectric complexes, more clusters of jejunal pressure activity and more ileal 
propulsive waves in IBS-D compared to controls, implying increased small bowel 
motility. The latter abnormality was associated with cramping abdominal pain32. 
Manometry of the left hemicolon in IBS patients has demonstrated increased colonic 
frequency patterns, a higher motility index, and an increase in mean number and 
peak amplitude of high amplitude propagating contractions (HAPCs), which coin-
cided with the occurrence of abdominal pain in more than 90%33. Other studies, 
however, have not been able to demonstrate significant differences in colonic motil-
ity between IBS patients and healthy controls34. Autonomic dysfunction may be seen 
as circumstantial evidence for altered intestinal motility in IBS. However, it remains 
elusive which intestinal motor abnormalities contribute to symptom generation.
Visceral hypersensitivity
Visceral hypersensitivity is considered a hallmark in IBS35,36 and has even been pro-
posed as a biological marker17. Typical findings in IBS patients are increased visceral 
sensitivity to nocious stimuli, such as rapid rectal balloon distension, while physi-
ological stimuli elicit similar responses as in controls17. The pathophysiology of this 
visceral hyperalgesia is poorly understood, but it may result from disturbances at 
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different levels of the brain-gut axis. First, sensitization of peripheral nerve endings 
at the intestinal level may occur during or after acute inflammation37,38, leading to 
higher excitability and/or increased firing of these neurons. Second, alterations in 
the spinal dorsal horn neurons and upregulation of spinal nerve endings may play 
a role in the extended viscerosomatic referral pattern that is often seen in IBS17,37. 
Third, altered processing of afferent visceral information in the brain, particularly in 
the prefrontal cortex, anterior cingulated cortex, and thalamus, has repeatedly been 
demonstrated in IBS patients14,39,40. These regions are not only involved in pain pro-
cessing but are also part of the emotional limbic system and are therefore involved 
in numerous psychological and cognitive events41,42. Although the prevalence of 
visceral hypersensitivity in IBS patients differs between studies and its role in the 
pathophysiology is not clear, it is one of the few reproducible phenomena in IBS.
Inflammation and immune system alterations
The role of low-grade inflammation and (mucosal) immune system activation in 
the pathogenesis of IBS has received much attention over the last decade. The risk 
to develop IBS after dysenteric illness is increased19,20,43. Histological studies found 
increased numbers of immunocompetent cells in colonic and small bowel mucosa of 
patients with post-infectious IBS (PI-IBS)21,44,45. Even more interestingly, large bowel 
mucosal samples in subgroups of IBS patients show activated mast cells with signs of 
degranulation and inflammatory mediator release in the proximity of mucosal nerve 
endings, especially in patients who are hypersensitive to balloon distension21,46. This 
implies that mucosal inflammation may contribute to symptom generation. In addi-
tion, increased or decreased secretion of several pro- and anti-inflammatory cytokines 
that are known to modulate the (intestinal) immune response47 may play a role in this 
mucosal inflammation. For instance, a number of single nucleotide polymorphisms 
(SNPs) in the promoter region of the gene coding for the anti-inflammatory cytokine 
interleukin-10 (IL-10), leading to increased production of IL-10, appear to be less 
prevalent in IBS patients22. Very recent data involving microarray gene expression 
profiling of sigmoid colon mucosa even suggest stable alterations in colonic mucosal 
immunity in IBS48. These data strongly suggest that inflammation of the gut mucosa 
plays a role in the clinical expression of IBS in at least a subset of patients.
Psychopathology
Symptoms in IBS are associated with psychological factors, which may affect clinical 
outcome23. Whether psychological disturbances contribute to the pathophysiology 
of IBS as such or only occur as comorbidity is not yet clear. Although an increased 
prevalence of several psychiatric conditions such as anxiety, depression and so-
matization has been demonstrated in IBS49-51, these disorders may particularly be 
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related to health care seeking51. There is also evidence to suggest that psychological 
disorders do not play a significant role in the pathophysiology of IBS when levels 
of visceral hypersensitivity are accounted for52. Alternatively, altered processing of 
afferent visceral information in the prefrontal cortex, anterior cingulated cortex, and 
thalamus has been demonstrated in IBS39,40. Nociception (becoming aware of a pain-
ful stimulus) and emotional pain management both occur in these brain regions, 
which are also part of the emotional limbic system41,42, suggesting that psychological 
disturbances may be related to visceral hypersensitivity and IBS. 
AIMS AND OUTLINES
The concept of the brain-gut axis as a model to improve our understanding of the 
pathophysiology of IBS has been the basis of research in IBS over the last decades 
and the framework for this thesis. The primary objective was to gain further insight 
in the many parameters and variables that are involved in this model, and their 
relationship. The second goal was to study the efficacy of a brief psychological 
group intervention for the treatment of IBS symptoms. Third, we aimed to test the 
validity of a previously published comprehensive working model of IBS, based on 
the brain-gut axis.
Evidence for abnormal activity of the autonomic nervous system, reflected in the 
cardiovascular system by altered heart rate variability (HRV)25,26 and in the diges-
tive system by disturbed motility32,33, suggests disturbed viscerosensory-autonomic 
reflexes in IBS. In rats, electrical stimulation of abdominal vagal afferents increases 
sympathetic outflow and also decreases baroreflex sensitivity (BRS), pointing to the 
possible involvement of the arterial baroreflex in IBS53. Altered baroreflex function-
ing during gastrointestinal stress (i.e., abdominal pain) may constitute a pathophysi-
ological key in IBS, as the arterial baroreflex not only modulates sympathetic and 
parasympathetic autonomic outflow, but also affects cortical arousal54 and somatic54,55 
and visceral53 pain perception. Since this topic has not been studied in humans, we 
evaluated systolic blood pressure, heart rate and BRS involvement in IBS patients 
and healthy controls under baseline conditions and during a gastrointestinal stressor 
(rectal balloon distension). The results of this study are presented in Chapter 2. 
Several gut peptides are known to be involved in the regulation of gastrointestinal 
motor and sensory function. For instance, cholecystokinin (CCK) stimulates colonic 
motility and increases rectal sensitivity to balloon distension in healthy individu-
als56,57. Motilin is involved in the regulation of interdigestive motility of the stomach 
and small intestine58, but also affects colorectal motor function59. Peptide YY (PYY) 
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delays proximal gastrointestinal motility60 and the number of PYY-containing colonic 
enteroendocrine cells is increased in symptomatic IBS patients after an acute infec-
tious gastroenteritis44. Chapter 3 investigates  plasma levels of gut peptides released 
from the upper (CCK and motilin) and lower (PYY) small intestine under fasting and 
postprandial conditions in IBS patients, as well as the influence of age, gender, IBS 
subtype and visceral hypersensitivity on gut hormone secretion.
With an increased risk of developing IBS after acute gastroenteritis19,20,43, it has 
become increasingly clear that inflammation and mucosal immune system activation 
may be important in IBS symptom generation61. Larger numbers of immunocompe-
tent cells are found in rectal mucosa of patients with post-infectious IBS up to 1 year 
after infection44. Since pro- and anti-inflammatory cytokines are important modula-
tors of the (intestinal) immune response, imbalances in cytokine secretion may play 
a role in the ongoing mucosal inflammation. A recent study showed that the high 
producer IL-10 genotype (anti-inflammatory cytokine; -1082 G/G Single Nucleotide 
Polymorphism, SNP) is less prevalent in IBS patients compared to healthy controls22. 
The study described in Chapter 4 was conducted to investigate the prevalence 
of gene promoter SNPs of IL-10 and TNF-α  (pro-inflammatory cytokine) that are 
known to be associated with low IL-10 or high TNF-α secretion, in IBS patients and 
in healthy controls. 
Chapter 5 studies reflex rectocolonic motor inhibition in IBS patients and healthy 
controls under both fasting and postprandial conditions. This inhibitory reflex has 
previously been demonstrated in healthy individuals62,63. Our study was undertaken 
to characterize this inhibitory reflex in IBS in an attempt to better understand the mo-
tor disturbances that occur in these patients, and in particular postprandial symptom 
deterioration64.
Visceral hypersensitivity appears to play an important role in the pathophysiology 
of IBS35,36 and has even been proposed as a biological marker17. Although processing 
of afferent visceral information and emotional pain management both occur in the 
same brain regions41,42, little is known about the relationship between psychologi-
cal variables and visceral hypersensitivity. Such information is relevant because it 
may provide a better understanding of the pathogenesis of IBS and its treatment. 
In Chapter 6, we explore the prevalence of rectal hypersensitivity, levels of psy-
chological distress and symptom severity in IBS patients, and we attempt to address 
which demographical, clinical and psychological variables predict the occurrence of 
visceral hypersensitivity in IBS.
Curative treatment for IBS is not available65 and therefore therapeutic interventions 
are directed towards reducing predominating symptoms. These include medication 
such as antispasmodics, laxatives or antidiarrhoeals in addition to patient education, 
reassurance, and dietary advice9. Novel therapies focus on serotonergic and psycho-
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tropic agents, but therapeutic gain is at best restricted to subgroups of patients66-69. 
The efficacy of psychological interventions such as cognitive behavioural therapy, 
dynamic psychotherapy and hypnotherapy has been demonstrated in a number of 
studies70-74. As most forms of psychotherapy incorporate a relaxation technique, we 
conducted a randomized controlled trial to determine short and long-term efficacy of 
relaxation training, a brief psychological group intervention, when added to standard 
medical care, on symptom severity and psychological wellbeing in IBS patients. The 
results of this study are described in Chapter 7.
With disturbances at different levels of the brain-gut axis as the central, concep-
tual framework for understanding the pathogenesis underlying IBS, a biobehavioral 
model would be of great assistance to verify different pathophysiological hypoth-
eses. One of few attempts to construct such a model came from Naliboff and col-
leagues in 1998, who proposed an initial but comprehensive working model of IBS, 
incorporating the central nervous system, visceral sensory and motor functioning, 
and cognitive-behavioral systems75. In Chapter 8, we evaluate a modified version 
of this model by using Structural Equation Modeling (SEM) in order to calculate 
reciprocal and chronological relationships between the model variables and thereby 
test its validity. 
Finally, Chapter 9 summarizes the various studies presented in this thesis and 
discusses the new insights that have been obtained in the light of the current knowl-
edge on the pathopysiology and clinic aspects of IBS.
16 Chapter 1
REFERENCES
 1. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. 
Functional bowel disorders and functional abdominal pain. Gut 1999;45 Suppl 2:II43-II47.
 2. Boekema PJ, van Dam van Isselt EF, Bots ML, Smout AJ. Functional bowel symptoms in a 
general Dutch population and associations with common stimulants. Neth J Med 2001;59:23-
30.
 3. Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ 1992;304:87-
90.
 4. Inadomi JM, Fennerty MB, Bjorkman D. Systematic review: the economic impact of irritable 
bowel syndrome. Aliment Pharmacol Ther 2003;18:671-82.
 5. Donker GA, Foets M, Spreeuwenberg P. Patients with irritable bowel syndrome: health status 
and use of health care services. Br J Gen Pract 1999;49:787-92.
 6. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the ir-
ritable bowel. BMJ 1978;2:653-4.
 7. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional 
Bowel Disorders. Gastroenterology 2006;130:1480-91.
 8. Drossman DA. Rome III: The Functional Gastrointestinal Disorders, 3rd edition. 2006 Degnon 
Associates, McLean, VA, USA.
 9. Mertz HR. Irritable bowel syndrome. N Engl J Med 2003;349:2136-46.
 10. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophys-
iological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004;20 Suppl 
2:1-9.
 11. Gupta V, Sheffield D, Verne GN. Evidence for autonomic dysregulation in the irritable bowel 
syndrome. Dig Dis Sci 2002;47:1716-22.
 12. Aggarwal A, Cutts TF, Abell TL, Cardoso S, Familoni B, Bremer J, Karas J. Predominant 
symptoms in irritable bowel syndrome correlate with specific autonomic nervous system 
abnormalities. Gastroenterology 1994;106:945-50.
 13. Naliboff BD, Derbyshire SW, Munakata J, Berman S, Mandelkern M, Chang L, Mayer EA. 
Cerebral activation in patients with irritable bowel syndrome and control subjects during 
rectosigmoid stimulation. Psychosom Med 2001;63:365-75.
 14. Verne GN, Himes NC, Robinson ME, Gopinath KS, Briggs RW, Crosson B, Price DD. Central 
representation of visceral and cutaneous hypersensitivity in the irritable bowel syndrome. 
Pain 2003;103:99-110.
 15. Clemens CH, Samsom M, Berge Henegouwen GP, Smout AJ. Abnormalities of left colonic 
motility in ambulant nonconstipated patients with irritable bowel syndrome. Dig Dis Sci 
2003;48:74-82.
 16. Chey WY, Jin HO, Lee MH, Sun SW, Lee KY. Colonic motility abnormality in patients with 
irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 
2001;96:1499-506.
 17. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological 
marker of patients with irritable bowel syndrome. Gastroenterology 1995;109:40-52.
 18. Lembo T, Munakata J, Mertz H, Niazi N, Kodner A, Nikas V, Mayer EA. Evidence for the 
hypersensitivity of lumbar splanchnic afferents in irritable bowel syndrome. Gastroenterology 
1994;107:1686-96.
 19. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel 
syndrome and its pathogenesis. Gut 2004;53:1096-101.
 20. Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastro-
enteritis: cohort study. BMJ 1999;318:565-56.
Introduction 17
 21. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, 
Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R. Activated mast cells 
in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. 
Gastroenterology 2004;126:693-702.
 22. Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes 
in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003;52:91-3.
 23. Drossman DA, McKee DC, Sandler RS, Mitchell CM, Cramer EM, Lowman BC, Burger AL. 
Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and 
nonpatients with irritable bowel syndrome. Gastroenterology 1988;95:701-8.
 24. Whitehead WE, Bosmajian L, Zonderman AB, Costa PT, Jr., Schuster MM. Symptoms of psy-
chologic distress associated with irritable bowel syndrome. Comparison of community and 
medical clinic samples. Gastroenterology 1988;95:709-14.
 25. Karling P, Nyhlin H, Wiklund U, Sjoberg M, Olofsson BO, Bjerle P. Spectral analysis of heart rate 
variability in patients with irritable bowel syndrome. Scand J Gastroenterol 1998;33:572-6.
 26. Orr WC, Elsenbruch S, Harnish MJ. Autonomic regulation of cardiac function during sleep in 
patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:2865-71.
 27. Spaziani R, Bayati A, Redmond K, Bajaj H, Bienenstock J, Collins SM, Kamath MV. Vagal 
dysfunction in irritable bowel syndrome assessed by rectal distension and baroreceptor sen-
sitivity. Neurogastroenterol Motil 2007; doi: 10.1111/j.1365-2982.2007.01042.x
 28. Tache Y, Stephens RL Jr, Ishikawa T. Central nervous system action of TRH to influence 
gastrointestinal function and ulceration. Ann N Y Acad Sci 1989;553:269-85.
 29. Altschuler SM, Bao XM, Bieger D, Hopkins DA and Miselis RR. Viscerotopic representation 
of the upper alimentary tract in the rat: sensory ganglia and nuclei of the solitary and spinal 
trigeminal tracts. J Comp Neurol 1989;283:248-68.
 30. Monnikes H, Ruter J, Konig M, Grote C, Kobelt P, Klapp BF, Arnold R, Wiedenmann B 
and Tebbe JJ. Differential induction of c-fos expression in brain nuclei by noxious and 
non-noxious colonic distension: role of afferent C-fibers and 5-HT3 receptors. Brain Res 
2003;966:253-64.
 31. Saper CB. The central autonomic nervous system: conscious visceral perception and auto-
nomic pattern generation. Annu Rev Neurosci 2002;25:433-69.
 32. Kellow JE and Phillips SF. Altered small bowel motility in irritable bowel syndrome is cor-
related with symptoms. Gastroenterology 1987;92:1885-93.
 33. Bassotti G, Sietchiping-Nzepa F, De Roberto G, Chistolini F and Morelli A. Colonic regular 
contractile frequency patterns in irritable bowel syndrome: the ‘spastic colon’ revisited. Eur J 
Gastroenterol Hepatol 2004;16:613-17.
 34. Katschinski M, Lederer P, Ellermann A, Ganzleben R, Lux G, Arnold R. Myoelectric and mano-
metric patterns of human rectosigmoid colon in irritable bowel syndrome and diverticulosis. 
Scand J Gastroenterol 1990;25:761-8.
 35. Bouin M, Plourde V, Boivin M, Riberdy M, Lupien F, Laganiere M, Verrier P, Poitras P. Rectal 
distention testing in patients with irritable bowel syndrome: Sensitivity, specificity, and pre-
dictive values of pain sensory thresholds. Gastroenterology 2002;122:1771-7.
 36. Whitehead WE, Holtkotter B, Enck P, Hoelzl R, Holmes KD, Anthony J, Shabsin HS, Schuster 
MM. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 
1990;98:1187-92.
 37. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 
1994;107:271-93.
 38. Olivar T, Cervero F, Laird JM. Responses of rat spinal neurones to natural and electrical 
stimulation of colonic afferents: effect of inflammation. Brain Res 2000;866:168-77.
18 Chapter 1
 39. Silverman DH, Munakata JA, Ennes H, Mandelkern MA, Hoh CK, Mayer EA. Regional cerebral 
activity in normal and pathological perception of visceral pain. Gastroenterology 1997;112:64-
72.
 40. Ringel Y, Drossman DA, Turkington TG, Bradshaw B, Hawk TC, Bangdiwala S, Coleman RE, 
Whitehead WE. Regional brain activation in response to rectal distension in patients with 
irritable bowel syndrome and the effect of a history of abuse. Dig Dis Sci 2003;48:1774-81.
 41. Bishop S, Duncan J, Brett M, Lawrence AD. Prefrontal cortical function and anxiety: control-
ling attention to threat-related stimuli. Nat Neurosci 2004;7:184-8.
 42. Bush G, Luu P, Posner MI. Cognitive and emotional influences in anterior cingulate cortex. 
Trends Cogn Sci 2000;4:215-22.
 43. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacte-
rial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal 
survey of patients. BMJ 1997;314:779-82.
 44. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increased 
rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability fol-
lowing acute campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 
2000;47:804-11.
 45. Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L, Martinez C, Casellas F, 
Saperas E, Malagelada JR. Diarrhoea-predominant IBS patients show mast cell activation and 
hyperplasia in the jejunum. Gut 2007;56:203-9.
 46. Park JH, Rhee PL, Kim HS, Lee JH, Kim YH, Kim JJ, Rhee JC. Mucosal mast cell counts cor-
relate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel 
syndrome. J Gastroenterol Hepatol 2006;21:71-8.
 47. Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical consider-
ations. Gastroenterology 1994;106:533-9.
 48. Aerssens J, Camilleri M, Talloen W, Thielemans L, Göhlmann HW, Van Den Wyngaert I, 
Thielemans T, De Hoogt R, Andrews CN, Bharucha AE, Carlson PJ, Busciglio I, Burton DD, 
Smyrk T, Urrutia R, Coulie B. Alterations in mucosal immunity identified in the colon of 
patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008;6:194-205.
 49. Walker EA, Roy-Byrne PP, Katon WJ, Li L, Amos D, Jiranek G. Psychiatric illness and ir-
ritable bowel syndrome: a comparision with inflammatory bowel disease. Am J Psychiatry 
1990;147:1656-61.
 50. Koloski NA, Boyce PM, Talley NJ. Somatization an independent psychosocial risk factor for 
irritable bowel syndrome but not dyspepsia: a population-based study. Eur J Gastroenterol 
Hepatol 2006;18:1101-9.
 51. Guthrie E,  Creed F, Fernandez L, Ratcliffe J, Van der Jagt J, Martin J, Howlett S, Read N, Barlow 
J, Thompson D, Tomenson B. Cluster analysis of symptoms and health seeking behaviour dif-
ferentiates subgroups of patients with severe irritable bowel syndrome. Gut 2003;52:1616-22.
 52. Posserud I, Syrous A, Lindström L, Tack J, Abrahamsson H, Simren M. Altered rectal per-
ception in irritable bowel syndrome is associated with symptom severity. Gastroenterology 
2007;133:1113-23.
 53. Saleh TM, Connell BJ, Allen GV. Visceral afferent activation-induced changes in sympathetic 
nerve activity and baroreflex sensitivity. Am J Physiol 1999;276:R1780-91.
 54. Mini A, Rau H, Montoya P, Palomba D, Birbaumer N. Baroreceptor cortical effects, emotions 
and pain. Int J Psychophysiol 1995;19:67-77.
 55. Dworkin BR, Elbert T, Rau H, Birbaumer N, Pauli P, Droste C, Brunia CH. Central effects of 
baroreceptor activation in humans: attenuation of skeletal reflexes and pain perception. Proc 
Natl Acad Sci USA 1994;91:6329-33.
 56. Niederau C, Faber S, Karaus M. Cholecystokinin’s role in regulation of colonic motility in 
health and in irritable bowel syndrome. Gastroenterology 1992;102:1889-98.
Introduction 19
 57. Sabate JM, Gorbatchef C, Flourie B, Jian R, Coffin B. Cholecystokinin octapeptide increases 
rectal sensitivity to pain in healthy subjects. Neurogastroenterol Motil 2002;14:689-95.
 58. Peeters TL, Vantrappen G, Janssens J. Fasting plasma motilin levels are related to the interdi-
gestive motility complex. Gastroenterology 1980;79:716-9.
 59. Kamerling IM, Burggraaf J, van Haarst AD, Oppenhuizen-Duinker MF, Schoemaker HC, Bi-
emond I, Jones R, Heinzerling H, Cohen AF, Masclee AA. The effect of motilin on the rectum 
in healthy volunteers. Br J Clin Pharmacol 2003;55:538-43.
 60. Pironi L, Stanghellini V, Miglioli M, Corinaldesi R, De Giorgio R, Ruggeri E, Tosetti C, Poggioli 
G, Morselli Labate AM, Monetti N. Fat-induced ileal brake in humans: a dose-dependent phe-
nomenon correlated to the plasma levels of peptide YY. Gastroenterology 1993;105:733-9.
 61. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I. Activation of the 
mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122:1778-83.
 62. Law NM, Bharucha AE, Zinsmeister AR. Rectal and colonic distention elicit viscerovisceral 
reflexes in humans. Am J Physiol Gastrointest Liver Physiol 2002;283:G384-9.
 63. Ng C, Danta M, Prott G, Badcock CA, Kellow J, Malcolm A. Modulatory influences on ante-
grade and retrograde tonic reflexes in the colon and rectum. Am J Physiol Gastrointest Liver 
Physiol 2004;287:G962-6.
 64. Simren M, Abrahamsson H, Bjornsson ES. An exaggerated sensory component of the gastro-
colonic response in patients with irritable bowel syndrome. Gut 2001;48:20-7.
 65. Camilleri M, Heading RC, Thompson WG. Clinical perspectives, mechanisms, diagnosis and 
management of irritable bowel syndrome. Aliment Pharmacol Ther 2002;16:1407-30.
 66. Rajagopalan M, Kurian G, John J. Symptom relief with amitriptyline in the irritable bowel 
syndrome. J Gastroenterol Hepatol 1998;13:738-41.
 67. Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with 
irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994;8:409-
16.
 68. Novick J, Miner P, Krause R, Glebas K, Bliesath H, Ligozio G, Ruegg P, Lefkowitz P. A random-
ized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from 
irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16:1877-88.
 69. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of 
alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. 
Lancet 2000;355:1035-40.
 70. Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, Rigby C, Thompson D, To-
menson B; North England IBS Research Group. The cost-effectiveness of psychotherapy and 
paroxetine for severe irritable bowel syndrome. Gastroenterology 2003;124:303-17.
 71. Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, Emmott S, Prof-
fitt V, Akman D, Frusciante K, Le T, Meyer K, Bradshaw B, Mikula K, Morris CB, Blackman CJ, 
Hu Y, Jia H, Li JZ, Koch GG, Bangdiwala SI. Cognitive-behavioural therapy versus education 
and desipramine versus placebo for moderate to severe functional bowel disorders. Gastro-
enterology 2003;125:19-31.
 72. Svedlund J, Sjodin I, Ottosson JO, Dotevall G. Controlled study of psychotherapy in irritable 
bowel syndrome. Lancet 1983;2:589-92.
 73. Gonsalkorale WM, Houghton LA, Whorwell PJ. Hypnotherapy in irritable bowel syndrome: a 
large-scale audit of a clinical service with examination of factors influencing responsiveness. 
Am J Gastroenterol 2002;97:954-61.
 74. Gonsalkorale WM, Miller V, Afzal A, Whorwell PJ. Long term benefits of hypnotherapy for 
irritable bowel syndrome. Gut 2003;52:1623-9.
 75. Naliboff BD, Munakata J, Chang L, Mayer EA. Toward a biobehavioral model of visceral 




CARDIOVASCULAR REFLEXES:  
ALTERED BAROREFLEX 
SENSITIVITY IN IRRITABLE 
BOWEL SYNDROME
Patrick P.J. van der Veek1, Cees A. Swenne2, Hedde van 
de Vooren2, Annelies L. Schoneveld3, Roberto Maestri4, 
and Ad A. M. Masclee1 
Departments of 1Gastroenterology and Hepatology and 
2Cardiology, Leiden University Medical Center, Leiden, The 
Netherlands, 3Leiden Foundation for ECG Analysis (SEAL), 
Leiden, The Netherlands, and 4Department of Biomedical 
Engineering, S. Maugeri Foundation - IRCCS, Scientific 
Institute of Montescano, Montescano, Italy
Am J Physiol Regul Integr Comp Physiol 2005;289:R970-6
22 Chapter 2
ABSTRACT
Background: Animal studies have demonstrated that visceral afferent stimulation 
alters autonomic cardiovascular reflexes. This mechanism might play an important 
role in the pathophysiology of conditions associated with visceral hypersensitivity, 
such as irritable bowel syndrome (IBS). As such studies in humans are lacking, 
we measured viscerosensory-cardiovascular reflex interactions in IBS patients and 
healthy controls. 
Methods: Blood pressure (SBP), heart rate (HR) and arterial baroreflex sensitivity 
(BRS) were studied in 87 IBS patients and 36 healthy controls under baseline condi-
tions and during mild (15 mmHg) and intense (35 mmHg) visceral stimulation by 
rectal balloon distension. BRS was computed from continuous ECG and arterial 
blood pressure signals (Finapres-method) during 5 min periods of 15/min metro-
nome respiration. 
Results: Baseline SBP and HR were not different between patients and controls. In 
both groups, SBP increased similarly during rectal stimulation, whereas HR decreased 
during mild and increased during intense stimulation. BRS was significantly higher 
in patients compared to controls at baseline (7.9±5.4 vs. 5.7±3.7 ms/mmHg, P=0.03) 
and increased significantly in both groups during mild stimulation. This increase per-
sisted in controls during intense stimulation, but BRS returned to baseline in patients. 
BRS was not significantly different between groups during rectal distension. 
Conclusion: This study demonstrates the presence of a viscerosensory-cardiovascular 
reflex in healthy individuals and in IBS patients. The increased BRS in IBS patients at 
baseline may either be a training-effect (frequent challenging of the reflex) or reflects 
altered viscerosensory processing at the nucleus tracti solitarii. 
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INTRODUCTION
Irritable bowel syndrome (IBS) is a frequently occurring functional disorder with a 
prevalence ranging from approximately 6 to 22%1,2. It is characterized by recurrent 
abdominal pain and disturbed bowel habits. In the absence of an established bio-
logical substrate, the diagnosis is symptom-based and made according to the Rome 
II criteria3.
IBS is a multifactorial condition in which disturbances in the brain-gut axis have 
been identified. In particular, visceral hypersensitivity, which may be induced by 
a number of factors such as post-inflammatory tissue injury4 or persistent mucosal 
immune activation5,6, is thought to play a central role in the pathophysiology7,8. 
In addition, abnormal activity of the autonomic nervous system, reflected in the 
cardiovascular system by altered heart rate variability (HRV)9,10 and in the gastroin-
testinal tract by disturbed motility11,12, has been reported. These observations suggest 
disturbed viscerosensory-autonomic reflexes in IBS.
Gastrointestinal functioning is controlled by the dorsal vagal complex (DVC)13. 
This is an integrated structure comprising the motor nucleus of the vagus (DMV) 
from which autonomic outflow to the colon arises; the nucleus ambiguus (NA), 
where parasympathetic outflow to the cardiovascular system is generated; and the 
nucleus tracti solitarii (NTS), which integrates viscerosensory input from the gut, 
cardiovascular system (e.g. carotid and aortic baroreceptors) and other organs14,15. 
Interneurons from the NTS also reach the NA.
Noxious viscerosensory information from the gut down to the splenic flexure 
is transmitted by sympathetic spinal fibers, while physiological information is car-
ried by cranial nerve afferents that terminate in the NTS. From here, interneurons 
project to the ventrolateral medulla (VLM), which governs sympathetic outflow, and 
to higher centers. Sensory information from the descending colon and rectum is 
exclusively conveyed by spinal afferent fibers that terminate in the thalamus, but 
collaterals also reach the NTS and VLM16,17. The key role of the NTS suggests that 
the altered autonomic outflow observed in IBS may result from an abnormal reflex 
response to disturbed afferent viscerosensory information from the gut.
Results of a study by Saleh et al. point to the possible involvement of the arte-
rial baroreflex in IBS. They demonstrated that, in rats, electrical stimulation of ab-
dominal vagal afferents increased sympathetic outflow and also decreased baroreflex 
sensitivity (BRS)18. Altered baroreflex functioning during gastrointestinal stress may 
constitute a pathophysiological key in IBS, as the arterial baroreflex not only modu-
lates sympathetic and parasympathetic autonomic outflow, but also affects cortical 
arousal19,20 and somatic19,21 and visceral18 pain perception.
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Thus far, no human studies have addressed BRS involvement in IBS. As, in gen-
eral, BRS is reduced in disease22-24, we expected that baseline BRS is depressed 
in IBS patients. Furthermore, we anticipated an exaggerated BRS reduction during 
gastrointestinal stress in IBS patients compared to healthy controls25. Both assump-
tions would explain at least part of the previously observed abnormal activity of 
the autonomic nervous system (i.e., increased sympethetic predominance) and the 
increased visceral pain perception in IBS patients. The following study was done to 
corroborate this hypothesis.
METHODS
The local ethics committee approved the study protocol.
Participants
Between March 2001 and July 2002, IBS patients were recruited through the out-
patient department of Gastroenterology and Hepatology of the Leiden University 
Medical Center and through local advertisement. Eligible patients were seen by one 
of the investigators (PvdV). Exclusion criteria were the presence of organic disease, 
previous major abdominal surgery apart from cholecystectomy and appendectomy, 
dependence on analgesics and pregnancy. Patients who were taking cardio-active 
or antihypertensive drugs were excluded. Other medication such as antispasmod-
ics, laxatives, bulking agents and occasional use of analgesics was permitted. All 
included patients met the Rome II criteria for IBS3. Age and sex matched healthy 
volunteers were recruited by advertisement. Each participant provided informed 
consent before entering the study.
Visceral stimulator
An electronic visceral stimulator, i.e. barostat (Synectics Visceral Stimulator, Synectics 
Medical, Stockholm, Sweden), was used to study the effect of a visceral stressor 
on blood pressure, heart rate and BRS. Using electronic feedback regulation, this 
device is able to apply isobaric distensions. Constant pressure is maintained within a 
highly compliant, polyethylene bag (maximum capacity 1000 mL) tied to the end of 
a multilumen tube (19 Fr) by injecting air when the rectal wall relaxes and aspirating 
air during rectal contraction26. Intrabag pressure is directly measured via a separate 
lumen.
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BRS instrumentation
The finger cuff of a noninvasive blood pressure measurement device (Finapres, 
TNO, Amsterdam, NL) was attached to the middle finger of the subjects’ right hand 
to continuously record arterial blood pressure and heart rate. When this did not yield 
a good signal, the cuff was attached to another finger on the same hand. The cuff 
of an automatic sphygmomanometer (Accutorr, Datascope Corp, Montvale, NJ, USA) 
was attached to the subject’s left upper arm. A surface ECG was obtained with a 
Marquette Case-12 electrocardiograph (Marquette Electronics Inc., Milwaukee, USA). 
Thoracic impedance was measured by two electrodes attached to the lateral sides 
of the lower part of the thorax to monitor subject’s compliance with the metronome 
respiration protocol described below. An indicator for metronome respiration was 
visualized on a computer screen. The ECG, finger blood pressure and thoracic im-
pedance signals were digitally stored (sampling rate 500 Hz, sample size 16 bits).
Study design
Recordings were performed in a quiet, air-conditioned room with a constant tem-
perature of 20 °C. No individuals except the investigator were allowed to enter the 
room during measurements. Subjects were allowed a standardized small, fat-free 
breakfast at 8:00 am. Upon arrival at our department at 11:00 am, a tap water enema 
was given to empty the rectosigmoid area. Next, subjects were placed in a bed, 
which was in a 6° head-down position to abolish gravitational effects of the abdomi-
nal contents on the rectal balloon. The bag was inserted into the rectum and the 
catheter was connected to the barostat. Subsequently, ECG, Finapres and Accutorr 
devices were connected during a 30 min adaptation period. In this period, aortic and 
carotid baroreceptors could adjust to the supine blood pressure that was maintained 
throughout the entire recording period.
The experimental procedure is outlined in Figure 1. Each BRS measurement se-
quence consisted of a 5-min 15/min metronome respiration episode, preceded by 
three Accutorr blood pressure measurements to determine systolic blood pressure 
(SBP). Metronome respiration at 0.25 Hz prevents the direct mechanical component 
of respiration and the respiratory gating effect to enter the low-frequency band (0.04-
0.15 Hz) in which we compute baroreflex sensitivity27,28. Subjects were asked not to 
speak during metronome respiration, but to report any discomfort. Free chosen tidal 
volume was permitted to assure comfortable breathing.
After a baseline BRS measurement procedure at 0 mmHg rectal pressure, a slow 
ramp distension (5-30 mmHg, 1 mmHg/min) was performed to measure rectal pain 
perception. This was done using a 10 cm Visual Analog Scale (VAS) anchored ‘none’ 
to ‘unbearable’ that was administered at every even pressure. Pain perception scores 
> 1 cm were considered significant. Perception measurements during the BRS mea-
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surement sequence were not feasible because of interference with metronome respi-
ration. After balloon deflation, BRS measurement sequences were carried out during 
isobaric phasic distensions of 15 mmHg (mild, non-painful stimulus) and 35 mmHg 
(intense, mostly painful stimulus)29. Each distension lasted 6 min and was preceded 
by a 4-min period at 5 mmHg. Metronome respiration commenced one minute after 
each rectal distension onset. A 25 mmHg isobaric distension was performed in be-
tween the mild and strong stimuli to provide a gradual transition.
BRS signal analysis
To characterize arterial baroreflex function we computed baroreflex sensitivity (BRS), 
the reflex-induced increase/decrease of the interval between heart beats in millisec-
onds when arterial blood pressure rises/falls by 1 mm Hg. First, the longest arrhyth-
mia free and stationary period in each metronome respiration episode was selected 
(sinus rhythm and a stationary signal are prerequisites for a reliable BRS value). 
Then, BRS was computed in the selected episode using the POLYAN software30. 
This algorithm calculates the transfer function between the systolic blood pressure 
variability (baroreflex input) and the interbeat interval variability (output), averaged 
over the 0.04-0.l5 Hz band. BRS assessment was deemed impossible if this period 
was less than 90 seconds. Data selection and BRS computations were performed by 
two independent analysts. 
The Accutorr arm cuff was not inflated during the BRS measurement procedures 
to avoid any possible interaction with the rectal distension stimulus. Instead, we cal-
culated blood pressure during this period by computing the difference between the 
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Figure 1. Study design. The three vertical lines next to shaded boxes denote the Accutorr systolic blood pressure measurements. 
Shaded boxes denote metronome respiration period for baroreflex sensitivity (BRS) assessment. B, baseline, M, mild rectal stimulation, I, 
intense rectal stimulation. Open boxes denote ramp distension (5-30 mmHg) or phasic rectal distensions of 15, 25 and 35 mmHg.
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BP during the subsequent BRS measurement procedure. This difference was added 
to the Accutorr BP measured prior to the BRS assessment.
Statistical analysis
Linear mixed model analysis was used to detect overall differences in BRS, SBP 
and HR between IBS patients and controls (SPSS for Windows 11.0, Chicago IL, 
USA). Condition (baseline or rectal distension), group (IBS patients or controls), 
and condition by group interaction were analyzed as separate contributors. Subjects 
with missing data were not excluded from the analysis. Within-group changes from 
baseline in BRS, SBP, HR, and pain perception scores were analyzed using t statistics 
or Wilcoxon Signed Ranks Tests, and between-group differences were compared by 
t statistics or Mann-Whitney tests where appropriate. Data are expressed as mean ± 
SD in text and tables and, for clarity purposes, as mean ± SE in figures. The level of 
significance was set at P≤0.05.
RESULTS
Subject characteristics
We screened 130 patients, 26 of whom did not meet Rome II criteria, and 40 healthy 
volunteers. All 40 volunteers and 104 patients provided informed consent. From 
these, 17 patients and 4 control subjects were excluded from the analysis: 10 patients 
and 1 control subject used cardio-active or antihypertensive medication, 4 patients 
and 3 controls had cardiac arrhythmias and 1 patient had a pacemaker. Two more 
patients were excluded due to technical difficulties during the BRS measurements. 
Thus, 87 patients and 36 controls were included in the final analysis. Mean age and 
gender distribution were comparable in patients and controls (Table 1). Pain percep-
tion was significantly increased in patients from 8 mmHg onward, but in controls 
from 22 mmHg onward, indicating hypersensitivity to balloon distension in patients 
(Fig 2).
Baseline assessment
Opposite to what we expected, baseline BRS was higher in IBS patients compared to 
controls (7.9 ± 5.4 versus 5.7 ± 3.7 ms/mmHg, P=0.03) (Fig 3). Baseline SBP (Table 
2) and HR (Table 3) were not significantly different between patients and controls.
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BRS, blood pressure and heart rate during phasic rectal distension
BRS
Figure 3 shows mean BRS in patients and controls during baseline and 15 and 
35 mmHg rectal distensions. The condition by group interaction was significant 
(P=0.01). BRS was not different between patients and controls during 15 mmHg (9.0 
± 5.7 versus 9.2 ± 6.4 ms/mmHg, respectively, P=0.68) and 35 mmHg distensions 
(7.3 ± 4.3 versus 7.9 ± 4.3 ms/mmHg, respectively, P=0.40). BRS was significantly 
increased in controls (P<0.0001) and in patients (P<0.05) during 15 mmHg, but only 
in controls (P=0.002) and not in patients (P=0.25) during 35 mmHg distensions.
Systolic blood pressure
Mixed model analysis showed that neither condition by group interaction nor the 
group factor was significant for systolic blood pressure (P=0.37 and P=0.41, respec-
tively), indicating that the SBP response to rectal distensions was similar in patients 
and control subjects. In contrast, condition was significant (P<0.0001), indicating that 
blood pressure changed similarly in both groups. SBP was significantly increased in 
controls (P=0.002) with a similar trend in patients (P=0.08) during 15 mmHg disten-
sion, and in both groups during 35 mmHg distension (P<0.001) (Table 2).
Heart rate
HR condition by group interaction was not statistically significant (P=0.13), nor was 
group (P=0.07), but condition was significant (P<0.0001). Compared to baseline, 
HR decreased significantly in patients (P<0.0001) and controls (P=0.003) during 15 
mmHg and increased significantly in patients (P<0.0001) and controls (P=0.05) dur-
ing 35 mmHg distension (Table 3). 
Table 1. Baseline characteristics of IBS patients and healthy controls
IBS (n=87) Controls (n=36)
Age (yr) 40.0 ± 13 39.5 ± 15
Females 60 (69) 21 (58)
Bowel habit 
diarrhea 31 (36) 0
constipation 27 (31) 0
alternating 22 (25) 0
currently unknown 7 (8) -
normal - 36 (100)
Numbers within parentheses show percentages. IBS, irritable bowel syndrome; n, number of patients or controls.
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Figure 2. Pain perception during ramp distension. Visual Analog Scale (VAS, range 0-10) scores for rectal pain perception (mean ± 
SE) during the ramp distension procedure in IBS patients (closed squares) and healthy controls (open squares). Asterisks denote the first 
pressure at which the perception score was significantly increased compared to 6 mmHg (P<0.05), which was at 8 mmHg for IBS patients 
























































Figure 3. BRS (mean ± SE) at baseline and during mild (15 mmHg) and intense (35 mmHg) rectal stimulation in IBS patients 
(closed squares) and healthy controls (open squares). Baseline BRS was significantly larger in patients compared to controls 
(#, P=0.025). * significant increase from baseline (P<0.05).
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DISCUSSION
Our study demonstrates that stimulation of visceral afferents by a standardized stimu-
lus, i.e., pressure-driven rectal balloon distension, produces significant changes in 
systolic blood pressure and heart rate in healthy subjects and in patients with IBS. 
Moreover, this stimulus increases baroreflex sensitivity in healthy individuals and in 
IBS patients. In addition, resting BRS is significantly larger in IBS patients compared 
to healthy subjects.
Physiologic mechanisms underlying the cardiovascular response to rectal distension
Heart rate and blood pressure
Several studies have reported that stimulation of visceral afferents produces cardio-
vascular responses, notably in blood pressure and heart rate. Yet, the results are 
contradictory, which may be caused by widely varying experimental designs. For 
instance, abdominal vagal nerve stimulation in anesthetized rats did not alter blood 
pressure and heart rate18. Azpiroz and colleagues reported that neither jejunal balloon 
distension below the perception threshold, nor distension at the discomfort thresh-
old or above affected heart rate in healthy volunteers (blood pressure data were 
not reported)31. Cardiovascular responses to colorectal distension were measured in 
rats32 and in humans33. In awake rats, blood pressure and heart rate increased during 
colorectal distension in a dose-dependent manner32. In healthy volunteers, a similar 
graded response was observed in blood pressure (heart rate was not reported)33. 
Table 3. Mean heart rate at baseline and during mild and intense rectal stimulation in IBS patients and healthy controls
baseline 15 mmHg P-value* 35 mmHg P-value†
IBS
(n=87)
67.1 ± 10.1 64.0 ± 9.6 <0.001 72.0 ± 14.7 <0.001
Controls
(n=36)
64.2 ± 9.3 61.4 ± 8.9 0.003 66.5 ± 12.0 0.05
P-value‡ 0.14 0.33 0.07
Data are expressed as mean ± SD. * 15 mmHg versus baseline; † 35 mmHg versus baseline; ‡ IBS patients versus control subjects.
Table 2. Mean systolic blood pressure at baseline and during mild and intense rectal stimulation in IBS patients and healthy controls
baseline 15 mmHg P-value* 35 mmHg P-value†
IBS
(n=87)
120.7± 14.8 122.5 ± 17.7 0.08 130.6 ± 13.6 <0.001
Controls
(n=36)
116.4 ± 12.7 121.6 ± 12.8 0.002 129.5 ± 14.5 <0.001
P-value‡ 0.23 0.91 0.90
Data are expressed as mean ± SD. * 15 mmHg versus baseline; † 35 mmHg versus baseline; ‡ IBS patients versus control subjects.
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Our findings are consistent with a graded hypertensive response in healthy individu-
als and in IBS patients. The response in heart rate was, however, biphasic in both 
groups: heart rate decreased during mild rectal distension (15 mmHg) but increased 
during more intense stimulation (35 mmHg).
Most likely, the primary autonomic response to the stimulus we applied is sympa-
thetic activation. This hypothesis is supported by the consistent blood pressure in-
creases as demonstrated in this study and by others32,33. The hypertension-associated 
baroreceptor loading reflexly reduces the increase in sympathetic outflow (thereby 
reducing the original blood pressure rise and tachycardic response) while enhancing 
vagal outflow (which lowers heart rate, but not peripheral vascular resistance and 
thereby blood pressure). Thus, a mild hypertensive stressor may leave heart rate 
unaffected or even cause a slight decrease. Thus far, heart rate decreases have been 
reported during mental stress34,35. To our knowledge, we are the first to demonstrate 
this phenomenon during viscerosensory stimulation.
In contrast, a high blood pressure increase (e.g. during 35 mmHg distension) 
will be counteracted by the baroreflex to a lesser degree as the baroreceptor fir-
ing characteristic is S-shaped36. Consequently, the significant baroreceptor loading 
during high pressure rectal distension will lead to less reduction of the increase in 
sympathetic tone and less stimulation of parasympathetic outflow. This may explain 
our finding that during high rectal distension pressure, not only blood pressure but 
also heart rate increased.
Individual heart rate responses differed in sign and magnitude. Approximately 
80% of our study population (IBS patients plus control group) exhibited a heart rate 
decrease during mild stimulation. Six percent (5/87 patients and 2/36 controls) had a 
heart rate decrease of more than 10 bpm and in one subject in the IBS group, heart 
rate lowered by 12 bpm from 62 to 50 bpm. On intake, this patient had reported 
defecation syncope on several occasions. It has been long hypothesized that strain-
ing during defecation (Valsalva maneuver) plays a dominant role in this form of 
fainting. However, recently, syncope was recorded during colonic air insufflation in 
a patient with recurrent defecation syncope that was not specifically associated with 
straining. A cardiac pacemaker resolved these symptoms completely37. It is hence 
conceivable that the colorectal-cardiovascular reflex response to mild distension as 
measured in our study provides an alternative clue to the mechanism that underlies 
this form of syncope.
Baroreflex sensitivity
We measured an increase in baroreflex sensitivity under mild rectal distension in 
healthy subjects and in IBS patients. During intense stimulation, the BRS increase 
compared to baseline persisted in healthy controls, albeit to a lesser extent, whereas 
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BRS returned to baseline in patients. These findings are opposed to our original 
hypothesis that BRS would lower under stress. This expectation was based on a 
study in rats, showing that sympathetic output increased and baroreflex sensitivity 
decreased following stimulation of general gastric afferents18. Several incompatibili-
ties may account for this difference. First, anesthetized rats were used18, while our 
study subjects were not sedated. Thus, cortical perception (stimulus awareness) may 
have played a role in the BRS increase we observed. In addition, it has been shown 
that anesthetic agents as used in the rat study considerably depress the arterial 
baroreflex38. Second, the insertion of catheters into the femoral artery and vein may 
additionally have influenced the autonomic conditions39 in the rat experiment. Third, 
it cannot be ruled out that the spinal afferent viscerosensory input caused by the 
rectal distensions in our study is processed differently at the level of the brainstem 
from the cranial nerve (vagal) afferent input in the rat study. 
The mechanism responsible for the BRS increase can only be speculated upon. 
Possibly, projections of the viscerosensory afferents ending at the NTS produce a 
neurotransmitter that directly enhances the baroreflex gain. Substance P, which is 
known to enhance the baroreflex by modulating the transmission from the barore-
ceptive afferents to the NTS neurons, would be a candidate neurotransmitter to 
achieve this effect10,40. Substance P production at the level of the NTS has been 
demonstrated for somatosensory afferents20, while a high density of substance-P-
containing fibers originating from the gastrointestinal tract have also been found in 
the pigeon NTS41. Alternatively, enhanced parasympathetic tone as a reflex response 
to rectal stimulation may have enhanced BRS by facilitating deeper modulation of 
the parasympathetic outflow, i.e. allowing increased heart rate fluctuation, rather 
than by increasing baroreflex gain.
Differences between IBS patients and healthy control subjects
Baseline supine heart rate and blood pressure were not significantly different be-
tween IBS patients and controls, although patients tended to have slightly higher 
values (Tables 2 and 3). The non-significant trend (P=0.14) to higher supine baseline 
HR values in IBS patients we observed was also reported by several other groups9,42-
46. HR was similar during mild distension in patients and controls (P=0.33), but again 
tended to be higher in IBS patients during intense rectal distension (P=0.07). Few 
published numerical data are available regarding baseline blood pressure differences 
between IBS patients and healthy controls. Levine et al. found that baseline systolic 
blood pressure was significantly higher in patients45.
The most striking difference between IBS patients and healthy control subjects 
was the 39% elevated BRS-value in patients (7.9 ± 5.4 versus 5.7 ± 3.7 ms/mmHg, 
P=0.03). This difference no longer existed during mild and intense rectal distension. 
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The marked elevated baseline BRS in IBS patients may provide an explanation for 
autonomic alterations reported in patients10,47,48. The baroreflex plays a key role in the 
generation of heart rate variability as it transfers respiration induced blood pressure 
variability into fluctuations in sympathetic and parasympathetic outflow, eventually 
leading to modulation of the discharge rate of the cardiac pacemaker28. Differences 
in heart rate variability (HRV) and HRV-derived assessments of the sympathovagal 
balance49,50 as reported by several research groups10,47,48 might therefore at least partly 
be explained by differences in baroreflex function.
Our study does not provide information on the basis of which the elevated base-
line BRS value in IBS patients and its functional role in IBS can be explained. We 
speculate that the frequently experienced viscerosensory stimuli, e.g., abdominal 
pain, entail a training-effect, possibly materialized in chronic elevated substance 
P concentrations at the NTS level20,40,41,51. Such a training-mechanism can only be 
further investigated in animal models of visceral afferent stimulation. Alternatively, 
the elevated baseline BRS value may reflect an intrinsic autonomic characteristic 
in which IBS patients differ from healthy individuals. Altered baroreflex function 
could witness altered information processing at the NTS level. For the esophagus, 
a vago-vagal reflex from/to the gastrointestinal tract (GI-GI reflex pathway) has 
been demonstrated involving the NTS as well as the NA52. In analogy, spino-spinal 
GI-GI sensorimotor reflex pathways, although not identified yet, may be involved in 
reflexes regarding the distal gut.
It is tempting to interpret the enhanced baseline baroreflex vigor as an anticipatory 
phenomenon and to expect benefits from that anticipation in the form of inhibition 
of cortical arousal19,25 and visceral pain perception18 during irritating stimuli such 
as abdominal pain. However, our finding that no differences in BRS values exist 
between IBS patients and control subjects during rectal distension renders such a 
hypothesis unlikely.
A limitation of our study was that we did not measure rectal perception during 
the applied rectal stimuli (phasic distensions), as this was not feasible due to the 
imposed metronome respiration. It may, however, be inferred from the pain scores 
during ramp distension (Fig 2) that pain perception was increased in IBS patients 
compared to controls. Furthermore, the lack of baseline values in the patient group 
prior to disease onset should be appreciated when interpreting our results. Finally, 
although we controlled for age and gender in this study, which have been shown 
to be strong determinants of spontaneous baroreflex sensitivity, there are other vari-
ables that may also affect baseline BRS53.
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Conclusions
In summary, our study provides evidence for the existence for a colorectal-cardio-
vascular reflex, characterized by a blood pressure increase, slight heart rate decrease, 
and an increase of baroreflex sensitivity during mild stimuli. Intense stimuli increase 
heart rate and blood pressure, while baroreflex sensitivity seems to be impaired 
compared to mild stimulation. This reflex, that was evident in normals as well as in 
IBS patients, might well be involved in defecation syncope.
Our study also provides evidence for baroreflex involvement in irritable bowel 
syndrome, as IBS patients have a higher baseline BRS-value than healthy controls. 
This finding renders the hypothesis unlikely that IBS patients are hypersensitive due 
to diminished baroflex function. We provide two possible explanations for the higher 
baseline BRS in IBS: 1) a “training-effect” (frequent challenging of the reflex by IBS-
associated abdominal discomfort); 2) altered information processing at the NTS that 
causes BRS increases and, in parallel, abnormal GI-GI sensorimotor reflexes. While 
the first explanation considers the autonomic changes as a consequence of IBS, the 
second one recognizes a role for the autonomic nervous system in the pathophysiol-
ogy of IBS and explains both altered HRV and changes in gastrointestinal motility as 
observed in this condition54. The latter hypothesis requires further corroboration.
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ABSTRACT
Background: Sensory and motor dysfunction of the gut are both important charac-
teristics of irritable bowel syndrome (IBS). Several gut peptides contribute to the 
regulation of gastrointestinal function but little is known on gut hormone secretion 
in IBS.
Methods: We evaluated perceptual thresholds and fasting and postprandial plasma 
levels of proximal (cholecystokinin (CCK), motilin) and distal (peptide YY) gut pep-
tides up to 1 hour after ingestion of a high caloric meal in 99 IBS patients and 40 age 
and sex matched healthy controls.
Results: Fasting plasma CCK levels were significantly elevated in patients (1.2 ± 0.8 
pM) compared to controls (0.8 ± 0.7 pM, P=0.006), as was the incremental post-
prandial CCK response (72 ± 73 versus 40 ± 42 pM·60 min, respectively; P=0.003). 
No differences in fasting and postprandial motilin or PYY levels were found. The 
postprandial PYY response was significantly increased in hypersensitive compared 
to normosensitive patients (215 ± 135 versus 162 ± 169 pM, P=0.048). Patients with 
a diarrhoea predominant bowel habit had higher fasting motilin levels compared to 
constipated patients or alternating type IBS patients  (82.1 ± 36.5 versus 60.8 ± 25.1 
versus 57.5 ± 23.9 pM, one-way ANOVA P=0.003).
Conclusion: IBS patients have increased fasting and postprandial plasma levels of 
CCK. Changes in plasma levels of motilin and PYY may contribute to the clinical 
expression of IBS, such as the presence of visceral hypersensitivity or predominant 
bowel habit.
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INTRODUCTION
Irritable Bowel Syndrome (IBS) is a frequently occurring disorder that has received 
much attention over the last decades. However, its pathophysiology remains poorly 
understood. Disturbances at different levels of the brain-gut-axis have been pro-
posed in symptom generation, including low-grade chronic intestinal inflammation1, 
immune system alterations2, autonomic dysfunction3, and altered central processing 
of afferent sensory input4. In particular, enhanced visceral perception is considered 
to be important as it has been reported that up to 94% of patients are hypersensitive 
to rectal balloon distension5. There is also evidence pointing to altered gut motility in 
IBS6. IBS patients exhibit abnormal postprandial colonic motor activity7 and reduced 
perception thresholds for gas, discomfort and pain8 after a meal. Symptoms often 
deteriorate postprandially9.
Several gut peptides are known to be involved in the regulation of gastrointestinal 
motor and sensory function. For instance, cholecystokinin (CCK) is a proximal gut 
hormone, released upon fat and protein ingestion, that delays gastric emptying10 and 
stimulates contraction of the gallbladder11 and exocrine pancreatic secretion12. Stud-
ies in healthy individuals have shown that infusion of CCK stimulates colonic motility 
and increases rectal sensitivity to balloon distension13,14. Motilin is also released from 
the proximal intestine and is involved in the regulation of interdigestive motility of 
the stomach and small intestine15, but also affects colorectal motor function16. Peptide 
YY (PYY) is a distal gut peptide that has been shown to delay proximal gastroin-
testinal motility17. Spiller et al. recently showed that the number of PYY-containing 
colonic enteroendocrine cells is increased in IBS patients who develop symptoms 
after an acute infectious gastroenteritis18.
Little is known about gut hormone secretion in patients with IBS. We hypothesize 
that changes in gut hormone secretion may contribute to the observed alterations in 
gut motor and sensory function in IBS. Therefore, we studied plasma levels of gut 
peptides released from the upper (CCK and motilin) and lower (PYY) small intestine 
under fasting and postprandial conditions in a large cohort of IBS patients. In addi-
tion, the influence of age, gender, IBS subtype and visceral hypersensitivity on gut 
hormone secretion was evaluated.
METHODS
Participants
Between March 2001 and July 2002, IBS patients between 18 and 65 years of age 
were invited to participate in a large clinical trial on psychological therapy, which in-
42 Chapter 3
cluded assessment of psychological function, autonomic nerve function, postprandial 
gut hormone secretion, rectal barostat measurements, and evaluation of the efficacy 
of relaxation training for the treatment of IBS. This study reports on postprandial gut 
peptide response tests.
Patients were recruited through a tertiary referral centre (the outpatient depart-
ment of Gastroenterology of the Leiden University Medical Centre (LUMC)) and 
through local advertisement. Healthy volunteers were recruited through advertise-
ment. Eligible participants were screened by one of the investigators (PvdV). All pa-
tients met Rome II criteria for IBS19. Exclusion criteria were organic disease, previous 
abdominal surgery (except cholecystectomy and appendectomy), and pregnancy. 
Use of antispasmodics, bulking agents, laxatives, and occasional use of analgesics 
was permitted. Informed consent was obtained from each participant. The LUMC 
ethics committee had approved the study protocol.
Hypersensitivity testing
An electronic barostat (Synectics Visceral Stimulator, Synectics Medical, Stockholm, 
Sweden) was used to assess visceral hypersensitivity. This device is able to maintain 
constant pressure within a highly compliant, polyethylene bag tied to the end of a 
multilumen tube, as described elsewhere20. Perception of rectal pain was quantified 
on a 100-mm Visual Analog Scale (VAS) at every even pressure, with end points rang-
ing from ‘none’ to ‘unbearable’. Pain thresholds were defined as the first pressure 
level at which perception scores exceeded 10 mm. Hypersensitivity to rectal balloon 
distension was defined as a pain threshold that was 2 SD or more below the mean 
threshold in healthy controls.
Subjects were permitted a small standardized breakfast at 8.00 AM and arrived at 
our department at 10.00 AM. A tap water enema was used to evacuate the rectum 
and the barostat bag was positioned as described previously21. Barostat recordings 
commenced after 30 min. The experimental protocol consisted of a slow ramp dis-
tension to assess rectal compliance. Intrabag pressure was increased at a rate of 1 
mmHg/min, from 5 to 30 mmHg. At all even pressures (6, 8…30 mmHg), patients 
rated the urge to defecate and pain using the 100-mm VAS scale. After the experi-
ment had ended, the rectal balloon was removed.
Meal
Fifteen minutes after the barostat experiment, an intravenous canula was inserted 
in the antecubital vein of one arm and a fasting blood sample was obtained (t=0). 
At 13.00 AM, patients were offered an 800 kcal solid meal, consisting of 2 slices of 
brown bread, 10 g of margarine, 1 slice of fat cheese, 1 slice of cooked ham, 350 
ml of semi-skimmed milk, 1 boiled egg, 300 ml of yoghurt, and 10 g of honey (44 
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g of protein, 46 g of fat and 69 g of carbohydrates). Additional blood samples were 
obtained at t = 15, 30, 45 and 60 min.
Plasma peptide assays
Blood samples were collected in ice-chilled tubes containing 2 g/L EDTA. All sam-
ples were centrifuged at rate of 3000 rpm for 15 min at a constant temperature of 
4 °C and stored at -20 °C until peptide levels were determined. Plasma CCK was 
measured by a sensitive and specific RIA as described previously22. Levels of PYY 
were determined using antiserum generated in rabbits by intracutaneous injections 
of synthetic human PYY (BACHEM AG, Bubendorf, Switzerland). PYY was labelled 
with 125I using chloramine T. There is no cross-reactivity with pancreatic polypeptide 
or vasoactive intestinal peptide. The detection limit is 10 pM and both PYY (1-36) 
and PYY (3-36) bind to the antibody in dilutions up to 1:250.000. Plasma motilin 
concentrations were determined using a sensitive and specific radioimmunoassay as 
described previously23.
Statistical analysis
All statistical analyses were carried out using SPSS for Windows, version 11.0.1 (SPSS 
Inc., Chicago IL, USA). An incremental postprandial response was computed for 
each peptide by calculating the incremental area under the curve. Linear mixed 
model analysis was used to detect overall differences in plasma peptide levels be-
tween groups over time. Plasma peptide level, subject group and the interaction 
were analysed as separate contributors to the model. Patient numbers were used 
to indicate repeated measurements. Demographical characteristics were compared 
between groups by Student-t or Mann-Whitney analysis and chi square analysis 
where appropriate. Between-group differences in plasma peptide concentrations 
were compared by Mann-Whitney or ANOVA with post-hoc Tukey’s correction for 
multiple group-wise comparisons. Within-group changes relative to fasting were 
analysed using Wilcoxon Signed Ranks Tests. Data are expressed as mean ± SD. The 
level of statistical significance was set at P<0.05.
RESULTS
Subject characteristics
We screened 130 patients and 40 healthy volunteers. Twenty-six patients did not 
meet Rome II criteria for IBS19. Blood sampling was unsuccessful in 5 patients, 
so that 99 patients and 40 healthy controls were included in the final analysis. All 
provided informed consent. Thirty-one patients (31%) were recruited through the 
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outpatient department, and 68 patients (69%) and all healthy controls were recruited 
through advertisement. Demographical and clinical characteristics are listed in Table 
1. Mean age and gender distribution was comparable between groups.
Plasma CCK
Fasting and postprandial plasma CCK levels are shown in Figure 1. Fasting plasma 
CCK concentrations were significantly higher in patients compared to controls (Table 
2). The postprandial plasma CCK response was significantly different between pa-
tients and controls (CCK concentration by group interaction, P<0.001). Plasma CCK 
concentrations increased significantly in patients and controls from 15 min onward 
(P<0.001 for all time points in both groups), reaching a peak at t=30 min in both 
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Figure 1. Fasting and postprandial plasma CCK concentrations in IBS patients (closed triangles) and controls (open triangles).  
* P<0.001 compared to fasting, † P<0.001 compared to controls.
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groups. The incremental postprandial CCK response was significantly increased in 
patients compared to controls (Table 2).
Plasma motilin
Fasting and postprandial motilin levels are shown in Figure 2. Fasting plasma motilin 
levels were not different between patients and controls. Plasma motilin concentra-















Age (yr) 41.9±14.0 41.1±12.7 42.2±14.6 39.7±15.0 43.2±17.2 37.6±13.5
CCK
fasting 1.2±0.8* 0.8±0.6 1.4±0.8† 0.8±0.7 0.9±0.5 0.8±0.8
AUC meal 71.7±72.6# 59.3±52.9 76.6±78.9 40.5±42.1 35.2±27.7 43.6±49.0
Motilin 
fasting 69.2±31.3 81.9±40.1‡ 64.2±25.8 65.3±29.5 70.2±32.0 62.4±28.1
AUC meal -615±1039 -813±1145 -536±991 -427±825 -594±899 -328±778
 PYY
fasting 17.5±6.0 16.4±4.3 17.9±6.5 17.5±8.9 15.1±3.1 18.9±10.8
AUC meal 181±159 153±163 192±157 247±294 228±228 258±331
AUC, Area Under the Curve. Fasting concentrations are expressed as pM. AUC is expressed as pM•60 min. * P=0.006 versus controls; 
























































Figure 2. Fasting and postprandial plasma motilin concentrations in IBS patients (closed triangles) and controls (open triangles). 
* P<0.001 compared to fasting.
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tions decreased significantly after the meal in both groups. The postprandial motilin 
response was similar in both groups (plasma motilin concentration by group interac-
tion P=0.49) (Table 2).
Plasma PYY
Figure 3 illustrates fasting and postprandial PYY levels in patients and controls. 
Fasting PYY concentrations were similar in patients and controls. The overall plasma 
PYY response was similar in both groups (PYY concentration by group interaction, 
P=0.80). Plasma PYY concentrations increased significantly in both groups from 
15 min to 60 min (P<0.001). The incremental postprandial PYY response was not 
significantly different between patients and controls (Table 2).
Influence of age and gender
Fasting CCK levels were significantly correlated with age in the whole group (r=0.33, 
P<0.001), but the postprandial CCK response was not (r=0.05, P=0.58). A small but 
significant correlation was found between age and fasting levels of motilin for the 
whole group (r=0.19, P=0.03). Age was neither correlated with the postprandial 
motilin response, nor with baseline nor postprandial levels of PYY.
A significant gender effect was found for fasting plasma levels of CCK (one-way 
ANOVA, P=0.001), which were significantly elevated in female IBS patients com-
pared to male IBS patients (Tukey’s P=0.012) and female controls (Tukey’s P=0.009) 
(Table 2 and Figure 4). This was not accounted for by age, as mean age was similar 
























































Figure 3. Fasting and postprandial plasma PYY concentrations in IBS patients (closed triangles) and controls (open triangles). 
* P<0.001 compared to fasting.
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independently correlated with fasting plasma CCK concentration (P=0.007 for gender 
and P<0.001 for age).
Figure 4 shows that postprandial CCK levels were also significantly increased in 
female IBS patients compared to the other subgroups. While the ANOVA indicated 
an overall difference in the incremental CCK response between these subgroups 
(P=0.05), no significant differences were found between female patients compared 
to male patients and female controls after adjustment for multiple comparisons 
(Table 2).
Fasting levels of motilin were significantly higher in male IBS patients compared 
to female patients (Tukey P=0.046). No differences were found between female and 
male control subjects (Table 2). Neither postprandial motilin levels nor fasting and 
postprandial levels of PYY were different between males and females (Table 2).
IBS subgroups
Fasting plasma levels of CCK and PYY were not different between the three IBS 
subgroups, but basal plasma concentrations of motilin were significantly increased 
in IBS-D compared to IBS-C and IBS-A (Table 3). No differences were found with 



























































Figure 4. Fasting and postprandial plasma CCK concentrations in female IBS patients (closed triangles), male IBS patients (open 
triangles), female controls (closed squares) and male controls (open squares). † P<0.001 compared to male patients and male and 
female controls.
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Visceral hypersensitivity and gut peptides
Two of 99 patients declined to participate in the barostat study. Thirty-two of the re-
maining 97 patients (33%) were classified as hypersensitive to rectal balloon distension. 
No differences between hypersensitive and normosensitive patients were found for 
fasting plasma levels of CCK, PYY and motilin or postprandial responses, apart from an 
increased plasma PYY response in hypersensitive patients (P=0.048) (Table 4).









Age (yr) 43.3 ± 13.0 39.0 ± 15.3 42.4 ± 14.1
Females n (%) 20 (59) 27 (79) 19 (86)
CCK
fasting 1.1 ± 0.9 1.3 ± 0.7 1.4 ± 0.8 0.364
AUC meal 63 ± 66 80 ± 66 68 ± 67 0.577
Motilin
fasting 82.1 ± 36.5† 60.8 ± 25.1 57.5 ± 23.9 0.003
AUC meal -655 ± 1390 -547 ± 774 -495 ± 867 0.846
PYY
fasting 17.6 ± 7.7 17.5 ± 3.7 18.3 ± 6.4 0.897
AUC meal 191 ± 168 185 ± 175 164 ± 123 0.829
AUC, Area Under the Curve. Fasting concentrations are expressed as pM. AUC is expressed as pM•60 min. * P-value for overall difference 
between subgroups (chi-square or one-way ANOVA) † P=0.011 versus IBS-C, P=0.009 versus IBS-A.







Age (yr) 41.3 ± 12.8 42.5 ± 14.8
Females n (%) 23 (72) 48 (74)
CCK 
fasting 1.2 ± 0.9 1.2 ± 0.8 0.908
AUC meal 73 ± 71 72 ± 75 0.214
Motilin
fasting 73.2 ± 30.1 67.0 ± 31.6 0.155
AUC meal -496 ± 1150 -678 ± 1000 0.710
PYY
fasting 18.9 ± 7.4 16.9 ± 5.1 0.220
AUC meal 215 ± 135 162 ± 169 0.048
AUC, Area Under the Curve. Fasting concentrations are expressed as pM. AUC is expressed as pM•60 min.
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DISCUSSION
Our study demonstrates that both fasting plasma CCK concentrations and the 
postprandial CCK response are significantly increased in IBS patients compared to 
healthy controls. In contrast, neither fasting plasma levels of peptide YY and motilin 
nor the postprandial responses of these peptides are different between patients and 
controls.
The effects of CCK on gastrointestinal function are well-known and include in-
creased sensitivity and motor activity of the distal gut10,11,13,14,24. Previous studies in 
patients with IBS have pointed to disturbed CCK release and altered organ sensitivity 
to CCK. Infusion of CCK in IBS patients leads to excessive intestinal motor activity25, 
reduced pain thresholds26, and increased gallbladder smooth muscle sensitivity27. A 
study by Sjölund et al. indicated that the release of CCK after ingestion of emulgated 
maize oil was higher in IBS patients compared to healthy controls28. Our findings in 
a large cohort of IBS patients confirm that postprandial CCK secretion is exagger-
ated in IBS. Additionally, we found that fasting levels of CCK were elevated in IBS 
patients. This was not observed by Sjölund et al., possibly due to the smaller sample 
size in that study (n=18).
One could argue whether the relatively small difference in postprandial plasma 
CCK concentrations between patients and controls (i.e., approximately twofold 
increase in IBS) is sufficient to contribute to exaggerated sensorimotor responses 
in IBS. Niederau et al demonstrated that only infusion of pharmacological doses 
of cerulein, a CCK agonist, resulted in significantly increased colonic motor activ-
ity13. Similarly, Sabate and colleagues showed decreased rectal sensory thresholds 
to balloon distension during CCK infusion at pharmacological but not physiological 
levels14. Unfortunately, these experiments were carried out only in healthy individu-
als. We previously demonstrated decreased rectal sensory thresholds during CCK 
infusion in IBS patients26. It is possible that increased sensitivity to CCK together with 
twofold increased postprandial plasma levels are, in part, responsible for altered 
gastrointestinal sensory and motor function in IBS.
Infusion of CCK has been shown to increase rectal pain sensitivity in IBS26. 
One could hypothesize that elevated plasma levels of CCK may contribute to the 
pathophysiology of visceral hypersensitivity5. Yet, our finding that neither fasting nor 
postprandial CCK levels were different between hypersensitive and normosensitive 
patients renders a contribution of changes in CCK secretion to the pathogenesis 
of enhanced visceral perception unlikely. However, increased CCK release after a 
meal may well be involved in the exaggerated postprandial colonic motor response 
in IBS patients6,7,13. There is also evidence to suggest that CCK infusion aggravates 
symptom severity in patients with functional abdominal pain syndromes, including 
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IBS29. Therefore, CCK antagonists such as loxiglumide are considered to have clinical 
potential in IBS30.
Plasma levels of CCK correlated significantly with age, which confirms previous 
findings31. Interestingly, the elevated fasting and postprandial plasma CCK levels in 
IBS patients were almost completely attributable to female patients. This was not ac-
counted for by age, as mean age was similar between groups. Our finding is particu-
larly interesting in view of the female predominance in IBS. Thus far, no studies on 
gender differences with respect to CCK secretion in humans have been published. 
One animal study, however, demonstrated gender differences in sphincter of Oddi 
sensitivity during CCK infusion, evidenced by a greater change in phasic wave am-
plitude in female compared to male dogs32. CCK probably does not play a role in IBS 
subtypes, as fasting and postprandial CCK levels were not different between patient 
subsets divided by bowel habit.
Fasting and postprandial plasma levels of motilin were comparable between IBS 
patients and controls. Similar results have been reported by others28,33, although 
increased8 and decreased28 motilin secretion after a meal has also been observed 
in IBS. Remarkably, plasma motilin levels decreased after meal ingestion in both 
groups. One should realise that motilin contributes to motility in the interdigestive 
and not in the digestive state, and is involved in triggering phase III of the migrat-
ing motor complex (MMC). Motilin levels fluctuate in accordance with the various 
phases of the MMC. Fasting motilin levels may have been obtained during phase III 
in some individuals, yielding higher mean plasma motilin concentrations, while in 
the first hour after meal ingestion phase III is suppressed, which may explain the 
observed decrease in plasma motilin concentrations. Furthermore, fasting motilin 
levels were significantly elevated in patients with diarrhoea predominance compared 
to those with constipation and alternating bowel habits. These findings may be clini-
cally important as motilin is known to stimulate human colonic motility in vitro34 and 
in vivo35 and may therefore play a role in the accelerated colonic transit that has been 
demonstrated in diarrhoea predominant IBS36.
Fasting and postprandial plasma peptide YY levels did not differ between IBS 
patients and controls, a finding that is in line with a previous study8. Others have 
more specifically studied the density of PYY secretory cells in the distal gut mucosa 
of IBS patients. One study suggested that local tissue levels of PYY in the descending 
colon are reduced in IBS patients compared to controls37. In contrast, another study 
showed increased numbers of PYY-containing enteroendocrine cells in rectal biopsy 
specimens of patients who developed IBS symptoms after an episode of acute dy-
senteric illness18. The latter findings point to a role for PYY in the pathophysiology 
of post-infectious IBS and visceral hypersensitivity. Our observation that patients 
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who were hypersensitive to rectal balloon distension have a greater PYY response 
supports this hypothesis.
Finally, it should be recognized that plasma hormone levels do not necessarily 
represent efficacy at target organ level. Peptides may act via endocrine, but also 
through paracrine and neurocrine pathways.
It is concluded that 1) fasting plasma motilin levels are significantly increased in 
diarrhoea subtype IBS patients, 2) postprandial PYY secretion is significantly in-
creased in patients with visceral hypersensitivity, and 3) fasting and postprandial 
CCK levels are significantly increased in (female) IBS patients. The observed changes 
in gut hormone secretion, especially of CCK, support a role for gut peptides in the 
pathophysiology of IBS.
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ABSTRACT
Background: Imbalances in the genetically controlled pro- and anti-inflammatory 
cytokine production may promote ongoing low-grade inflammation after an acute 
gastroenteritis, and, subsequently, IBS (post-infectious IBS, PI-IBS). We studied gene 
promoter single nucleotide polymorphisms (SNPs) of tumor necrosis factor α (TNF-α, 
pro-inflammatory) and interleukin 10 (IL-10, anti-inflammatory) in IBS patients and 
controls. 
Methods: DNA was extracted from peripheral blood leucocytes of 111 IBS patients 
and 162 healthy controls. Genotype and allele frequencies were assessed by analyz-
ing SNPs at position –308 (TNF-α) and -1082 and -819 (IL-10). 
Results: Homozygous high producers for TNF-α (A/A) were rare (overall prevalence 
2.6%). The heterozygous TNF-α genotype (G/A, high producer) was significantly 
more prevalent in IBS compared to controls (41% versus 26%, P=0.02). More patients 
(41%) than controls (30%) were positive for the A allele (P=0.044; OR 1.68, 95% CI 
1.01-2.79), with a similar trend for diarrhoea (54%) versus constipation and alternat-
ing subtypes (<33%, P=0.079), but not for subgroups according to a history of acute 
gastroenteritis. IL-10 genotypes were similarly distributed in patients and controls for 
both SNPs. Possession of a high producer TNF-α and a low producer IL-10 genotype 
was significantly more prevalent in IBS (9%) versus controls (3%, P=0.035; OR 3.11, 
95% CI 1.03-9.36) and in diarrhoea (20%) compared to other IBS subtypes (<4%, 
P=0.026). 
Conclusion: Our results support the emerging hypothesis that genetically determined 
immune activity plays a role in the pathophysiology of IBS. Future studies in larger, 
clinically relevant, IBS subgroups are warranted to establish definite associations 
with cytokine gene polymorphisms. 
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INTRODUCTION
Irritable Bowel Syndrome (IBS) is a common functional bowel disorder characterized 
by recurrent abdominal pain and altered bowel habits1,2. Several mechanisms have 
been proposed in the pathophysiology of IBS, including visceral hypersensitivity3,4, 
altered gut motility5,6 and psychosocial factors7.8. In addition, inflammation and mu-
cosal immune system activation may be important9. Recent studies demonstrated an 
increased risk for developing IBS after dysenteric illness10-12 and increased numbers 
of immunocompetent cells in rectal mucosa of patients with post-infectious IBS 
(PI-IBS) up to 1 year after infection13, implying that low-grade inflammation may 
contribute to symptom generation.
Pro- and anti-inflammatory cytokines are important modulators of the immune 
response and play a role in intestinal inflammation14. Cytokine production is under 
genetic control and imbalances in cytokine secretion may affect disease susceptibil-
ity and clinical outcome of various conditions. For instance, secretion of tumor 
necrosis factor alpha (TNF-α), a pro-inflammatory cytokine15, is associated with a 
single nucleotide polymorphism (SNP) in the promoter region of the TNF-α gene 
(G→A substitution at position –308)16,17. Possession of the A allele (A/A or G/A) is 
associated with increased TNF-α production18. Homozygotes for the A allele have 
worse outcome of cerebral malaria19 and virus-induced renal failure20. Likewise, pro-
duction of the counter-inflammatory cytokine interleukin 10 (IL-10)21 is associated 
with SNPs at positions –1082 (G→A) and –819 (C→T)22. Genetic predisposition for 
low IL-10 production (A/A for the –1082 and T/T for the –819 SNP)22 is associated 
with inflammatory bowel disease, particularly ulcerative colitis23, and acute rejection 
after liver transplantation24. IL-10 knock-out mice spontaneously develop chronic 
enterocolitis25. A recent study by Gonsalkorale et al.26 showed that the high producer 
IL-10 genotype (-1082 G/G) is less prevalent in IBS patients compared to healthy 
controls. However, persisting low-grade inflammation may result from decreased 
production of anti-inflammatory cytokines, e.g. IL-10, as well as from high levels 
of pro-inflammatory cytokines such as TNF-α27 or IL-1beta28, or from imbalance be-
tween these cytokines. Our primary aim was therefore to study gene promoter SNPs 
of IL-10 and TNF-α in IBS patients and in healthy controls. In addition, we aimed 
to explore the frequencies of these SNPs in IBS subgroups based on post-infectious 




Patients were recruited through the outpatient department of Gastroenterology and 
Hepatology of the Leiden University Medical Center (LUMC) and through advertise-
ment in a local newspaper. Healthy control subjects were recruited among spouses 
of non-IBS patients who attended our department and through advertisement. All 
participants were screened by one of the investigators (PvdV) and all patients met 
Rome II criteria for IBS1. Exclusion criteria for both groups were: presence of organic 
disease, previous abdominal surgery (cholecystectomy and appendectomy excluded), 
pregnancy and dependence on analgesics. Although the presence of immunological 
(astma, celiac disease) or other disorders was not excluded by means of physical, 
radiological or laboratory investigations, patients were explicitly requested to report 
the presence of any disease, now or in the past, and to specify any GI disorder in 
particular. Informed consent was obtained from each participant. The LUMC ethics 
committee had approved the study protocol.
Study design
Each subject completed a questionnaire concerning medical history and current 
abdominal symptoms and bowel habits. In a separate item, we explored whether 
symptom onset was associated with an episode of acute diarrhoea, fever and vomit-
ing. Subsequently, blood samples were obtained. 
Genotype assessment
Blood samples were collected in ice-chilled tubes containing EDTA and transported 
to the laboratory on ice. All samples were centrifuged at 1000 g for 10 min at 4°C. 
DNA was extracted from peripheral blood leucocytes according to the salting out 
procedure29. Polymerase chain reaction-restriction fragment length polymorphism 
(PCR-RFLP) technique was used to determine the TNF-α G-308A, IL-10 G-1082A and 
C-819T SNPs. Genotype assessment was done as previously described30-32. Briefly, 
gene specific primers were used to generate 147 bp (TNF-α) and 360 bp (IL-10) 
products. Restriction enzyme digestion yielded fragments, which were analyzed by 
electrophoresis on a 4% agarose gel and visualized under UV light (Fig 1A and 1B). 
Statistical analysis
We aimed to enroll at least 100 subjects in both groups, based on 1) a 24% preva-
lence of the high producer IL-10 genotype (G/G) in the Dutch population31, 2) a 
power of 0.80, and 3) 11% difference in genotype prevalence between IBS patients 
and controls26. Genotype frequencies were compared between groups by Pearson’s 
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chi-square analysis for each polymorphism. Allele and high/low producer genotype 
frequencies were compared by calculation of odds ratios. Data are expressed as 
mean (SD) or as number of cases (percentage) where appropriate. The level of 
significance is set at P≤0.05.
RESULTS
Subject characteristics
A total of 111 IBS patients and 162 healthy control subjects were eligible and in-
cluded in the study. Table 1 displays patient and control group characteristics.
Twenty-three patients (21%) reported symptom onset after an episode of acute 
diarrhoea, vomiting and fever, and were marked as PI-IBS. Fifteen patients (13%) 
did not report their current bowel habit. Normal bowel habits were reported by 139 












































Figure 1B. Example of the IL-10 genotyping method using PCR-RFLP. G/G, high producer; G/A, intermediate producer; A/A, low 
producer.
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per month) without abdominal pain was reported by 23 controls (Rome II negative). 
In both groups, more than 95% of participants were of Caucasian origin.
TNF-α and IL-10 genotype and allele frequencies
Genotype and allele frequencies for TNF-α are shown in Table 2. Homozygote high 
producers were rare (overall prevalence 2.6%). The heterozygous genotype (G/A) 
was significantly more prevalent in IBS patients compared to controls (41% versus 
26%, P=0.02), with more patients than controls being positive for the A allele (A/A 
or G/A; 41% versus 30%, P=0.044; odds ratio (OR) 1.68, 95% confidence interval (CI) 





Females 76 (84) 61 (98)
Age 48.6 (12.9) 37.6 (15.6)
Bowel habit
diarrhoea 32 (35) 6 (10)
constipation 24 (27) 4 (6)
alternating 31 (34) 4 (7)
currently unknown 13 (15) -
normal - 86 (139)
Numbers without parentheses show percentages, numbers within parentheses show absolute numbers or SD (Age). IBS, irritable bowel 
syndrome; n, number of patients or controls.





n % n %
Genotype
A/A (high) 1 1 6 4
A/G (high) 45 41† 42 26
G/G (low) 65 59 114 70
Genotype
A+ (A/A or A/G) 46 41‡ 48 30
A- (G/G) 65 59 114 70
Allele frequency
-308A (high) 47 21 54 17
-308G (low) 175 79 270 83
† χ2=7.83, P=0.020 versus controls; ‡ χ2=4.07, P=0.044 versus controls; odds ratio (OR) 1.68, 95% CI 1.01 - 2.79.
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1.01 - 2.79). A allele frequencies were not different between patients and controls 
(21% versus 17%, P=0.18; OR 1.34, 95% CI 0.87 - 2.07). 
Table 3 shows genotype and allele frequencies for the IL-10 G-1082A SNP. The 
low producer genotype (A/A) was similarly distributed in patients and controls (23% 
versus 21%, P=0.93). Likewise, frequencies of the A allele (low IL-10 production) 
were comparable between IBS patients and controls (48% versus 47%, P=0.71; OR 
1.07, 95% CI 0.76 - 1.50). Similar results were obtained for the IL-10 C-819T SNP. 
Frequencies of the low-producer genotype (T/T) did not differ between patients 
and controls (6% versus 7%, P=0.73), nor did T allele frequencies (24% versus 27%, 
respectively, P=0.43; OR=0.85, 95% CI 0.58 – 1.27). 
Combined high TNF-α and low IL-10 producer genotypes
Possession of both a low producer IL-10 genotype (–1082 A/A) and a high producer 
TNF-α genotype (-308 A/A or G/A) may make an individual particularly susceptible 
to an exaggerated inflammatory response or prolonged low-grade inflammation. 
Therefore we explored the frequencies of the presence of both genotypes in patients 
and controls. This combination was considerably more prevalent in IBS patients 
compared to controls (9% versus 3%, P=0.035; OR 3.11, 95% CI 1.03 - 9.36) (Table 
4). The frequencies of the other genotype combinations were similar in patients and 
controls (Table 4). The combination of a high producer TNF-α genotype (A/A or 
G/A) and the other low producer IL-10 genotype (-819 T/T) was not significantly 
different between patients (3%) and controls (1%) (P=0.16; OR 4.47, 95% CI 0.46 – 
43.56; other combinations not shown). 





n % n %
Genotype
G/G (high) 29 26 45 28
G/A (intermediate) 57 51 83 51
A/A (low) 25 23 34 21
Genotype
G+ (G/G or G/A) 86 77 128 79
G- (A/A) 25 23 34 21
Allele frequency
-1082G (high) 115 52 173 53
-1082A (low) 107 48 151 47
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IBS subgroups
Exact statistical comparisons between some subgroups according to reported post-
infectious symptom onset or predominant bowel habit were not feasible due to 
small numbers in these groups. Yet, explorative analysis indicated a trend for the 
high producer TNF-α genotypes (A/A or G/A) to be more prevalent in IBS-D (54%) 
patients compared to IBS-C (33%) and IBS-A patients (29%) (P=0.079) (Table 5), but 
was found to be present in 48% of PI-IBS patients compared to 40% of non-PI-IBS 
patients (P=0.49) (Table 5). No differences were found regarding the IL-10 geno-
types. Furthermore, the prevalence of a combined high producer TNF-α and low 
producer IL-10 genotype (-1082 A/A) appeared remarkably higher in IBS-D (20%) 
compared to IBS-C (4%) and IBS-A (3%) (P=0.026), but was similar in the PI-IBS and 
non-PI-IBS subgroups (9% versus 9%, P=0.95) (Table 5). 





n % n %
Combination
high TNF-α / low IL-10 10 9† 5 3
low TNF-α / high IL-10 50 45 85 53
high TNF-α / high IL-10 36 32 43 27
low TNF-α / low IL-10 15 14 29 18
† χ2=4.45, P=0.035 versus controls; OR 3.11, 95% CI 1.03 - 9.36.
Table 5. TNF- and IL-10 genotype distributions and combinations in PI-IBS and non-PI-IBS patients, and in IBS subgroups according 











n % n % n % n % n %
TNF-α G-308A
high (A+) 11 48 35 40 19 54† 9 33 10 29
low (A-) 12 52 53 60 16 46 18 67 24 71
IL-10 G-1082A
high (G+) 19 83 67 76 24 69 24 89 26 77
low (G-) 4 17 21 24 11 31 3 11 8 24
Combined
high TNF-α / low IL-10 2 9 8 9 7 20‡ 1 4 1 3
low TNF-α / high IL-10 10 44 40 46 12 34 16 59 17 50
high TNF-α / high IL-10 9 39 27 31 12 34 8 30 9 27
low TNF-α / low IL-10 2 9 13 15 4 11 2 7 7 21
† χ2=5.08, P=0.079 compared to IBS-C and IBS-A; ‡ χ2=7.33, P=0.026 compared to IBS-C and IBS-A.
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DISCUSSION
This study demonstrates that the high producer TNF-α genotype is more prevalent 
in IBS patients compared to healthy controls. Although homozygous high producers 
were rare in both groups, the heterozygous genotype, which is also associated with 
a high TNF-α production phenotype17, was present in 41% of patients versus only 
26% of controls. 
TNF-α is produced by monocyte-derived activated macrophages, which have a 
crucial role in chronic inflammatory states such as Inflammatory Bowel Disease33 
and rheumatoid arthritis34. It has been shown that patients with persisting symp-
toms after an acute infectious gastroenteritis have a fivefold increase in the number 
of these activated macrophages in the rectal lamina propria13. Macrophage TNF-α 
production can be stimulated by enteric pathogens such as Campylobacter jejuni, 
Salmonella and Shigella35, which are important in the onset of PI-IBS13,36,37. Increased 
macrophage TNF-α production in patients carrying the A allele may contribute to 
the ongoing low-grade inflammation that is demonstrable in a subgroup of patients 
after an infectious enteritis13,28. The largest proportion of individuals positive for the 
A allele was indeed found in the PI-IBS group (48%) relative to the non-PI-IBS (40%), 
although this did not reach statistical significance. This does, however, not account 
for individuals carrying the A allele in the non-PI-IBS group. It is possible that low-
grade inflammation can be provoked by unknown non-infectious stimuli, especially 
in patients who are genetically predisposed to an enhanced pro-inflammatory re-
sponse. In addition, several other pro- and anti-inflammatory cytokines apart from 
TNF-α play a role in the regulation of the inflammatory process and may be involved 
in persistent low-grade inflammation. Finally, recall bias may have affected the com-
position of the PI-IBS and non-PI-IBS groups, as some patients had symptoms for 
more than 15 years. 
Genotype frequencies for IL-10 at positions –1082 and –819 were not different 
between IBS patients and controls. We found that the high producer genotype (-1082 
G/G) was present in 26% of patients and 28% of control subjects. These findings are 
in contrast with the recent preliminary observations by Gonsalkorale et al., showing 
a significant reduction in the high producer IL-10 genotype frequency in IBS patients 
compared to controls (21% versus 32%)26. When comparing these and our data, it 
is important to recognize that genotype frequencies vary according to ethnicity31,38. 
For instance, a recent study showed that the frequency of the high producer IL-10 
genotype is much higher in the Irish population (34%) than in Africans (9.5%) or 
Singapore Chinese (0%)39. In our patient and control groups, more than 95% of 
individuals were of Caucasian origin, and the IL-10 –1082 high producer genotype 
frequencies that we found in controls (28%) are similar to those previously reported 
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in the Dutch population (24%)31. Although the study by Gonsalkorale et al.26 provides 
no information on the ethnic origin of patients and controls, this may well explain 
the disparity between their study and ours. 
The role of the C–819T SNP in IL-10 production is incompletely understood. This 
polymorphism is in linkage disequilibrium with C–592A, another SNP in the promot-
er region of the IL-10 gene40. Three haplotypes for the G-1082A, C-819T and C-592A 
SNPs are common in Caucasians, i.e. GCC, ACC, and ATA, respectively. Although 
a direct link between the C-819T SNP and levels of IL-10 production has not yet 
been established, the GCC/GCC genotype is more common in IL-10 high producers, 
whereas ATA/ATA is associated with low IL-10 production22. In our study, the –819 
SNP was similarly distributed in patients and controls, supporting our observation 
that the genetic make-up for IL-10 production levels does not differ between these 
groups. However, other SNPs in the promoter region of the IL-10 gene may also be 
associated with increased or decreased IL-10 production. For instance, recent studies 
indicate that T-3575A, G-2849A, and C-2763A SNPs are associated with susceptibility 
to systemic lupus erythematosus41 and leprosy42 and disease severity in leprosy42. It 
may therefore be important to address these and other SNPs and haplotypes in IBS 
in future studies.
The combined presence of a high producer TNF-α and low producer IL-10 (-1082 
A/A) genotype within one individual was 3 times more prevalent in IBS patients 
compared to controls. This finding is clinically relevant, since IL-10 is known to 
inhibit TNF-α synthesis as well as the initial inflammatory response21. Individuals 
with an inherited predisposition to produce high levels of TNF-α, which are not 
adequately counterbalanced due to a genetically determined low IL-10 secretion, 
may be particularly at risk to develop ongoing low-grade inflammation and IBS-like 
symptoms. However, only 1 in 10 patients had this genotype combination, implying 
that other mechanisms are also important in the pathogenesis of IBS.
Our study was not primarily designed to compare patient subgroups based on 
post-infectious symptom onset or predominant bowel habit. Patient numbers in 
these subgroups were small and therefore these results should be interpreted with 
caution. However, our data indicated that the proportion of individuals positive for 
the high producer TNF-α A-allele was relatively large in IBS patients with a diar-
rhoea predominant bowel habit (54%) compared to patients with constipation (33%) 
or alternating bowel habits (29%). Moreover, the combination of a high producer 
TNF-α genotype and a low producer IL-10 genotype appeared more prevalent in 
IBS-D compared to IBS-C and IBS-A (20% versus 4% and 3%, respectively). These 
are potentially interesting results, as several studies indicate that TNF-α is associated 
with the occurrence of diarrhoea. For instance, TNF-α is an important mediator of 
distal colonic secretion43,44 and stool TNF-α concentrations are elevated in IBD45 and 
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infectious HIV-related diarrhoea46. Decreased IL-10 mediated inhibition of TNF-α 
may further add to its biological actions in patients with this specific genotype 
combination. Our data indicate that IBS subgroups may exhibit different cytokine 
producer genotypes that might be involved in disease expression, and further studies 
in larger populations are warranted to confirm these preliminary results. 
In conclusion, we have demonstrated that the high producer TNF-α genotype 
is more prevalent in IBS patients compared to healthy controls. Whereas the low 
producer IL-10 genotype is similarly distributed, the combination of a high producer 
TNF-α genotype and a low producer IL-10 genotype is also more prevalent in IBS. 
Our study contributes to the growing body of evidence that altered immune activa-
tion may be important in at least a subset of IBS patients. Future studies should 
further address the role of cytokine production in the pathophysiology of IBS and 
focus on clinically relevant subgroups. 
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Background: Motor and sensory dysfunction of the gut are present in a subset of 
patients with irritable bowel syndrome (IBS). Recent studies have demonstrated the 
presence of a recto-colonic inhibitory reflex in healthy humans. It is not known 
whether this reflex exists in IBS. 
Methods: We studied rectal compliance, perception and the recto-colonic reflex 
by measuring volume responses of the descending colon to rectal distentions by 
barostat in 26 IBS patients and 13 healthy controls under both fasting and postpran-
dial conditions. 
Results: In the fasting state, rectal distention inhibited colonic tone and phasic mo-
tility to a similar extent in health and IBS. After a meal, rectal distention inhibited 
colonic tone and phasic motility to a lesser degree (P<0.05) in IBS than health. Under 
postprandial but not fasting conditions, rectal distentions of increasing intensity were 
associated with higher pain scores in IBS than in health. 
Conclusion: Rectal distention inhibits tonic and phasic motility of the descending 
colon in healthy controls and in IBS patients. Postprandially this recto-colonic in-
hibitory reflex is impaired and attenuated in IBS patients compared to controls. 
These findings point to an altered reflex function in IBS and have implications for 
pathophysiology and therapy.
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INTRODUCTION
Irritable bowel syndrome (IBS) is a functional bowel disorder that affects 5 to 20% 
of the general population and is characterized by recurrent abdominal pain and 
disturbed bowel habits1,2. The pathophysiology of IBS is poorly understood, but 
disturbances at various levels of the brain-gut-axis have been identified, including 
post-inflammatory changes3, inappropriate mucosal immune activation4,5, hyperex-
citability of spinal dorsal horn neurons6 and altered central processing of sensory 
afferent information7. These alterations may result in visceral hypersensitivity, which 
is considered a hallmark of IBS8. In addition, motor dysfunction may occur in IBS. 
However, disturbed gut motor and sensory functions are present only in a subset of 
IBS patients, emphasizing the need for alternative explanations for the pathophysiol-
ogy of IBS.
Reflex inhibition of proximal gastrointestinal motor activity in response to stimula-
tion of a distal segment of the small bowel has been demonstrated in healthy indi-
viduals9,10. Recent observations in humans11-13 suggest the presence of recto-colonic 
and colorectal reflexes in the large bowel. These reflexes differ from the peristaltic 
reflex as they affect intestinal motility at much more distant segments. To date, the 
recto-colonic reflex has not been characterized in IBS. 
Symptoms in IBS are typically provoked by a meal or, when already present, 
deteriorate postprandially. Simren et al. demonstrated that duodenal lipid perfusion 
reduces perception thresholds for first sensation, gas, discomfort and pain in IBS 
patients, but only for gas in healthy controls14. These data suggest an exaggerated 
sensory response to a meal in IBS. Our aim was to evaluate the recto-colonic reflex 
in IBS patients under both fasting and postprandial conditions and to compare the 
results with those obtained in healthy controls.
METHODS
Subjects
Twenty-six IBS patients between 18 and 65 years of age were recruited at the outpa-
tient department of Gastroenterology and Hepatology of the Leiden University Medi-
cal Centre (LUMC). The diagnosis of IBS was based on Rome II criteria2. Medication 
for IBS was permitted but had to be stopped 4 days prior to the experiment. Thirteen 
healthy control subjects were recruited through advertisement. All participants pro-
vided informed consent and the LUMC ethics committee had approved the study 
protocol. Patient characteristics are shown in Table 1.
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Barostat
Two electronic barostats (Synectics Visceral Stimulator, Synectics Medical, Stock-
holm, Sweden) were used to study the recto-colonic reflex. One barostat was used 
to perform phasic rectal distentions, while the other measured changes in colonic 
tone. Pressure and volume were continuously monitored and recorded on a personal 
computer (Polygram for Windows SVS module, Synectics Medical, Stockholm, Swe-
den). The barostat assembly is shown in Figure 1.





Age (yr) 40.5 ± 15.8 37.2 ± 11.3
Females n (%) 16 (62) 6 (46)
Bowel habit n (%)
diarrhea 11 (42) 0
constipation 5 (19) 0
alternating 10 (39) 0
normal 0 13 (100)

















Figure 1. Dual barostat assembly with one bag in the rectum (R) and one bag in the descending colon (C). Both bags are connected 
to separate barostats.
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Experimental design
All experiments were performed on one day to reduce subject discomfort. Therefore, 
we were unable to randomize the intervention (meal versus fasting), but all measure-
ments were performed in the same order, i.e. first under fasting and thereafter under 
fed conditions. 
The bowel was cleansed with 2 liters of polyethylene glycol (KleanPrep®) the day 
before the experiment. After an overnight fast, subjects reported at our department 
at 7.30 AM and received a tap water enema. A flexible guide wire was placed in the 
transverse colon by endoscopy. Then a barostat catheter with bag was positioned 
over the guide wire into the descending colon under fluoroscopic control. A sec-
ond barostat catheter was placed in the rectum, approximately 5 cm from the anal 
verge. Experiments were performed with subjects in a 10° recumbent supine posi-
tion (Trendelenburg), lying in a bed. 
The experimental protocol is shown in Figure 2. After a 30-min resting period, 
colonic operating pressure (OP, defined as the pressure that provides a continuous 
intrabag volume of 80 ml) was determined during slow ramp distention (1 mmHg/
min increments until 80 ml bag volume was reached). Next, colonic bag pressure 
was set at OP and kept constant throughout the experiment. After 30 min, a rectal 
distention protocol was started, consisting of 5 phasic bag distentions of 10, 15, 20, 
25 and 30 mmHg of 5 min duration each. Each distention was followed by a 5 min 
rest period at 5 mmHg. The rectal distention protocol ended after 50 min and was 
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Figure 2. Experimental design. Two identical phasic rectal distention paradigms were performed during fasting and after meal 
ingestion, while colonic bag pressure was set at operating pressure. Meal ingestion consisted of 200 ml of Nutridrink (t=115 min, black 
circle), followed by 40 ml of Nutridrink at the beginning of each rectal distention (grey circles). Urge and pain perception was scored at 
30 sec after rectal distention onset (triangles).
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min, subjects ingested a 200 ml liquid test meal (Nutrison, Nutricia, Zoetermeer, 
The Netherlands; 600 kCal; 13% proteins, 48% carbohydrates, 39% fat). The rectal 
distention protocol was repeated 15 min after the onset of meal ingestion. An ad-
ditional 40 ml of Nutrison was administered at the beginning of each rectal disten-
tion to maintain a nutritional steady state during the experiment. At the end of the 
experiment, the position of both bags was checked using fluoroscopy, and the bags 
were removed.
The perception of urge to defecate and abdominal pain was quantified on a 100-
mm Visual Analogue Scale (VAS) at 30 sec after the onset of rectal distention, with 
end points ranging from ‘none’ to ‘unbearable’.
Data analysis
Rectal compliance was calculated by measuring the slope of the volume-pressure 
relationship from the onset of distention until the maximum pressure was reached. 
Mean colonic volumes during rectal distention were computed per minute. Subse-
quently, the relative change was calculated as the maximal volume per distention 
divided by the average volume in the 5-min pre-distention period (baseline volume). 
Phasic motility was defined as a 10% volume reduction below baseline, lasting for 
10 - 60 seconds, and expressed as number of phasic volume events (PVEs)/5 min.
Statistical analysis
Linear mixed model analysis (SPSS for Windows 11.0.1, SPSS Inc., Chicago IL, USA) 
was performed to detect differences in colonic bag volume changes, perception 
scores and number of PVEs, over time, between patients and controls. Group, condi-
tion (rectal distention level) and group by condition interaction were analyzed as 
separate contributors to the model. Changes relative to the 10-mmHg distention and 
pre- and postprandial values within groups were analyzed using paired t statistics 
or Wilcoxon Signed Ranks Tests where appopriate. Between-group differences were 
compared by unpaired t statistics or Mann-Whitney tests. Correlations were calcu-
lated using Pearson’s linear regression analysis. Data are expressed as mean ± SD. 
P-values less than 0.05 were considered significant.
RESULTS
Baseline barostat characteristics
Rectal compliance was reduced in IBS patients compared to controls, but the dif-
ference was only significant in the fed state (patients versus controls, fasting state: 
101 ± 35 ml/5 mmHg versus 131 ± 86 ml/5 mmHg, P=0.13; Fig 3A; fed state 110 
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± 37 ml/5 mmHg versus 140 ± 52 ml/5 mmHg, P=0.05; Fig 3B). However, analysis 
of covariance showed that postprandial compliance was not significantly different 
between health and IBS after adjusting for fasting compliance. No significant dif-
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Figure 3A. Rectal compliance expressed as mean volumes (ml ± SEM) during successive distentions in healthy control subjects 


























































Figure 3B. Rectal compliance expressed as mean volumes (ml ± SEM) during successive distentions in healthy control subjects 
(squares) and IBS patients (triangles) under postprandial conditions.
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colonic bag volumes, and number of PVEs in the fasting state and colonic volumes 
and number of PVEs in the postprandial state (Table 2). 
Colonic volume during rectal distentions
Relative colonic bag volumes during rectal distentions in the fasting state are shown 
in Figure 4A. Mixed model analysis showed that colonic volumes differed across 
rectal distentions (condition, P<0.001). However, the magnitude of colonic relaxation 
was not different between IBS patients and healthy controls (interaction, P=0.70). 
Figure 5 represents an example of the colonic tracing during fasting in a healthy 
control subject.







Operating pressure (mmHg) 14.5 ± 4.5 12.6 ± 4.0 0.21
Baseline colonic volume (ml) 137 ± 42 122 ± 33 0.26
PVEs (n/5 min in predistention episode) 2.9 ± 2.8 3.7 ± 2.8 0.42
Postprandial
Baseline colonic volume (ml) 145 ± 42 125 ± 55 0.21
PVEs (n/5 min in predistention episode) 4.6 ± 2.3 4.3 ± 3.0 0.70

























































 Figure 4A. Colonic bag volumes (% ± SEM) relative to baseline during rectal distentions in healthy control subjects (grey bars) and 
IBS patients (black bars) under fasting conditions.
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During the postprandial period, the interaction between condition and group was 
significant (P=0.01), suggesting that the effect of rectal distention on colonic volume 
differed between patients and controls. Figure 4B suggests that colonic relaxation 






































Figure 4B. Colonic bag volumes (% ± SEM) relative to baseline during rectal distentions in healthy control subjects (grey bars) and 






































Figure 5. Example of a colonic volume tracing (upper curve) during increasing phasic rectal distentions (lower curve) in a healthy 
volunteer. From 15 mmHg onward, colonic volume increases while the number of PVEs is reduced. The colonic bag volume returns to 
baseline after the rectal distention protocol has ended.
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Phasic motility
During fasting, rectal distentions inhibited colonic motility, reflected by reduced 
number of PVEs to a similar degree in both groups (condition, P<0.001; group by 
condition interaction, P=0.41) (Fig 6A). 
In the absence of rectal distention, more PVEs were observed after compared to 
before a meal. The increase was significant in IBS patients from 3.4 ± 2.6 to 4.6 ± 
 


































































































 Figure 6B. Number of colonic Phasic Volume Events (PVEs) ± SEM at baseline and during rectal distentions under postprandial 
conditions.
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2.3 PVE’s/5 min (P=0.02), but not in controls (from 3.9 ± 3.4 to 4.3 ± 3.0 PVE’s/5 
min, P=0.52). During rectal distention after a meal, analysis of colonic PVEs revealed 
an interaction (P<0.05) between condition and group. Figure 6B suggests that more 
PVE’s occurred in patients compared to controls.
Perception
Urge
During fasting, urge scores increased similarly in patients and controls at increas-
ing bag pressures (condition, P<0.001; group by condition interaction, P=0.87) (Fig 
7A). Similarly, urge increased significantly in both groups after the meal (condition, 
P<0.001), without significant between-group differences (P=0.95 for the interac-
tion). 
Pain
Under fasting conditions, pain scores in patients appeared higher compared to con-
trols, but the interaction was not significant (P=0.08) (Fig 7B). Postprandially, the 
group by condition interaction for pain was significant (P=0.01). Figure 7B shows 






















































Figure 7A. Perception of urge to defecate during fasting in patients (open squares) and controls (open triangles) and after meal 
ingestion in patients (closed squares) and controls (closed triangles).
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DISCUSSION
This is the first study to compare fasting and postprandial recto-colonic reflexes in 
health and IBS. Colonic motility was characterized by assessing tone and phasic 
volume events with a barostat. Our results show that 1) in controls, colonic tone and 
phasic volume events decline during rectal distention under fasting and postprandial 
conditions, 2) during fasting, colonic relaxation during rectal distention is compa-
rable between IBS patients and healthy controls, and 3) after a standardized meal, 
colonic relaxation during rectal distention is impaired  in IBS patients compared to 
controls. Under fasting conditions, rectal distention inhibited colonic tone and phasic 
volume events in an intensity-dependent manner in both health and IBS. 
Reflex inhibition of colonic motility during rectal distention has previously been 
demonstrated in humans. Law et al. showed that colonic bag volumes increased dur-
ing ramp and phasic rectal distentions in healthy volunteers11. In addition, our results 
also suggest for the first time that the magnitude of colonic relaxation was correlated 
to the intensity of rectal distention during fasting conditions. By contrast, Ng et al. 
reported that while 7 out of 14 subjects exhibited colonic dilatation during rectal 
distention, there was no significant overall group response12. Among our healthy 
subjects, colonic volumes increased by 10% or more in 9 of 13 subjects during rectal 
distention by 25 mmHg and in 10 of 13 subjects during 30 mmHg distention. Our 
results therefore support the observations by Law et al.11 that a recto-colonic inhibi-
tory reflex exists in humans. Differences in study design may explain the discrepancy 






















































Figure 7B. Perception of pain du ing f sting in patients open squares) and controls (open triangles) and after meal ingestion in 
patients (closed squares) and controls (closed triangles).
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volume response to only one rectal distention, while in our study and that of Law et 
al. several rectal distentions were employed and a dose response relationship could 
be established. Recently, Ng et al. studied the colorectal reflex by dual barostat as-
sembly and found the reflex to be significantly attenuated in IBS patients compared 
to controls13. 
Under postprandial conditions, reflex inhibition of colonic motility, as measured 
by colonic volumes, was impaired in IBS patients compared to healthy controls. It is 
unlikely that the differences were attributable to differences in baseline colonic bag 
volumes, which were not significantly different. However, similar to previous stud-
ies, IBS patients had an exaggerated postprandial colonic contractile response15,16. 
Perhaps, exaggerated postprandial colonic motor activity impairs the ability of the 
colon to relax and thereby attenuates rectocolonic reflexes in IBS patients after a 
meal. 
Consistent with previous studies, pain scores during rectal distentions were higher 
in IBS patients than in controls8,17. Furthermore, patients experienced more pain in 
the fed state compared to controls, while preprandial pain scores were not different 
between groups. Simren et al. showed that duodenal lipid infusion reduced percep-
tion thresholds for first sensation, gas, discomfort and pain in IBS patients, but only 
for gas in healthy controls14, suggesting an exaggerated sensory response to a meal 
or nutrients in IBS patients. Recently, Caldarella and colleagues demonstrated that in-
traduodenal infusion of lipids reduced thresholds for discomfort during rectal disten-
tion in IBS patients, but not in healthy controls. However, thresholds for perception 
were significantly lower in IBS compared to controls, with no additional effect of 
lipid infusion18. Our findings confirm these findings, and clinical observations sug-
gest that IBS symptoms deteriorate after a meal. However, the repeated distentions in 
our study may have also contributed to increased postprandial pain perception19. 
The role of postprandial recto-colonic inhibitory reflexes in the pathophysiology 
of IBS is not clear. Recent reports point to impaired reflexes at other locations in 
the gastrointestinal tract in patients with functional bowel disorders. For instance, 
impaired reflex fundic relaxation following intestinal administration of nutrients has 
been shown in patients with functional dyspepsia20. Our finding that colonic relax-
ation during rectal distention is impaired after a meal, taken together with the more 
pronounced effect of a meal on rectal sensation in IBS compared to controls, is 
consistent with the hypothesis of a generalized disturbance of postprandial colonic 
sensori-motor functions in IBS. This impairment should primarily be looked upon as 
a marker of disturbed gastrointestinal motor and sensory function, perhaps attribut-
able to autonomic dysfunctions. In addition, disordered reflexes may also contribute 
to IBS symptoms, particularly postprandial exacerbation.
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Finally, all measurements were performed in the same order, i.e. increasing rectal 
pressure distentions during fasting conditions followed by the same sequence after 
a meal. This was done to minimize discomfort to participating subjects. This is, 
however, a potential limitation of the study.
In conclusion, we have demonstrated the existence of a recto-colonic inhibitory 
reflex in healthy individuals and in IBS patients. The magnitude of this response is 
in the same range in both groups under fasting conditions, but is impaired in IBS 
patients after a meal. Since the role of disturbed colonic motor and sensory function 
in IBS has not been fully elucidated, future studies should focus on the involvement 
of retrograde reflexes in the pathophysiology of functional bowel disorders and 
characterize recto-colonic reflex dysfunction in IBS subgroups.
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ABSTRACT
Background & Aims: Visceral hypersensitivity is a hallmark of irritable bowel syn-
drome (IBS), but the relationship with clinical symptoms and psychological factors 
has not been fully established. We aimed to 1) evaluate these variables in a large 
cohort of IBS patients, recruited from both hospital and general practice, and in 
healthy controls; 2) assess which of these factors predicts the occurrence of visceral 
hypersensitivity in IBS. 
Methods: Rectal compliance and perception (intensity, perception thresholds; VAS 
0-100 mm) were assessed by a rectal barostat study (ramp distension) in 101 IBS 
patients and 40 healthy volunteers. IBS symptom severity was scored using a 14-day 
5-item diary. Anxiety, depression, somatization, vigilance, pain coping, dysfunctional 
cognitions, psychoneuroticism, and quality of life were assessed using psychometric 
questionnaires. 
Results: Rectal compliance was significantly reduced in IBS patients compared to 
controls (P<0.01), as were thresholds for pain (27 ± 15 vs. 35 ± 8 mmHg; P<0.01) 
and urge (P<0.05). Levels of anxiety, depression, neuroticism, somatization and dys-
functional cognitions were significantly increased in IBS patients vs. controls while 
pain coping and quality of life were significantly worse. Hypersensitivity to rectal 
distension occurred in 33% of patients and was associated with increased symptom 
severity (P=0.016), but not with demographical characteristics or psychological dis-
turbances. 
Conclusion: Hypersensitivity to balloon distension occurs in 33% of IBS patients 
and is predicted by symptom severity but not by psychological or demographical 
characteristics.
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INTRODUCTION
Irritable Bowel Syndrome (IBS) is characterized by recurrent abdominal discomfort 
or pain and disturbed bowel habits1. Several pathophysiological mechanisms have 
been suggested in symptom generation, including altered intestinal motility2, auto-
nomic dysfunction3,4, inflammation5,6, and immune system alterations6-8. Particularly, 
visceral hypersensitivity appears to play an important role9,10 and has been proposed 
as a biological marker of IBS11.
Visceral hypersensitivity may result from disturbances at different levels of the 
brain-gut axis, in which peripheral sensitization of intestinal nerve endings12, hyper-
excitability of spinal dorsal horn neurons13 and altered central processing of visceral 
afferent information14 are implicated. Abnormalities in regional brain activation, es-
pecially in areas involved in pain processing such as the anterior cingulated cortex 
and thalamus, have been reported in IBS patients in response to rectal balloon 
distension15. These regions belong to the emotional limbic system and are involved 
in psychological and cognitive events16,17. 
IBS symptomatology is associated with psychological factors and these may affect 
clinical outcome18. For instance, psychological distress is more prevalent among 
IBS patients who seek health care19. Little is known about the relationship between 
psychological variables and visceral hypersensitivity. Such information is relevant 
because it may provide a better understanding of the pathogenesis of IBS and its 
treatment. The few studies that explored this relationship have been criticized be-
cause of methodological shortcomings such as sample size and patient selection 
(tertiary referrals)9,11,19.
The aims of the present study were to 1) explore in a large cohort of IBS patients 
the prevalence of rectal hypersensitivity, levels of psychological distress and IBS 
symptom severity, and 2) assess which demographical, clinical and psychological 
variables predict the occurrence of visceral hypersensitivity in IBS.
METHODS
Participants
This study was part of a large randomized controlled trial of psychological treatment 
in IBS, the results of which will be published elsewhere. IBS patients between 18 
and 65 years of age were invited to participate. Baseline evaluation included detailed 
psychological assessment, rectal barostat measurements and IBS symptom severity 
scores. 
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To obtain a representative sample from the IBS population, patients were recruited 
from both the hospital IBS population (patients referred to the outpatient Department 
of Gastroenterology of the Leiden University Medical Center) and from the general 
population through local advertisement. Healthy volunteers were recruited through 
advertisement for comparison with the patient sample. All eligible participants were 
screened by one of the investigators (PvdV). Each patient met Rome II criteria for 
IBS1. Exclusion criteria were organic disease, previous abdominal surgery (except 
cholecystectomy and appendectomy), and pregnancy. Use of antispasmodics, laxa-
tives, bulking agents and occasional use of analgesics was permitted. We used the 
Mini International Neuropsychiatric Interview (Dutch version 5.0.0)20 to exclude pa-
tients with severe psychopathology (psychosis or risk of suicide). Informed consent 
was obtained from each participant. The Leiden University Medical Center ethics 
committee had approved the study protocol.
Barostat
An electronic barostat (Synectics Visceral Stimulator, Synectics Medical, Stockholm, 
Sweden) was used to assess rectal compliance and perception. This device measures 
rectal motor activity as volume changes in a rectal balloon, in which constant pres-
sure is maintained by injecting air when the rectal wall relaxes and aspirating air dur-
ing rectal contraction. Intrabag pressure is directly measured via a separate lumen. 
Maximal airflow is 38 mL/s. Pressure and volume are continuously monitored and 
recorded on a personal computer (Polygram for Windows SVS module, Synectics 
Medical, Stockholm, Sweden).
Visceroperception
Perception of urge to defecate and abdominal pain during rectal distension was 
quantified on a 100-mm Visual Analogue Scale (VAS). End points ranged from ‘none’ 
to ‘intolerable’. 
Demographical characteristics
The demographical group characteristics of interest were age, sex, and level of 
health care (general practice or referral).
Symptom severity
Patients and controls rated the severity of any abdominal discomfort, abdominal 
pain, constipation, diarrhea, and bloating, daily for 14 days, on a 5-point Likert scale 
(0 = no symptoms, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe symptoms) 
using a symptom diary card. A composite score was computed by summing up the 
14-day mean scores for each symptom (range 0-20). 
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Psychological assessment
A battery of questionnaires was administered to both IBS patients and control sub-
jects to determine the following psychological characteristics of each group. 
Anxiety and depression. We the used the Symptom Checklist 90 (SCL-90) to mea-
sure levels of anxiety (10 items) and depression (16 items). The SCL-90 is a validated 
survey and consists of 90 items addressing a range of physical and psychological 
problems21. 
Psychoneuroticism. The level of psychoneuroticism was determined by summing 
up all 90 items of the SCL-90.
Somatization. We used the abridged Dutch version (NVM) of the Minnesota Mul-
tiphasic Personality Inventory (MMPI) to measure somatization, which is 1 of 5 
subscales on this questionnaire22.
The role of the abovementioned psychological factors in IBS has been studied 
previously9,10,19. In addition, we considered the following psychological variables 
relevant, as they may confound the abovementioned determinants:  
Vigilance. We used the previously validated 10-item Somatosensory Amplification 
Scale (SAS)23 to determine the extent to which an individual is likely to report en-
hanced perception of physical symptoms (i.e. lower cognitive perception thresholds). 
Cognitions. The recently developed 31-item Cognitive Scale for Functional Bowel 
Disorders (CSFBD) was used to measure patients’ levels of dysfunctional cognitions 
concerning their IBS24. 
Pain coping. Pain coping was measured by 1 of 4 subscales of the Pain Coping 
and Cognition List (PCCL). This inventory has been widely used in The Netherlands 
and awaits future validation. Patients were asked to rate the extent to which they 
agreed with 11 statements concerning pain coping on a 7-point scale, ranging from 
“I completely disagree” to “I completely agree”. 
Somatic symptoms. The SCL-90 was also used to record non-IBS-related somatic 
symptoms. There are 12 items concerning general complaints, including headache, 
vertigo, backache, myalgia, difficulties with breathing, intolerance for high or low 
temperatures, dysphagia, etc. 
Quality of life. Quality of life was assessed using the validated SF-36 question-
naire25. This survey measures quality of life in 8 domains, i.e. physical functioning, 
social functioning, role limitations due to physical problems and emotional prob-
lems, mental health, vitality, bodily pain and general health.
Experimental design
A small standardized, low caloric breakfast was permitted at 8.00 AM on the day of 
the barostat recordings. After arrival at our department at 10.00 AM, subjects filled 
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out all questionnaires consecutively. Each participant was allowed the necessary 
time to complete the questionnaires, which took 80-90 min on average. 
After completion, the rectum was evacuated using a tap water enema. Participants 
were then placed in a hospital bed and with the subject in the left lateral position, a 
lubricated and tightly folded highly compliant, polyethylene bag (maximum capacity 
1000 mL) tied to the end of a multilumen tube (19 Fr) was inserted through the anus 
and positioned in the rectal ampulla. Bag position was checked by manual inflation 
of 150 mL of air and subsequent retraction of the catheter until prevented by the 
external anal sphincter. After balloon deflation, the catheter was introduced an ad-
ditional 2 cm, secured to the subjects upper leg by a piece of tape, and connected to 
the barostat. The hospital bed was placed in a 15° recumbent supine position (Tren-
delenburg) to avoid interference of abdominal mass with barostat measurements. 
Barostat measurements commenced approximately 4 hours after the light breakfast.
The experimental protocol consisted of a slow ramp distension to assess rectal 
compliance. Intrabag pressure was increased at a rate of 1 mmHg/min, starting at 
5 mmHg, until a maximum of 30 mmHg. Patients rated the urge to defecate and 
level of abdominal pain on the 100 mm VAS scale at all even pressures (6, 8,…, 
30 mmHg). After the experiment had ended, the rectal balloon was deflated and 
removed and each participant was provided with a 14-day symptom diary card and 
a stamped envelope to return the diary. Subjects were instructed to start filling out 
their symptom diary on the day after the experiment. 
Barostat analysis
Dynamic compliance was assessed by calculating volume increments for each indi-
vidual pressure step in each study participant. Compliance was defined by the largest 
volume increment (i.e., the steepest slope of the pressure-volume curve) for each 
participant and averaged over groups. Perception scores are expressed as the mean 
score at each pressure step. Perception thresholds were defined as the first pressure 
level at which perception scores exceeded 10 mm. 
Visceral hypersensitivity
Patients with a pain perception threshold ≥ 2 SD below the mean threshold in con-
trols were considered to be hypersensitive to balloon distension. 
Statistical analysis
We aimed to enroll at least forty subjects in each group to be able to detect a 5 
mmHg difference in mean pain threshold, which we considered clinically relevant, 
with a power of 0.80 and SD of 8 mmHg based on previous studies by our group.
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All statistical analyses were carried out using SPSS for Windows, version 11.0.1 
(SPSS Inc., Chicago IL, USA). Demographical characteristics were compared between 
groups by Student-t, Mann-Whitney or chi square analysis as appropriate. Differences 
in rectal compliance and visceroperception were analyzed for statistical significance 
using mixed models, using patient numbers as indicator for repeated measurements. 
One model analyzed pressure, volume, and pressure by volume interaction as sepa-
rate contributors to the model; a second model did the same for pressure, visceral 
perception, and pressure by perception interaction. Compliance, perception of urge 
and pain at maximum rectal pressure (30 mmHg) and perception thresholds for 
urge were compared by Mann-Whitney (patients versus controls) or Kruskal-Wallis 
analysis (IBS subgroups). Because the pain threshold during ramp distension was 
not reached in all participants (see results), the best estimates for the mean pain 
threshold and SD was obtained by Maximum Likelihood Estimation using software 
for parametric survival models. Normal distribution for the pain scores was assumed. 
These estimates were compared by log rank analysis. 
Finally, binary logistic regression and backward stepwise analysis (method Likeli-
hood Ratio; entry at 0.05 probability, removal at 0.10 probability) was performed to 
identify demographical, clinical (symptom severity) and psychological characteristics 
that predict the occurrence of visceral hypersensitivity. Age, gender, health care 
level, predominant bowel habit, post-infectious symptom onset, rectal compliance, 
symptom severity, anxiety, depression, somatic symptoms, psychoneuroticism, dys-
functional cognitions regarding functional bowel disorders, vigilance, pain coping, 
somatization, and quality of life (general health subscale) were entered in the analy-
sis as separate predictors. Data are expressed as mean ± SD. The level of significance 
was set at P<0.05.
RESULTS
Subject characteristics
We screened 130 patients, 26 of whom did not meet Rome II criteria, and 40 healthy 
volunteers. Two patients declined to participate in the barostat study, and one pa-
tient was diagnosed with conversion disorder. All healthy volunteers and 101 pa-
tients provided informed consent and were included in the final analysis. Thirty-one 
patients (31%) were recruited through the outpatient department and 70 patients 
(69%) were recruited through advertisement. All patients in the latter group had 
previously consulted a physician and had been evaluated for their abdominal symp-
toms. Healthy controls were also recruited through advertisement.
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Demographical, clinical and psychological characteristics of patients and controls 
are listed in Table 1. Mean age and male to female ratio were not different between 
groups. Symptom severity and levels of anxiety, depression, psychoneuroticism, so-
matization, other somatic symptoms, and dysfunctional cognitions were all slightly 
but significantly increased in IBS patients compared to healthy controls. Pain cop-
ing scores were significantly reduced in IBS. Compared to controls, patients had 






Age (yr) 42.0 ± 13.9 39.7 ± 15.0





Not specified/normal (controls) 8 100
Symptoms
IBS symptom score (0-20) 4.4 ± 2.5* 0.43 ± 0.57
Psychological profile
Anxiety (10-50) 13.4 ± 4.6† 12.2 ± 3.7
Depression (16-80) 22.5 ± 6.9* 20.7 ± 8.3
Somatic symptoms (12-60) 18.3 ± 5.6* 15.0 ± 3.7
Psychoneuroticism (90-450) 123.8 ± 31.9* 113.3 ± 30.7
Dysfunctional cognitions (31-217) 110.3 ± 35.8* 85.7 ± 37.3
Vigilance (0-40) 9.7 ± 5.8 7.7 ± 4.7
Pain coping (6-1) 3.4 ± 1.0† 3.7  ± 0.8
Somatization (0-2) 0.6 ± 0.4* 0.3 ± 0.3
Quality of life (0-100)
Physical functioning 82.0 ± 20.4* 94.1 ± 10.5
Role limitations-physical 60.0 ± 42.0* 87.2 ± 28.6
Bodily pain 62.1 ± 19.6* 90.3 ± 16.1
Mental health 75.2 ± 16.3 78.5 ± 13.4
Role limitations-emotional 80.8 ± 35.3 91.0 ± 26.8
Social functioning 73.2 ± 23.7* 90.9 ± 14.3
Vitality 58.5 ± 16.9* 70.8 ± 15.8
General health 61.2 ± 18.8* 75.1 ± 14.6
Score ranges from best to worst are indicated after each parameter. Data are expressed as mean ± SD. * P<0.01 versus healthy controls; 
† P < 0.05 versus healthy controls.
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impaired quality of life on 6 out of 8 SF-36 subscales. Psychological measures were 
not different between patients from the tertiary referral center and those from the 
general population (Table 2).
Rectal compliance and perception
Rectal compliance was significantly reduced in the IBS group compared to healthy 
control subjects (29.7 ± 12.6 ml/mmHg versus 41.8 ± 18.3 ml/mmHg, P<0.0001) (Fig 
1A). Subgroup analysis showed that rectal compliance was particularly reduced in 
patients with a diarrhea predominant bowel habit (IBS-D; P=0.04) and those with 
alternating bowel habit (IBS-A; P=0.05) compared to constipation predominant IBS 
(IBS-C) (Fig 1B). 
Urge perception at high rectal pressure distension (30 mmHg) was not significantly 
different between IBS patients (6.6 ± 2.7 cm) and controls (6.1 ± 2.6 cm) (P=0.30). 
The pressure-urge curves were also not significantly different between patients and 
controls (pressure by group interaction P=0.82; Fig 2). In contrast, pain perception at 
high rectal pressure was significantly increased in IBS patients compared to controls 
(2.5 ± 2.7 cm versus 1.0 ± 1.4 cm, P=0.003) and the pressure-pain curves differed 
significantly between groups (pressure by group interaction P<0.0001; Fig 3). No 
differences between IBS subgroups were found (Table 3).
Perception thresholds
Urge thresholds were reached in all participants, but were somewhat reduced in IBS 
patients (15.6 ± 6.1 mmHg) compared to controls (18.1 ± 6.0 mmHg) (P=0.042). No 
differences were found between IBS subgroups (Table 3). In contrast, only 10 of 40 
control subjects (25%) compared to 55 of 101 IBS patients (54%) reached the thresh-
old for rectal pain during balloon distension (χ2=10.01, P=0.002) (Fig 4). Maximum 
Likelihood Estimation of the mean pain threshold and SD in each group and subse-





Anxiety (10-50) 12.9 ± 3.4 13.7 ± 5.0
Depression (16-80) 22.2 ± 5.1 22.7 ± 7.6
Somatic symptoms (12-60) 18.6 ± 4.0 18.2 ± 6.3
Psychoneuroticism (90-450) 122.1 ± 22.5 124.6 ± 35.7
Dysfunctional cognitions (31-217) 109.6 ± 34.2 110.6 ± 36.7
Vigilance (0-40) 8.2 ± 4.2 10.4 ± 6.3
Pain coping (6-1) 3.5 ± 1.0 3.4  ± 1.0
Somatization (0-2) 0.7 ± 0.3 0.6 ± 0.4
Score ranges from best to worst are indicated following each parameter. Data are expressed as mean ± SD.
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quent log rank analysis showed that the threshold was significantly reduced in IBS 
patients (27.5 ± 15.1 mmHg) compared to controls (35.3 ± 8.2 mmHg) (P=0.0009), 


























































































Figure 1. Dynamic rectal compliance (ml/mmHg) in IBS patients and controls (A.) and IBS-D, IBS-C and IBS-A patients and 
controls(B.). Compliance was significantly increased in all IBS patients compared to controls and in IBS-C compared to IBS-D and IBS-A. 
Data are expressed as mean ± SEM.
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Visceral hypersensitivity
The threshold for hypersensitivity to balloon distension was set at 18.9 mmHg (35.3 
minus 16.4 mmHg). Thirty-three IBS patients (33%) compared to 0 controls were 
identified as hypersensitive to balloon distension (χ2=17.06, P<0.0001) (Table 4). 
Thus, pain thresholds fell outside the range of control subjects in approximately 1 















































Figure 2. Intensity of urge perception in 101 IBS patients (squares) and 40 controls (triangles). Urge did not differ between patients 















































Figure 3. Intensity of pain perception in 101 IBS patients (squares) and 40 controls (triangles). Pain perception was significantly 
increased in patients compared to controls (pressure by group interaction, P<0.0001).  Data are expressed as mean ± SEM.
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Predictors of visceral hypersensitivity
Of all tested variables, only IBS symptom severity remained as a predictor of vis-
ceral hypersensitivity in the logistic regression analysis (OR=1.25, 95% CI 1.04-1.50; 
P=0.016). Table 5 lists demographical, clinical and psychological characteristics in 
hypersensitive and normosensitive patients. IBS symptom scores were significantly 
higher in hypersensitive compared to normosensitive patients (5.4 ± 2.5 versus 4.0 ± 
2.4, P=0.007). No other differences were found.












27.2 ± 11 35.2 ± 14 † 26.6 ± 11 29.7 ± 13* 41.8± 18
Urge at
30 mmHg (cm)
6.5 ± 2.9 6.7 ± 2.6 6.7 ± 2.9 6.6 ± 2.7 6.1 ± 2.6
Pain at
30 mmHg (cm)
2.2 ± 2.6 2.9 ± 2.7 2.6 ± 3.0 2.5 ± 2.7* 1.0 ± 1.4
Threshold urge 
(mmHg)
16.9 ± 6.6 14.2 ± 5.6 15.6 ± 6.1 15.6 ± 6.1‡ 18.0 ± 6.0
Threshold pain 
(mmHg)
31.3 ± 18 23.6 ± 13 29.6 ± 15 27.5 ± 15* 35.3 ± 8.2
* P<0.01 compared to controls; † P<0.05 compared to IBS-D and IBS-A; ‡ P<0.05 compared to controls. Data for the group with 



























IBS     controls 
Figure 4. Individual pain thresholds in IBS patients and healthy controls. Significantly more patients (N=55, 54%) compared to 
controls (N=10, 25%) reached the pain threshold before the end of the ramp distension (dotted line, 30 mmHg).
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Table 4. Visceral hypersensitivity in IBS patients and healthy controls
Hypersensitive Normosensitive
IBS (n=101) 33 (33%)* 68 (67%)
Controls (n=40) 0 (0%) 40 (100%)
* P<0.001 compared to controls.





Age (yr) 40.7 ± 12.4 42.6 ± 14.5
Female sex (%) 73 74





Not specified/normal 3 10
Post-infectious (%) 11 13
Dynamic compliance 31.8 ± 14.9 28.6 ± 11.3
IBS composite score 5.4 ± 2.5* 4.0 ± 2.4
Dyscomfort 1.38 ± 0.8‡ 1.17± 0.62
Pain 1.34 ± 0.95† 0.98 ± 0.72
Constipation 0.73 ± 0.64† 0.37 ± 0.56
Diarrhea 0.45 ± 0.86 0.48 ± 0.69
Bloating 1.37 ± 0.79† 1.01 ± 0.75
General health 62.7 ± 16.4 60.5 ± 19.9
Anxiety 13.9 ± 5.0 13.2 ± 4.4
Depression 23.1 ± 6.5 22.3 ± 7.1
Somatic symptoms 19.0 ± 4.5 18.0 ± 6.1
Psychoneuroticism 126.5 ± 32.2 122.5 ± 32.0
Dysfunctional cognitions 106.8 ± 35.3 111.9 ± 36.1
Vigilance 9.2 ± 5.3 9.9 ± 6.1
Pain coping 3.5 ± 1.1 3.3  ± 0.9
Somatization 0.6 ± 0.4 0.6 ± 0.4
Antispasmodics (%) 15 12
Laxatives or bulking agents (%) 30 31
* P=0.007 versus normosensitive patients (range 0 (no symptoms) to 20 (worst imaginable)); † P<0.02 
versus normosensitive patients; ‡ P=0.072 versus normosensitive patients.
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DISCUSSION
The present study shows that 1) visceral hypersensitivity is an important feature of 
irritable bowel syndrome, but not present in all patients, and 2) hypersensitivity to 
rectal balloon distension is predicted by IBS symptom severity, but not by demo-
graphical or psychological characteristics.
Our data confirm previous findings that rectal compliance and pain thresholds are 
reduced and that the intensity of pain perception is increased in IBS patients when 
compared to healthy controls. Urge intensity at any given pressure was similar in 
patients and controls, with slightly lower thresholds for urge in IBS patients. Our 
observation that pain perception rather than urge is increased, is consistent with 
other reports demonstrating decreased perception thresholds in IBS only for noxious 
stimuli, and not for stool11.
It is presumed that a phasic distension protocol (i.e. rapid balloon inflation to pre-
defined pressure levels) is the preferred procedure to test visceral hypersensitivity, 
since this would elicit rectal sensations at lower volumes or pressures compared 
to slow ramp distension26,27. However, we chose to perform only ramp distensions 
because we considered rectal compliance to be an important factor in the model on 
predictors of visceral hypersensitivity, and compliance is best measured by means 
of slow ramp distension27. Phasic distensions were not performed, since assessment 
of sensory thresholds during phasic distensions after preceding ramp distension may 
introduce perceptual response bias, and phasic distensions prior to ramp disten-
sion may affect subsequent rectal compliance measurements. The pain thresholds 
we observed during ramp distension are similar to those reported by others using 
phasic distensions10,28,29, which supports previous findings that the type of distension 
procedure (phasic, ramp, etc) does not affect perception30.
One of our main findings is that hypersensitivity to balloon distension was less 
likely to occur in patients with milder symptoms. This challenges the view that vis-
ceral hyperalgesia is a biological marker of IBS11, since hypersensitivity may be absent 
in Rome II positive patients with mild symptoms. The difference in the proportion 
of hypersensitive patients between that study (95%) and ours (33%) may in part be 
due to the use of different parameters to define visceral hypersensitivity. Mertz et al. 
used 3 parameters to score rectal perception simultaneously (i.e. perception thresh-
olds, intensity of sensations and altered viscerosomatic referral), whereas we only 
identified patients having decreased pain thresholds and not those having decreased 
discomfort thresholds or altered pain referral patterns. It is, of course, essential to 
use equal definitions of visceral hypersensitivity when comparing its prevalence 
between studies. Since no accepted definition of visceral hypersensitivity is currently 
available, we decided to use a statistical point of view and consider patients with a 
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pain perception threshold ≥ 2 SD below the mean threshold in healthy controls as 
hypersensitive to rectal balloon distension. In general, this method is accepted to 
define ‘outliers’. While this cut-off is arbitrary, our data suggest that hypersensitivity 
to rectal distension is not a suitable biological marker to identify patients with IBS.
The pathophysiology of visceral hyperalgesia in IBS remains poorly understood. 
Recent evidence suggests that disturbances may occur at different levels of the brain-
gut axis. First, sensitization of peripheral nerve endings at the intestinal level may 
occur during or after acute inflammation12,13, leading to higher excitability and/or 
increased firing of these neurons. Second, some studies suggest that alterations in 
the spinal dorsal horn neurons may provide an explanation for the extended vis-
cerosomatic referral pattern that is often seen in IBS11,12. Third, altered processing 
of afferent visceral information in the brain, particularly in the prefrontal cortex, 
anterior cingulated cortex, and thalamus, has repeatedly been demonstrated in IBS 
patients15,31. These regions are not only involved in pain processing but are also part 
of the emotional limbic system and are therefore involved in numerous psychologi-
cal and cognitive events16,17. Since nociception (becoming aware of a painful stimu-
lus) and emotional pain management both occur in similar regions of the brain, we 
hypothesized that psychological disturbances are related to visceral hypersensitivity. 
However, our results do not support this hypothesis, as none of the psychological 
variables we studied predicted the occurrence of hypersensitivity to balloon disten-
sion. These findings substantiate previous observations that psychological charac-
teristics as anxiety, somatization, and neuroticism do not correlate with sensory 
thresholds9,11,19. Similar results were obtained in recent study, in which multivariate 
analysis demonstrated that abdominal pain and bloating were significantly associated 
with altered rectal perception whereas psychological symptoms were not32. Our data 
also show that rectal hyperalgesia is not associated with other psychological fac-
tors (vigilance, dysfunctional cognitions, pain coping), demographical characteristics 
(age, gender), quality of life, or predominant bowel habit.
Previously Whitehead et al. proposed a model for psychological factors that influ-
ence pain perception in IBS33. It was suggested that low pain thresholds in IBS are 
influenced by two related cognitive traits, i.e. selective attention to gut sensations 
and a tendency to interpret these sensations as symptoms of disease. Our data 
show that neither vigilance (selective somatic attention) nor cognitions regarding 
functional bowel disorders (interpretation of normal sensations as symptoms of dis-
ease) were different between hypersensitive and normosensitive IBS patients. These 
findings suggest that hypersensitive patients do not perceive or manage their symp-
toms differently from normosensitive patients. Although vigilance and cognitions on 
functional bowel disorders differed significantly between patients and controls, these 
parameters were not associated with increased rectal sensitivity.
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We aimed to obtain a representative sample from the IBS population by recruiting 
patients both from the outpatient clinic and by advertisement. Levels of psycho-
logical distress were low and did not differ significantly between groups. One may 
argue that low levels of psychopathology explain why we found no correlation 
between psychological variables and visceral hypersensitivity, since a certain degree 
of parameter variability is required for correlations to be detected. Although some 
studies found significantly more psychological disturbances in IBS patients recruited 
from tertiary care18,19,34, one of these studies found no relation between psychologi-
cal distress and visceral hypersensitivity in clinic patients with IBS19, supporting our 
finding that visceral hypersensitivity is not affected by psychopathology, regardless 
of level of health care.
Allowing patients to take antispasmodics, laxatives and, occasionally, analgesics 
during barostat measurements is a limitation of this study as it may interfere with vis-
ceral sensitivity and affect sensory thresholds in general. While use of these medica-
tions was similar in hypersensitive and normosensitive patients (Table 5), prohibiting 
the use of these medications may have further increased the number of patients with 
hypersensitivity to balloon distension in both groups.
In conclusion, we found that patients with IBS have impaired rectal compliance 
and reduced sensory thresholds to rectal distension compared to controls. Visceral 
hypersensitivity is present in one third of our IBS population and is associated with 
increased symptom severity. Although psychological parameters do not predict the 
occurrence of visceral hypersensitivity, this does not exclude a common neuropsy-
chological basis in the pathophysiology of IBS. Future studies should focus on the 
role of the brain-gut axis in the development of irritable bowel syndrome. 
ACkNOWLEDGEMENTS
We thank Saskia le Cessie of the Department of Medical Statistics for statistical advice 
and our colleagues at the Department of Gastroenterology and Hepatology for as-
sistance in the barostat measurements.
101Predictors of visceral hypersensitivity in IBS
REFERENCES
 1. Thompson WG, Longstreth GF, Drossman DA et al. Functional bowel disorders and func-
tional abdominal pain. Gut 1999;45  Suppl 2:II43-II47.
 2. Chey WY, Jin HO, Lee MH et al. Colonic motility abnormality in patients with irritable bowel 
syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 2001;96:1499-506.
 3. Aggarwal A, Cutts TF, Abell TL et al. Predominant symptoms in irritable bowel syndrome cor-
relate with specific autonomic nervous system abnormalities. Gastroenterology 1994;106:945-
50.
 4. Van der Veek PP, Swenne CA, Van de Vooren CA, et al.Viscerosensory-cardiovascular reflexes: 
altered baroflex sensitity in irritable bowel syndrome. Am J Physiol  2005;289:R970-6.
 5. Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastro-
enteritis: cohort study. BMJ 1999;318:565-6.
 6. Gwee KA, Collins SM, Read NW et al. Increased rectal mucosal expression of interleukin 
1beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003;52:523-6.
 7. Gonsalkorale WM, Perrey C, Pravica V et al. Interleukin 10 genotypes in irritable bowel 
syndrome: evidence for an inflammatory component? Gut 2003;52:91-3.
 8. Van der Veek PP, van den Berg M, Kroon YE, et al. Role of tumor necrosis factor-alpha 
and interleukin-10 gene polymorphisms in irritable bowel syndome. Am J Gastroenterol 
2005;100:2510-6.
 9. Whitehead WE, Holtkotter B, Enck P et al. Tolerance for rectosigmoid distention in irritable 
bowel syndrome. Gastroenterology 1990;98:1187-92.
 10. Bouin M, Plourde V, Boivin M et al. Rectal distention testing in patients with irritable bowel 
syndrome: Sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroen-
terology 2002;122:1771-7.
 11. Mertz H, Naliboff B, Munakata J et al. Altered rectal perception is a biological marker of 
patients with irritable bowel syndrome. Gastroenterology 1995;109:40-52.
 12. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 
1994;107:271-93.
 13. Olivar T, Cervero F, Laird JM. Responses of rat spinal neurones to natural and electrical 
stimulation of colonic afferents: effect of inflammation. Brain Res 2000;866:168-77.
 14. Verne GN, Himes NC, Robinson ME et al. Central representation of visceral and cutaneous 
hypersensitivity in the irritable bowel syndrome. Pain 2003;103:99-110.
 15. Silverman DH, Munakata JA, Ennes H et al. Regional cerebral activity in normal and patho-
logical perception of visceral pain. Gastroenterology 1997;112:64-72.
 16. Bishop S, Duncan J, Brett M et al. Prefrontal cortical function and anxiety: controlling atten-
tion to threat-related stimuli. Nat Neurosci 2004;7:184-8.
 17. Bush G, Luu P, Posner MI. Cognitive and emotional influences in anterior cingulate cortex. 
Trends Cogn Sci 2000;4:215-22.
 18. Drossman DA, McKee DC, Sandler RS et al. Psychosocial factors in the irritable bowel syn-
drome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gas-
troenterology 1988;95:701-8.
 19. Guthrie E,  Creed F, Fernandez L, Ratcliffe J, Van der Jagt J, Martin J, Howlett S, Read N, Bar-
low J, Thompson D, Tomenson B. Cluster analysis of symptoms and health seeking behaviour 
differentiates subgroups of patients with severe irritable bowel syndrome. Gut 2003;52:1616-
22.
 20. Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Inter-
view (M.I.N.I.): the development and validation of a structured diagnostic psychiatric inter-
view for DSM-IV and ICD-10. J Clin Psychiatry 1998;59 Suppl 20:22-33.
102 Chapter 6
 21. Derogatis LR, Rickels K, Rock AF. The SCL-90 and the MMPI: a step in the validation of a new 
self-report scale. Br J Psychiatry 1976;128:280-9.
 22. Dahlstrom GW, Welsh G.S., Dahlstrom L.E. An MMPI handbook. Volume I: clinical interpreta-
tion. Minneapolis: University of Minnesota Free Press, 1972.
 23. Speckens AE, Spinhoven P, Sloekers PP et al. A validation study of the Whitely Index, the 
Illness Attitude Scales, and the Somatosensory Amplification Scale in general medical and 
general practice patients. J Psychosom Res 1996;40:95-104.
 24. Toner BB, Stuckless N, Ali A et al. The development of a cognitive scale for functional bowel 
disorders. Psychosom Med 1998;60:492-7.
 25. Brazier JE, Harper R, Jones NM et al. Validating the SF-36 health survey questionnaire: new 
outcome measure for primary care. BMJ 1992;305:160-4.
 26. Sun WM, Read NW, Prior A et al. Sensory and motor responses to rectal distention vary ac-
cording to rate and pattern of balloon inflation. Gastroenterology 1990;99:1008-15.
 27. Whitehead WE, Delvaux M. Standardization of barostat procedures for testing smooth muscle 
tone and sensory thresholds in the gastrointestinal tract. The Working Team of Glaxo-Well-
come Research, UK. Dig Dis Sci 1997;42:223-41.
 28. Chang L, Munakata J, Mayer EA, et al. Perceptual responses in patients with inflammatory 
bowel disease. Gut 2000;47:497-505.
 29. Naliboff BD, Munakata J, Fullerton  S, et al. Evidence for two distinct perceptual alterations 
in irritable bowel syndrome. Gut 1997;41:505-12.
 30. Hammer HF, Phillips SF, Camilleri M et al. Rectal tone, distensibility, and perception: repro-
ducibility and response to different distensions. Am J Physiol 1998;274:G584-G90.
 31. Ringel Y, Drossman DA, Turkington TG et al. Regional brain activation in response to rectal 
distension in patients with irritable bowel syndrome and the effect of a history of abuse. Dig 
Dis Sci 2003;48:1774-81.
 32. Posserud I, Syrous A, Lindström L, et al. Altered rectal perception in irritable bowel syndrome 
is associated with symptom severity. Gastroenterology 2007;133:1113-23.
 33. Whitehead WE, Palsson OS. Is rectal pain sensitivity a biological marker for irritable bowel 
syndrome: psychological influences on pain perception. Gastroenterology 1998;115:1263-71.
 34. Longstreth GF, Hawkey CJ, Mayer EA et al. Characteristics of patients with irritable bowel 
syndrome recruited from three sources: implications for clinical trials. Aliment Pharmacol 
Ther 2001;15:959-64. 
7
SHORT AND LONG TERM 
BENEFIT OF RELAXATION 
TRAINING FOR IRRITABLE 
BOWEL SYNDROME
Patrick P.J. van der Veek1, Yanda R. van Rood2, and Ad 
A.M. Masclee1
Departments of 1Gastroenterology and Hepatology and 
2Psychiatry, Leiden University Medical Center, Leiden, The 
Netherlands
Aliment Pharmacol Ther 2007;26:943-52
104 Chapter 7
ABSTRACT
Background: Psychotherapy is effective in treating Irritable Bowel Syndrome (IBS), 
but the effect of relaxation training (RT), a brief psychological group intervention, 
is not known. 
Aim: To determine the efficacy of RT in a large cohort of IBS-patients. 
Methods: Ninety-eight IBS-patients were included in this randomized controlled trial. 
Forty-six patients received standard medical care (CON) and 52 received four 90-
minute sessions of RT in small groups in addition to standard medical care. IBS 
symptom severity, medical consumption and quality of life were assessed at baseline 
in patients and in 38 healthy controls and evaluated in patients at 3, 6 and 12 months 
after intervention. 
Results: IBS symptom severity was significantly reduced in the RT group compared to 
CON at 3, 6 and 12 months after treatment (time by treatment interaction, P=0.002). 
The number needed to treat for long term improvement was 5. Quality of life was 
improved (General Health, P=0.017; Health Change, P=0.05). Frequency of doctor 
visits was reduced (P=0.039). 
Conclusion: Relaxation training is a brief group intervention that significantly im-
proves symptom severity, general health perception and medical consumption in IBS 
patients immediately after, as well as 6 and 12 months after intervention. 
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INTRODUCTION
Irritable Bowel Syndrome (IBS), a frequently occurring functional bowel disorder, 
is characterized by recurrent abdominal discomfort or pain accompanied by altered 
bowel habits1. IBS has considerable economic impact2, accounting for total annual 
direct costs of £ 45.6 million on average in the United Kingdom3. In the Netherlands, 
health care utilization and absence from work in IBS patients is approximately twice 
that of the general population4. 
Since curative treatment is currently not available5, therapeutic interventions are 
directed against predominating symptoms. These interventions include antispasmod-
ics, laxatives or antidiarrhoeals in addition to patient education, reassurance, and 
dietary advice6. Novel therapies focus on serotonergic and psychotropic agents, but 
therapeutic gain is at best restricted to subgroups of patients7-10. In addition to phar-
macotherapy, efficacy of psychological interventions such as cognitive behavioural 
therapy, dynamic psychotherapy and hypnotherapy has been demonstrated in a 
number of studies11-15. Most of these interventions, however, require multiple ses-
sions in individual patients and are therefore time-consuming and expensive. 
Relaxation training (RT) is a brief psychological intervention that can not only be 
provided to individuals, but also to groups of patients. Most forms of psychotherapy 
incorporate a relaxation technique, but sound data on the efficacy of RT as solitary 
treatment for IBS are lacking16. Two studies on the efficacy of RT in IBS provided 
promising results but had methodological limitations (small patient number, high 
drop-out rate)17-18. We conducted a randomized controlled trial to determine short 
and long-term efficacy of group RT, when added to standard medical care (CON), in 
a large cohort of IBS patients.
MATERIALS AND METHODS
Patients
Between March 2001 and July 2002, IBS patients between 18 and 65 years of age 
were invited to participate. To obtain a representative sample from the IBS popula-
tion, patients were recruited both through the outpatient Department of Gastroenter-
ology and Hepatology of the Leiden University Medical Centre (LUMC) and through 
advertisement in a local newspaper. All eligible patients were screened by one of 
the investigators (PvdV) to confirm that each participant met Rome II criteria for 
IBS1. Exclusion criteria were presence of any organic disease (particularly inflamma-
tory bowel disease and thyroid disease), previous abdominal surgery (except chole-
cystectomy and appendectomy), pregnancy and dependence on analgesics. Use 
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of antispasmodics, laxatives, bulking agents and occasional use of analgesics was 
permitted. The Mini International Neuropsychiatric Interview (Dutch version 5.0.0)19 
was used to exclude patients with psychotic disorder, substance use disorder or risk 
of suicide. Thirty-eight age and sex-matched healthy volunteers were included for 
baseline comparisons. Informed consent was obtained from each participant. The 
study protocol was approved by the LUMC ethics committee.
Study design
Randomization
This study was designed and conducted as a randomized controlled trial. To guaran-
tee participation of 5 patients per RT group, block wise randomization was carried 
out in 10 patients using sealed envelopes by a co-worker who was not involved in 
the study. The day and time of treatment was decided on the agenda of the trainers, 
not of the patients. Patients randomized to RT, who were unable to attend all sched-
uled sessions, were asked to participate in the subsequent RT group. If this was not 
possible, they were replaced by a patient from the control group (CON) who was not 
yet informed about the randomization results. This procedure was also performed by 
the same co-worker (Fig 1).
Patient characteristics
Baseline demographics, clinical characteristics and quality of life were assessed in 
patients and in healthy volunteers. To further characterize the patient group, levels 
of anxiety, depression, somatic symptoms and psychoneuroticism were measured 
in patients and healthy controls using the Symptom Checklist 9020. The presence of 
dysfunctional IBS related cognitions was assessed by the Cognitive Scale for Func-
tional Bowel Disorders21.
Intervention
During the screening visit, all patients received information on gut function in IBS. 
The physician provided a positive diagnosis for IBS with explanation and a rationale 
for the specific symptoms. In the control treatment arm patients were instructed 
to have, upon request and for the duration of the study, free access to specialized 
gastroenterological care including symptom-oriented pharmacotherapy. No attempt 
was made to control for contact time between therapist and patient in the control 
versus the RT arm. The primary aim was to make the control condition credible, 
plausible and acceptable for the patient. Patients in the RT group were also allowed 
free access to specialized gastroenterological care and pharmacotherapy.




 130 met Rome II criteria for IBS
25 declined to give 
informed consent 
105 randomized to relaxation 
training + standard medical care 
(RT, N=54) or standard medical 
care alone (CON) N=51) 
1 psychiatric illness 
1 organic disease 














13 unable to attend 5 sessions 
included in control group, 13 
from control group randomly 
relocated to RT group 
Figure 1. Patient flow during randomisation and number of patients during each phase of the study
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A treatment group of 5 or 6 patients was guided by one of three experienced thera-
pists and one of two trainees. Two of three therapists were professional cognitive 
behavioural therapists and one had nearly finished training. They co-operated with 
the trainees, who were postgraduate psychologists. Before RT commenced, trainers 
met each patient individually for 45 minutes to get acquainted to one another and 
to explain the treatment rationale. Briefly, the therapists explained to patients that 
abdominal pain involuntarily induces muscle tension. Chronic muscle tension not only 
maintains abdominal pain, but can also lead to other IBS-associated symptoms, such 
as borborygmi, indigestion and bloating. By applying relaxation techniques, patients 
should be able to counteract chronic muscle tension and subsequently experience 
symptom relief. 
RT consisted of weekly 90-min sessions for 4 weeks and one booster session after 
3 months. Exercises were audiotaped to facilitate home practice. Training was given 
according to a written treatment protocol (available on request). Training sessions 
focused on 1) recognition of muscle tension (progressive relaxation technique), 2) 
relaxation of muscles (suggestive relaxation technique) combined with breathing re-
training, as most IBS patients show evidence of breathing pattern disorders, 3) teach-
ing the patient to elicit a quick relaxation response by prompt recognition of muscle 
tension and subsequent relaxation, and 4) implementation into daily life. In the 
booster session, patients shared their experiences and were encouraged to continue 
using relaxation techniques. All sessions were videotaped and reviewed to monitor 
therapists’ adherence to the treatment protocol. Before randomization, all patients 
were informed through the consent form that they would be randomized to either 
RT or standard medical care (CON). On request, patients were notified that, when 
randomized to standard treatment alone, it would be possible to receive RT after 
ending of the trial, but only if the efficacy of RT for IBS had been demonstrated.
Outcome measures
Patients used a symptom diary card to rate the severity of abdominal discomfort, 
abdominal pain, constipation, diarrhoea, bloating, as well as overall symptom se-
verity, daily for 14 days, on a 5-point Likert scale (0 = no symptoms, 1 = mild, 2 = 
moderate, 3 = severe, 4 = very severe symptoms). The primary outcome measure 
was the IBS composite score, computed as the sum of the 14-day mean scores for 
abdominal pain, discomfort, constipation, diarrhoea and bloating (score range 0-20). 
Secondary outcome measures were: the number of symptom-free days (i.e. overall 
symptom rating is zero) (score range 0-14); overall symptom rating (i.e., the severity 
of all symptoms rated together rather than each symptom separately; score range 
0-4); quality of life (SF-36)22; and medical consumption defined by 1) the number of 
doctor visits in the previous 3 months and 2) the number of analgesics and laxatives/ 
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antidiarrhoeals used in the previous 14 days. All outcome measures were evaluated 
at baseline and 3, 6 and 12 months after RT.
Missing data
In case certain questions in the SCL-90 were not answered, subscales of anxiety, de-
pression, somatic symptoms or psychoneuroticism could not be calculated and were 
regarded as missing. In these cases subscale scores were calculated as ((observed 
score x the number of scale items) / (the number of scale items - number of missing 
items)). The same approach was used for missing items on subscales of the SF-36 
and the Cognitive Scale for Functional Bowel Disorders. The statistical package dealt 
with missing subscale scores for all primary and secondary outcome parameters by 
inserting the mean score of the other patients for that parameter.
Statistical analysis
We aimed to enrol fifty patients per treatment arm, based on: 1) 20 % difference in 
improvement in IBS composite score (RT versus CON) one year after therapy, which 
we considered clinically relevant; 2) power of 0.80 and standard deviation of the 
relative improvement of 47%, based on previous studies by our group, and 3) 20% 
dropout rate.
Patients’ baseline scores were compared to scores in healthy volunteers by one-
way analysis of variance (ANOVA). Treatment efficacy with respect to primary and 
secondary outcome measures was assessed by a mixed model analysis (SPSS for 
Windows, 11.0). Patients who had missing data were not excluded from the analysis 
(see above). Confounders of baseline IBS composite scores, time, treatment con-
dition (i.e., relaxation training versus standard treatment) and time by treatment 
interaction were all analyzed as separate contributors to the model. Patient numbers 
were used as indicator for repeated measurements.
Responders to therapy were identified using Jacobson and Truax’ criteria for ‘clini-
cal significant change’ on the IBS composite score23. This change, defined as the 
extent to which treatment puts an individual outside the range of the patient popula-
tion or within the range of the non-patient population, was determined by calcula-
tion of a reliable change index (RC). This is the difference between pre- and post-
test scores divided by the standard error of the difference. An RC larger than 1.96 
indicates true change in post-test versus pre-test scores. Differences in responder 
versus non-responder distributions between groups were calculated by chi-square 
analysis. Binary logistic regression was used to determine which of the following 
demographical, clinical and psychological variables could predict therapy success: 
age, sex, recruitment strategy (outpatient clinic or advertisement), IBS subgroup 
(diarrhoea, constipation, alternating type), treatment (relaxation or standard medical 
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care), general health (SF-36), anxiety (SCL-90), depression (SCL-90), somatisation 
(SCL-90), psychoneuroticism (SCL-90), dysfunctional cognitions (Cognitive Scale for 
Functional Bowel Disorders), frequency of doctor visits, frequency of analgesic use.
We assessed the efficacy of RT by an intention-to-treat analysis. Data are expressed 
as mean ± SEM. The level of significance is set at P<0.05.
RESULTS
Patients’ characteristics
We screened 130 patients of whom 105 provided informed consent. Fifty-four patients 
were randomized to RT and 51 patients to CON (Fig 1). Seven patients were excluded 
from the analysis: 1 patient had conversion disorder (diagnosed during the individual 
session with the therapist), 1 patient had ulcerative colitis (diagnosed after randomiza-
tion), and 5 patients did not return any of the symptom diaries. Ninety-eight patients 
were included in the final analysis (RT group, 52; CON group, 46). Sixty-eight patients 
were recruited through advertisement and 30 through the outpatient department. 
Some patients did not return 1 or 2 symptom diaries during follow-up, despite regular 
reminders by telephone to do so (n=9 at 3 months, n=9 at 6 months, n=15 at 12 
months, Fig 1). These patients were included in the final analysis (see Missing data). 
Thirteen patients who were randomized to RT were unable to attend treatment ses-
sions (mostly due to other obligations such as work) and were included in the CON 
group. These patients were replaced by 13 patients in the CON group (see above).
Table 1 lists baseline demographical and clinical characteristics of both treatment 
groups and healthy controls. IBS patients had higher symptom scores, impaired quality 
of life on 6 out of 8 SF-36 subscales, more IBS related dysfunctional cognitions and 
higher medical consumption. Levels of anxiety and depression did not differ. Baseline 
IBS composite scores were higher in patients recruited through the outpatient clinic ver-
sus patients recruited through advertisement (5.50 ± 0.4 versus 3.85 ± 0.3, P=0.002).
Intention-to-treat analysis
Primary outcome: IBS composite score
IBS composite scores showed a significantly larger reduction in patients who re-
ceived RT compared to patients who received standard medical care (CON) (time 
by treatment interaction, P=0.002; Fig 2). Although baseline composite scores were 
higher in hospital-recruited patients compared to advertisement-recruited patients, 
the time-by-treatment interaction remained significant after correction for recruit-
ment (P=0.002).
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Age (yr) 42.9 ± 1.9 41.7 ± 2.1 39.7 ± 2.4
Female sex (%) 75 72 63
Ethnicity (% Caucasian) 96 89 95
Employment (%) 64 61 -*
Married (%) 84† 70 61
Children (%) 61 52 58
Alcohol use (%) 70 78 94
Current smoking (%) 20 39† 13
Recruitment (% advertisement) 69 70 100
Bowel habit (%)
Diarrhoea 36 30 0
Constipation 25 48 0
Alternating 31 15 0
Normal or not specified 8 7 100
IBS symptoms 
IBS symptom severity score (0-20) 4.32 ± 0.3 4.41 ± 0.4 0.43 ± 0.1 †
N of symptom free days (0-14) 2.31 ± 0.4 3.02 ± 0.6 0.89 ± 0.3 †
Overall symptom rating (0-4) 1.29 ± 0.1 1.32 ± 0.1 0.13 ± 0.0 †
Psychological profile
Anxiety (10-50)‡ 13.2 ± 0.6 13.8 ± 0.7 12.2 ± 0.6
Depression (16-80)‡ 21.6 ± 0.8 23.6 ± 1.2 20.7 ± 1.4
Somatic symptoms (12-60)‡ 17.8 ± 0.7 19.0 ± 0.9 15.0 ± 0.6 †
Psychoneuroticism (90-450)‡ 119.8 ± 3.8 128.0 ± 5.4 113.3 ± 5.1
Dysfunctional cognitions (31-217)§ 108.1 ± 5.1 111.9 ± 5.1 85.6 ± 6.3 †
Quality of life (0-100) **
Physical functioning 84.2 ± 2.6 79.3 ± 3.3 94.1 ± 1.7 †
Role limitations-physical 58.2 ± 6.0 63.3 ± 6.0 87.2 ± 4.7 †
Bodily pain 63.2 ± 2.6 60.5 ± 3.1 90.3 ± 2.6 †
Mental health 77.3 ± 2.1 73.0 ± 2.6 78.5 ± 2.2
Role limitations-emotional 85.6 ± 4.4 77.0 ± 5.6 91.0 ± 4.4
Social functioning 78.8 ± 2.7 67.1 ± 3.9 90.9 ± 2.4 †
Vitality 61.3 ± 2.2 55.8 ± 2.7 70.8 ± 2.6 †
General health 61.3 ± 2.7 61.6 ± 2.7 75.1 ± 2.4 †
Health change 52.9 ± 3.0 49.5 ± 3.3 53.5 ± 2.5
Medical consumption
Doctor visits (n/3 months) 1.6 ± 0.1 1.7 ± 0.1 0.7 ± 0.1 †
Analgesics (n/14 days) 2.4 ± 0.7 2.1 ± 0.5 0.6 ± 0.2 
Laxative/antidiarrhoeal (n/14 days) 5.4 ± 1.3 4.7 ± 1.2 0.0 ± 0.0 † 
Data are presented as mean ± standard error. Numbers in parentheses indicate the range of possible scores for a particular item, with the 
lower number indicating the best possible score and the higher number indicating the worst possible score. * unknown; † P<0.01 versus 




The number of days without any symptoms (i.e. overall symptom rating was zero) 
increased significantly more in RT versus CON (time-by-treatment interaction, 


































































































 Figure 3. Number of symptom-free days (per 14 days) after 3, 6 and 12 months follow-up in the RT and CON group (time by 
treatment interaction, P=0.027).
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ment in patients who received RT compared to CON (time-by-treatment interaction, 
P=0.021; data not shown).
Patients in the RT group showed significantly more improvement on the SF-36 
General Health (P=0.017) (Fig 4A) and Health Change subscales (P=0.05, Fig 4B). 







































































































Figure 4. (A.) General Health score (SF-36) after 3, 6 and 12 months follow-up in the RT and CON group (time by treatment 
interaction, P=0.017). (B.) Health Change score (SF-36) after 3, 6 and 12 months follow-up in the RT and CON group (time by 
treatment interaction, P=0.05).
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(data not shown). Table 2 shows that time by treatment interaction was significant 
for the number of doctor visits (P=0.039), indicating that patients in the RT group 
visited their physician less frequently than patients in the CON group. This differ-
ence was most pronounced at 12 months post-treatment. No differences were found 
between the RT and CON groups regarding use of medication.
Response to therapy
According to the Jacobson and Truax’ criteria, 8 treated patients (17%) versus 1 
control (2%) were significantly improved at 3 months after therapy (P=0.026); 8 
treated patients (17%) versus 0 controls were significantly improved at 6 months 
(P=0.007) and 10 treated patients (23%) versus 1 control (3%) were significantly 
improved one year after therapy (P=0.009). The number needed to treat (NNT) for 
long-term improvement was 5 (95% confidence interval (CI) 3.0-15.2). Responders at 
1-year follow-up showed similar levels of baseline anxiety (13.4 ± 5.1, range 10-50) 
as non-responders (12.4 ± 2.6; P=0.41). Binary logistic regression revealed that of all 
tested demographical, clinical and psychological variables, only treatment condition 
predicted therapy success (P=0.04). Within the RT group, pre-treatment symptom se-
verity was significantly higher in 12-month responders compared to non-responders 
(6.90 ± 0.8 versus 3.61 ± 0.3, P<0.001).
DISCUSSION
This is the first randomized controlled trial that has assessed the long-term effect of 
group-based relaxation training on symptoms and quality of life in a large cohort of 
Table 2. Medical consumption
Month of study
Measure baseline 3 6 12 P-value*
Doctor visits†
relaxation 1.6 ± 0.1 2.0 ± 0.2 1.6 ± 0.2 1.4 ± 0.2
0.039
standard medical care 1.7 ± 0.1 1.9 ± 0.3 1.4 ± 0.2 2.0 ± 0.3
Analgesics ‡
relaxation 2.4 ± 0.7 2.0 ± 0.7 2.5 ± 0.9 2.7 ± 0.9
0.464
standard medical care 2.1 ± 0.5 1.6 ± 0.5 1.2 ± 0.4 1.9 ± 0.5
Laxatives/antidiarrhoeals ‡
relaxation 5.4 ± 1.3 3.7 ± 1.1 2.6 ± 0.9 3.2 ± 1.0
0.496
standard medical care 4.7 ± 1.2 3.4 ± 0.9 2.5 ± 0.8 4.0 ± 1.2
Data are presented as mean ± standard error. * P-value for time by treatment interaction; † number of doctor visits per 3 months; 
‡ number of tablets per 14 days.
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IBS patients. This study shows that RT leads to significant symptom improvement, 
comparable to symptom reduction obtained with more comprehensive psychothera-
pies11-13,18,26. For example, Creed et al. found that 15 months after psychodynamic in-
terpersonal therapy, which consisted of 8 individual sessions, typical IBS pain scores 
showed approximately 20% reduction11. Boyce et al. found that after 1 year, bowel 
symptom severity was reduced by 21% in IBS patients who received RT (8 individual 
sessions) and by 19% in patients who received cognitive behavioural therapy (8 
individual sessions)18. In both trials, symptom reduction was similar between the 
treatment group and the group receiving routine clinical care. Our results show that 
12 months after five group sessions of RT, IBS composite scores had dropped 34% in 
the RT group and 12% in the CON group, i.e. a difference of 22%. 
Our study extends preliminary data and provides evidence for the efficacy of 
relaxation training in treating IBS. The first explorative study on this topic suggested 
that symptom reduction 4 weeks after RT was greater in patients who received treat-
ment (n=8) compared to control patients who only monitored symptoms (n=8)17. In 
our study, symptom improvement increased over time in patients who received RT 
and was most pronounced after 12 months follow-up, the endpoint of this study. 
It is unlikely that this increase resulted from symptom fluctuation (a key feature of 
IBS), because symptom severity remained unchanged in the CON group. In our 
opinion, routine use of relaxation techniques in daily life, embedded in a clear 
rationale, provides patients with a useful tool to cope with their symptoms, and this 
may have a crucial role in the continuation of symptom improvement. The rationale 
for treatment that was provided to patients may also have contributed to patient 
compliance in our study: only 16 of 98 patients were lost to long-term follow-up. In 
a recently published trial, dropout was over 50%, which possibly explains why this 
study did not find greater efficacy for either relaxation training or cognitive behav-
ioural therapy versus routine clinical care in IBS18. Although some of our patients 
were sceptical towards the concept of RT as treatment for IBS, all were enthusiastic 
once the rationale had been clarified.
We acknowledge that inclusion of patients in the CON group who were initially 
randomized to RT but were unable to attend the scheduled training sessions, may 
have introduced selection bias. Additional analyses, in which these patients were in-
cluded in the RT group (RT, n=65; CON, n=33), showed similar results for reduction 
in IBS composite score, overall symptom rating and gain in number of symptom-free 
days compared to the primary analysis, but statistical significance was not reached 
(data not shown). In our opinion, this is not surprising as 13 of 65 ‘RT’ patients 
(20%) in this analysis did not receive treatment. When these 13 patients were ex-
cluded from the analysis (RT, n=52; CON, n=33), which has been recommended by 
some authors25, the IBS composite score was significantly reduced in the RT group 
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compared to CON (data not shown), suggesting that RT is indeed beneficial in IBS 
patients who are treated with RT. Since demographical, clinical and psychological 
characteristics did not differ between these 13 patients and other patients (data not 
shown), we believe that adding these patients to the control group (which remained 
stable during the one year follow-up) did not change outcome in this group.
Whereas some trials included only referred patients11, we recruited Rome II-positive 
patients from both the hospital and from the general population, i.e. not only those 
who seek health care. This strategy was chosen to avoid selection bias, because pa-
tients who seek health care represent only a minority of the entire IBS population27, 
and symptoms in this subgroup are usually more severe24,28. However, inclusion of 
patients with mild symptom severity may also complicate the interpretation of our 
results, as less improvement can be expected in this group. Although no additional 
analysis was performed, it is likely that patients with high symptom severity benefit 
most from RT simply because their symptom scores can decrease more than low 
baseline symptom scores. However, our primary finding that, on average, a mixed 
group of IBS patients having both severe and mild symptoms profits from RT further 
highlights the potential benefit of this therapy in an individual patient. 
We aimed for a reliable distinction between responders and non-responders and 
therefore used the strict Jacobson and Truax criteria to measure clinical significant 
improvement23 in IBS composite score. It is clinically relevant to use outcome mea-
sures that represent symptom improvement, since this is the primary outcome of 
interest in IBS16. Most trials have used such endpoints, for instance overall symptom 
rating15 and symptom reduction scores11,17, although some investigators used other 
outcome measures such as satisfaction with treatment12. According to the Jacobson 
and Truax criteria, significantly more treated patients (23%) than controls (3%) were 
improved 12 months after therapy. However, the reliable change index (RC) that 
was utilized to define responders is in part dependent on pre-treatment score as it is 
calculated by the difference between pre- and post-treatment scores divided by the 
standard error of the difference in the whole group. As a consequence, significant 
improvement could not be measured in 12 patients in the CON group and 15 in 
the RT group due to low pre-treatment scores (data not shown). The higher pre-
treatment symptom severity we found in the responder group is therefore associated 
with the definition of responder according to the Jacobson and Truax criteria. This 
may underestimate true improvement.
A limitation of our study is the comparison of RT to a standard medical care 
control group. We cannot exclude that the efficacy of RT is the result of non-specific 
therapy factors, such as attention and support. A number of control interventions 
are available for comparison with psychological treatment, but not all of them are 
appropriate25. For instance, a waiting list control group, in which patients do not 
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receive any treatment until the trial ends, may generate negative expectations with 
respect to symptom improvement, and these patients may be less inclined to report 
improvement25. Furthermore, the use of a placebo pill might discourage patients 
who are interested in trying behavioural intervention to participate, while most IBS 
patients have already tried several drugs to improve their symptoms, without the 
expected results25.
We are aware that therapist attention and support might contribute to a positive 
effect of RT. This may explain the difference in doctor visits between the two groups, 
since patients in the control group had no additional scheduled interactions whereas 
patients in the RT group did. Yet, we did not control for this because RT is a minimal 
intervention and contains elements of patient education as part of the treatment. It 
is likely that an intervention controlling for attention and support also contains these 
elements and thereby resembles RT. Controlling for the amount of contact time (5 
times 90 minutes in this study) by employing an inert patient-therapist interaction 
may create an artificial situation. This may further increase the likelihood that patient 
education or some other form of IBS-related support takes place.
Although using standard medical care as a control intervention has methodological 
restrictions, such as creating a negative expectation with respect to improvement 
when assigned to ‘more of the same treatment’, we expected this effect to be less 
prominent than in the case of a waiting list control group. Nevertheless, informing 
these patients that they would not receive any other but their present treatment 
makes symptom improvement in this group less probable. This may have amplified 
the differences between treated patients and controls. We attempted to minimize the 
possible effects of non-specific therapy factors, such as attention and support, by 
providing highly structured training sessions to patients in the RT group. In addi-
tion, all patients in the CON group had free access to medical support from a senior 
gastroenterologist during the trial period, allowing patients in this group to receive 
the attention and support they demanded, while we were able to monitor medical 
consumption. In general, our main objective was to determine the efficacy of group 
RT as such, inspired by a previous smaller pilot study17, rather than to assess in detail 
which aspect of RT is responsible for its beneficial effect (i.e., relaxation, attention, 
support, group dynamics, etc.). 
Finally, it is important to recognize that standard medical care, which was pro-
vided to all patients, is essential in treating IBS and cannot be replaced by relaxation 
training alone. Dietary advice, which is considered the mainstay in IBS treatment, 
may improve symptoms considerably, especially in patients who report symptom 
deterioration after a meal. Evidence suggests that some dietary components, such 
as dairy products and cereals, are involved in abnormal colonic fermentation and 
increased colonic gas production, leading to postprandial symptom worsening29. 
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Furthermore, patient education on the natural course and prognosis of IBS and 
reassurance with respect to the benign character of IBS symptoms are also essential. 
These are hallmarks in present-day treatment of IBS and should not be left out.
In conclusion, our study has demonstrated short and long term beneficial effects 
of RT compared to standard medical treatment, which highlights this treatment as a 
promising intervention for IBS. RT reduces symptom severity, increases the number 
of symptom-free days and improves general health satisfaction immediately after 
therapy. Symptom improvement increases over time until at least 12 months after RT. 
Patient selection may be important since those patients with high symptom severity 
are likely to benefit most from RT. The efficacy of RT compared to sham intervention 
remains to be clarified, but the cost-effectiveness of RT compared to other psycho-
logical therapies for IBS deserves further evaluation.
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Background: The pathogenesis of irritable bowel syndrome (IBS) is probably mul-
tifactorial with dysfunction at different levels of the brain-gut axis. The aim of this 
study was to evaluate an existing biobehavioral model of IBS symptom generation 
in a large group of patients.
Methods: In 104 IBS patients, we assessed symptom severity by a symptom diary, age 
and gender, visceral hypersensitivity using a barostat, autonomic function by measur-
ing arterial baroreflex sensitivity and psychological functioning using questionnaires. 
Structural Equation Modeling was used to calculate reciprocal and chronological 
relationships between model variables.
Results: Analysis of the adjusted original model indicated poor fit (Satorra-Bentler 
scaled chi-square p-value .019, comparative fit index (CFI) .842), which was caused 
by omission of 2 paths (illness behavior-IBS symptoms and trauma-IBS symptoms). 
The revised model yielded good fit (Satorra-Bentler, p=.274; CFI=.967). The trimmed 
model, obtained by deleting non-significant paths, explained 16.2% of the variance 
in IBS symptoms. Illness behavior completely mediated the effect of cognitions on 
IBS symptoms and partly mediated the effect of trauma on IBS symptoms. The fit of 
this alternative model was significantly better than the fit of the non-trimmed model 
(Satorra-Bentler, p=.43; CFI=.996). The trimmed alternative model explained 16.0% 
of the variance in IBS symptoms.
Conclusion: The proposed biobehavioral model could not be validated. Whereas 
visceral hypersensitivity and IBS symptom severity significantly correlate, autonomic 
function and IBS symptoms do not. Cognitive-behavioral aspects are important in the 
clinical expression of IBS, with illness behavior playing an intermediate and central 
role. 
123Testing a biobehavioral model of IBS
INTRODUCTION
Irritable Bowel Syndrome (IBS) is a chronic functional bowel disorder character-
ized by recurrent abdominal pain and altered bowel habits such as diarrhea and/or 
constipation1. IBS is the most frequent functional gastrointestinal disorder with an 
estimated prevalence of 6 to 22%2,3 and substantial economic impact4,5. Despite the 
growing body of literature, the pathophysiology of IBS remains poorly understood 
and a variety of mechanisms have been proposed in symptom generation. These 
include enhanced visceral sensitivity6,7, disturbed intestinal motility8,9, autonomic 
dysfunction10,11, inflammatory processes12,13, altered immune activity14,15, altered pro-
cessing of afferent sensory information16,17 and psychological disturbances18,19. These 
alterations probably reflect dysfunction at different levels of the brain-gut axis, a 
conceptual framework which has recently emerged in an attempt to improve our un-
derstanding of the etiology, pathogenesis and clinical expression of IBS20. Although a 
biobehavioral model of IBS based on the brain-gut axis would be of great assistance 
to gain further insight in the relationship between these disturbances, few attempts 
have been made to construct such a model. 
In 1998, Naliboff and colleagues proposed an initial but comprehensive work-
ing model of IBS, incorporating the central nervous system, visceral sensory and 
motor functioning, and cognitive-behavioral systems21. This biobehavioral model 
implies that internal or external stimuli, for example dysenteric illness or sexual or 
physical abuse, affect visceral sensory and motor function either directly or by an 
arousal-induced autonomic response (‘ANS stress response’), that is, hypervigilance. 
Furthermore, the model suggests that visceral motor and sensory disturbances sub-
sequently give rise to IBS symptoms, and that prolonged symptom duration will lead 
to alterations in illness behavior, environmental responses and health beliefs. These 
biobehavioral changes in turn increase hypervigilance and, ultimately, deteriorate 
IBS symptoms. Thus, the proposed model represents the clinical manifestation of 
IBS as interplay between biological and psychological factors, which is in agree-
ment with the current concept of IBS as a multifactorial condition22,23. It also pro-
vides a verifiable theoretical framework that may improve our understanding of the 
pathophysiological mechanisms involved in IBS.
The aim of the present study was to evaluate this biobehavioral model of IBS21 in a 
large group of patients. We tested the validity of the model using Structural Equation 
Modeling (SEM), as it allows calculation of reciprocal and chronological relationships 
between the model variables. Lackner and colleagues have recently shown that SEM 
is a valid method to test a sequential model of pain processing in IBS24. The ratio 
between the number of observed variables and the number of patients restricted 
testing possibilities using a model with latent variables and therefore constrained us 
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to perform a path analysis (as was done by Lackner et al.). To apply a path analysis 
to the working model proposed by Naliboff et al., we modified the model slightly, 
that is, we eliminated the feedback loop from IBS symptoms, illness behavior, en-
vironmental responses, health beliefs, and vigilance back to IBS symptoms21 (see 
Fig 1). Furthermore, as IBS has a female predominance of unknown origin25 and 
is less common in the elderly26, we included age and gender in the model. Based 
on the proposed model, the existing literature, and the abovementioned statistical 
restrictions, we built the following hypotheses (Fig 1):
1. Trauma involving the abdomen, e.g., acute gastroenteritis, abdominal surgery, or 
sexual or physical abuse, will influence IBS symptom severity by modification of 
autonomic functioning and/or visceral sensitivity27-29.
2. Autonomic dysfunction (reflected by low baroreflex sensitivity (BRS)-values) is 
associated with increased visceral sensitivity and hypervigilance30-32.
3. Hypervigilance will lead to increased IBS symptom severity, either directly or by 
influencing visceral sensitivity.
4. Dysfunctional cognitions regarding functional bowel disorders lead to hypervigi-
lance and increased IBS symptom severity33.
5. Illness behavior aggravates dysfunctional cognitions34.
6. Visceral hypersensitivity will lead to increased IBS symptom severity6,35-37.
7. In older patients, autonomic functioning (BRS) is impaired38, while vigilance is 
increased. 
8. Levels of vigilance are higher in female patients39.
METHODS
Participants
Between March 2001 and July 2002, IBS patients between 18 and 65 years of age 
were invited to participate in a clinical trial assessing the effect of a brief psychologi-
cal intervention on IBS symptom severity. This trial included baseline psychologi-
cal assessment, combined autonomic nerve functioning and rectal sensitivity testing 
(day 0), and IBS symptom severity measurements (day 1 to 14). All these data were 
used for the present study. 
Patients were recruited through a tertiary referral centre (the outpatient department 
of Gastroenterology of the Leiden University Medical Center (LUMC)) and through 
local advertisement. All eligible participants were screened by one of the investiga-
tors (PvdV). All patients met Rome II criteria for IBS1. Exclusion criteria were organic 
disease, previous abdominal surgery (except cholecystectomy and appendectomy), 
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and pregnancy. Use of antispasmodics, laxatives, bulking agents and occasional 
use of analgesics was permitted. We used the Mini International Neuropsychiatric 
Interview (Dutch version 5.0.0)40 to exclude patients with psychotic disorder, or risk 
of suicide. Informed consent was obtained from each participant. The LUMC ethics 
committee had approved the study protocol.
Measures
IBS symptom severity
Patients rated the severity of 5 symptoms, i.e. discomfort, abdominal pain, consti-
pation, diarrhea, and bloating, daily for 14 days, on a 5-point Likert scale (0 = no 
symptoms, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe symptoms) using a 
symptom diary card. A composite score was computed by summing up the 14-day 
mean scores for each symptom (range 0-20).
Visceral sensitivity
An electronic barostat (Synectics Visceral Stimulator, Synectics Medical, Stockholm, 
Sweden) was used to assess visceral perception. This device maintains constant 
pressure within an infinitely compliant balloon by injecting air when the rectal wall 
relaxes and aspirating air during rectal contraction41. A slow rectal ramp distension 
procedure was performed (1 mmHg increase/min, maximum 30 mmHg), during 
which rectal pain perception was quantified on a 100-mm Visual Analogue Scale 
(VAS)42 at every even pressure. End points ranged from ‘none’ to ‘intolerable’. 
Autonomic function
Autonomic function was assessed by measuring arterial baroreceptor reflex sensitiv-
ity (BRS). BRS is defined as the prolongation of the interval between heart beats 
(milliseconds) induced by aorta and carotid baroreceptor activation when, due to 
any cause (e.g. stress or pain), arterial blood pressure rises by 1 mmHg. We chose 
to use BRS rather than more conventional autonomic measures, such as heart rate 
variability, because the arterial baroreflex not only modulates sympathetic and para-
sympathetic autonomic outflow, which governs gastrointestinal motor function, but 
also affects cortical arousal31,32 and somatic32,43 and visceral30 pain perception. Thus, 
BRS may well be involved in conditions associated with altered visceral sensory 




A history of trauma involving the abdomen was assessed by asking patients whether 
they ever experienced 1) sexual abuse, 2) physical violence or abuse involving the 
abdomen, and/or 3) abdominal illness, e.g. acute gastroenteritis, appendicitis etc. 
Scores ranged from 0 (no trauma, answer is ‘no’ to all questions) to 3 (answer is ‘yes’ 
to all questions).
Vigilance
We used the Somatosensory Amplification Scale (SAS)45,46 to determine the extent to 
which an individual is likely to report enhanced perception of physical symptoms 
(i.e. lower cognitive perception thresholds). This scale comprises 10 items, with each 
item being scored on a 0 (‘this statement does not apply to me’) to 4 (‘this statement 
is fully applicable to me’) scale, yielding a total score range from 0 (best score) to 
40 (worst score).
Dysfunctional cognitions
The recently developed 31-item Cognitive Scale for Functional Bowel Disorders (CS-
FBD) was used to measure patients’ levels of dysfunctional cognitions concerning 
their IBS47. Scores for individual items range from 1 (I completely agree) to 7 (I com-
pletely disagree), which yields a total score ranging from 31 (best) to 217 (worst).
Illness behavior
Illness behavior was assessed using the 6-item illness behavior subscale of the Illness 
Attitude Scale (IAS) 45,48. Scores for individual items range from 0 (‘not at all’) to 4 
(‘very much’). The total score was divided by the number of items, yielding an illness 
behavior subscale score ranging from 0 (best score) to 4 (worst score). 
RESULTS
Subjects
We screened 130 patients of whom 26 did not meet Rome II criteria1, so that 104 
patients were included in the analysis. Mean age was 42.0 ± 13.9 years. Seventy-four 
patients (71%) were female. Thirty-three patients (32%) were recruited through the 
outpatient department and 71 patients (68%) were recruited through advertisement 
in a local newspaper. 
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Preliminary analyses
Descriptive statistics and normality
Means, standard deviations, skewness and kurtosis values for each quantitative vari-
able are displayed in Table 1. We used standard errors of √(6/N) and √(24/N) to 
evaluate the skewness and kurtosis values, respectively. Two variables showed both 
a significant positive skewness and kurtosis value: BRS, and vigilance (z > |3.29|; 
p < .001). Visceral pain showed a significant positive skewness value (z = 3.97; p < 
.001).
Missing data
Table 1 shows the number of patients (n) per variable. Only BRS had a high number 
of missing values (20, being 19.2%). Little’s test of missing completely at random 
(MCAR) revealed that this assumption was not rejected (χ2= 77.395, DF = 72, p = 
.311). Missing values were imputed before the path model analysis using an Expecta-
tion Maximization approach (see the Computational Note). Because of the existence 
of non-normally distributed variables, the corrections of Satorra and Bentler (1988) to 
the test statistics of the path model were computed (see the Computational Note).  
Outliers
We examined model based outliers using linear regression analyses for each of the 
regression equations derived from the path model (see Fig 1). For each subject in 
each regression equation, we inspected Cook’s distance, a measure of the change 
in regression coefficients produced by leaving out that subject. No outliers (i.e., a 
Cook’s distance > 1) were detected. The normalized estimate of the multivariate 
kurtosis was 1.52, indicating no multivariate outliers were present.
Table 1. Descriptive statistics of the quantitative model variables in 104 IBS patients
Variable n Mean SD Skewness Kurtosis
Trauma (0-3) 103 0.64 0.67 0.76 0.30
BRS 84 7.93 5.42 1.64 4.35
Visceral pain (0-10) 101 2.50 2.67 0.97 -0.31
Vigilance (0-40) 103 9.68 5.75 1.48 3.87
Cognitions (31-217) 101 110.57 35.56 0.36 -0.28
Illness behavior (0-4) 103 1.88 0.63 0.25 -0.22
IBS symptoms (0-20) 98 4.43 2.52 0.69 0.73
Age 104 41.67 13.83 0.01 -1.05
Score range for each variable is denoted between parentheses when applicable.
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Model tests
Figure 1 shows the biobehavioral model of IBS that was tested. A dashed arrow is 
displayed if a negative coefficient was expected for that path. Important features of 
the model are the sequential links between a) trauma, visceral pain, and IBS (com-
parable to the ‘visceral’ component in Naliboff’s model); b) trauma, BRS, vigilance, 
visceral pain, and IBS (the ‘central nervous system’ component in Naliboff’s model); 
c) illness behavior, cognitions, and IBS (the ‘cognitive-behavioral’ component in 
Naliboff’s model). The model contains four exogenous variables (i.e., trauma, age, 
gender and illness behavior), which were assumed to be uncorrelated. The p-value 
of the Satorra-Bentler scaled chi-square was .019 (χ2 = 39.22; df = 23), indicating poor 
model fit. The robust estimates of the non-normed fit index (NNFI) and comparative 
fit index (CFI) were .752 and .842, respectively, also indicating a poor fit.
The standardized residual matrix revealed that the ill fit was caused by the omis-
sion of two paths, one between illness behavior and IBS symptoms, and one be-
tween trauma and IBS symptoms (the corresponding residuals were .274 and .258). 
The model was revised accordingly. The revised model yielded good fit, indicated 
by the robust estimates of the test-statistics (Satorra-Bentler χ2 = 24.40, df = 21, p 
= .274; robust NNFI = .943; robust CFI = .967; robust RMSEA = .040). The model 
explained 18.9% of the variance in IBS symptoms. The path coefficients of this model 
were examined and those being not statistically significant were deleted in a special 
way. To control the False Discovery Rate (FDR) in the case of multiple testing, we 
used a procedure described by Benjamini and Hochberg. Because we hypothesized 
Age Gender Illness Behavior
BRS Vigilance Cognitions
Visceral painTrauma  
IBS symptoms
Figure 1. The biobehavioral testmodel of IBS adapted by Naliboff et al. Dashed arrows indicate a negative coefficient. Note the 
sequential links between a) trauma, visceral pain, and IBS (visceral component); b) trauma, BRS, vigilance, visceral pain, and IBS 
(central nervous system component); c) illness behavior, cognitions, and IBS (cognitive-behavioral component). The model contains four 
exogenous variables (i.e., trauma, age, gender and illness behavior).
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a priori the sign of the path coefficients, we computed for each path coefficient a 
one-sided p-value, using the robust estimates of the standard errors. In line with 
Lackner et al.24, a family of tests was defined as the path coefficients leading from 
the exogenous variables to a given endogenous variable. The within-family error 
rates were controlled using the FDR method. The trimmed model was re-fit and the 
test statistics yielded a comparable fit as the non-trimmed model (Satorra-Bentler 
χ2 = 30.76, df = 27, p = .28; robust NNFI = .951; robust CFI = .963; robust RMSEA = 
.037).  The standardized path coefficients of this trimmed model are shown in Figure 
2. Three of the values of the path coefficients differed a value of .01 with those of 
the non-trimmed model, the remaining path coefficients were equal. The values of 
the standardized error variances are displayed in the circles. The trimmed model 
explained 16.2% of the variance of IBS symptoms.
Ancillary analyses
The biobehavioral model proposed by Naliboff et al. suggests that the effect of 
illness behavior on IBS symptoms is possibly mediated by environmental response 
and health beliefs (operationalized as “cognitions” in the present study). The model 
tests of Figure 1 revealed that a direct path was needed from illness behavior to 
IBS symptoms. By adding this path to the model, the coefficient of the path from 
cognitions to IBS symptoms was no longer significant (see Figure 2). This result lead 














Figure 2. Trimmed model showing the standardized path coefficients after deleting non-significant paths and addition of a path 
between illness behavior and IBS symptoms and a path between trauma and IBS symptoms. This was necessary due to ill model fit in 
the initial analysis, in which these paths were omitted.  The values of the standardized error variances are displayed in the circles. The 
trimmed model explains 16.2% of the variance of IBS symptoms.
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us to formulate the following alternative hypothesis: the effect of cognitions on IBS 
symptoms is mediated by illness behavior. 
We tested if illness behavior met the conditions to be considered as a mediator by 
means of four linear regression analyses (also see the Computational Note). Cogni-
tions were significantly associated with both illness behavior and IBS symptoms 
(two-tailed p < .05). Illness behavior was significantly associated with IBS symptoms. 
The effect of cognitions on IBS symptoms was no longer significant (two-tailed p 
= .82) when the effect of illness behavior on IBS symptoms was controlled. The 
corresponding standardized regression coefficient decreased from .21 to .03 when 
illness behavior was added to the regression analysis. These findings support the 
hypothesis that illness behavior mediates the effect of cognition on IBS symptoms 
completely.
Investigation of the standardized residuals of the trimmed model (Fig 2) revealed 
a relatively large residual (0.21) between trauma and illness behavior. This result in-
dicated that the model could be improved by adding an additional path from trauma 
to illness behavior. The addition of this path gave us the possibility to investigate 
whether the effect of trauma on IBS symptoms was also mediated by illness behav-
ior. We tested this hypothesis by a series of linear regression analyses as mentioned 
above (also see the Computational Note). Trauma was significantly associated with 
both illness behavior and IBS symptoms (two-tailed p < .05). The effect of trauma on 
IBS symptoms was no longer significant (p = .06) when the effect of illness behavior 
on IBS symptoms was controlled. The corresponding standardized regression coef-
ficient decreased from .24 to .18 when illness behavior was added to the regression 
analysis. These findings support the hypothesis that illness behavior mediates partly 
the effect of trauma on IBS symptoms. 
On the basis of the results, we formulated an alternative model to Figure 1. We 
added three paths, one from trauma to illness behavior, one from trauma to IBS 
symptoms and one from illness behavior to IBS symptoms. Furthermore, we re-
versed the direction of the path from cognition to illness behavior. The fit of this 
model was significantly better than the fit of the non-trimmed model of Figure 2 
(Satorra-Bentler χ2 = 20.42, df = 20, p = .43; robust NNFI = .993; robust CFI = .996; 
robust RMSEA = .014).  We used the within-family FDR-procedure to remove non-
significant path coefficients from this model. The fit of the trimmed model, displayed 
in Figure 3, was also good (Satorra-Bentler χ2 = 26.93, df = 26, p = .41; robust NNFI 
= .987; robust CFI = .991; robust RMSEA = .019). The model explained 16.0% of the 
variance in IBS symptoms.  
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DISCUSSION
The biobehavioral model proposed by Naliboff et al. was one of the first attempts 
to improve our understanding of the pathophysiology and clinical expression of ir-
ritable bowel syndrome (IBS). In the present study, this model was operationalized 
to be able to determine the effect of 1) Autonomic Nerve System (ANS) function, 2) 
local (visceral) factors, and 3) cognitive-behavioral aspects on IBS symptom severity, 
as well as the interaction between these domains. Our data do not support the op-
erationalized version of the biobehavioral model presented in Figure 1. In particular, 
we found no association between ANS functioning (represented by baroreceptor 
reflex sensitivity) and IBS symptom severity. While the working model indicates that 
autonomic dysfunction modulates IBS symptoms by increasing visceral sensitivity 
and/or inducing hypervigilance, these path coefficients were not significant. This 
leads to rejection of hypotheses 1 and 2 (see Introduction), and raises the ques-
tion whether ANS-stress responses are involved in symptom generation. However, 
a growing body of literature highlights ANS alterations in IBS patients10,11,16,17,49, with 
most studies suggesting sympathetic predominance or reduced parasympathetic ac-
tivity. It is likely that altered autonomic functioning is involved in the pathophysiol-
ogy of IBS, but this probably takes place through different mechanisms than those 
proposed in the model, for example by modifying intestinal motility50. Our finding 
that ANS functioning was significantly correlated to (hyper)vigilance without af-



















Figure 3. Alternative model to Figure 1 after paths were added between trauma and illness behavior, trauma and IBS symptoms 
and illness behavior and IBS symptoms and non-significant paths were deleted. Reversal of the path direction from cognitions to illness 
behavior yielded a significantly better fit than the fit of the non-trimmed model of Figure 2.
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exposure to aversive visceral stimuli in IBS patients leads to habituation of visceral 
perception, while central processing of anticipation of visceral pain (i.e., vigilance) 
remains activated51.
The relationship between visceral pain during rectal balloon distension and IBS 
symptoms has been established in the last decades and was confirmed by our model. 
Hypothesis 6 can thus be accepted. The model also predicts that visceral pain or 
hypersensitivity would be defined by a history of ‘abdominal trauma’ (sexual or 
physical abuse, inflammatory processes), autonomic dysfunction, and vigilance. Yet, 
none of these path coefficients were significant, thereby rejecting hypotheses 1, 2 
and 3. One explanation may be that the level of visceral sensitivity is determined by 
other factors that are currently unknown, or were not the subject of investigation. A 
possible candidate is the presence of psychiatric comorbidity, for example depres-
sion52. Alternatively, it is possible that 1) other measures for assessment of abdominal 
trauma, ANS function and vigilance, are required, or 2) these domains interact in a 
different way than proposed in the model.
The working model suggests that illness behavior influences cognitions, which in 
turn modulate symptom severity. This association was indeed present, but not in the 
form we anticipated. A better model fit was achieved when the proposed correla-
tion between illness behavior and cognitions was inversed and an additional path 
from illness behavior to IBS symptoms was added. The alternative model proposes 
illness behavior as a mediator between cognitions and IBS symptoms and omits the 
direct relationship between cognitions and symptoms that was initially assumed. 
This suggests that dysfunctional cognitions on IBS do not  affect symptom severity 
by themselves but are modulated by a patient’s approach to his or her symptoms 
(illness behavior). These findings lead to rejection of hypotheses 4 and 5. More-
over, these results present cognitions as an autonomic or exogenous variable in the 
model, rather than illness behavior. The final model suggests that more dysfunctional 
cognitions lead to altered illness behavior and, subsequently, to increased symptom 
severity. The hypothesized effect of illness behavior on IBS symptoms is thereby 
confirmed, although the model by Naliboff postulates an indirect association involv-
ing environmental response, health beliefs and vigilance.
An interesting finding of this study is that a history of ‘abdominal trauma’ leads 
to increased IBS symptoms, but in a different way than we expected. Whereas the 
working model predicts that a history of abdominal trauma aggravates IBS symptoms 
by increasing visceral pain perception, the alternative model shows that the effect of 
trauma on IBS symptoms is mediated by illness behavior. The effect of sexual and/
or physical abuse on illness behavior has long been established53, but the relation-
ship with abdominal illness such as acute gastroenteritis (another form of ‘trauma’) 
is less clear. Moreover, it has been shown that long-lasting gut dysmotility and vis-
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ceral hyperalgesia develop in mice after transient colonic inflammation54, suggesting 
a relationship between abdominal illness (i.e., colonic inflammation) and visceral 
hypersensitivity. Our sample-size was too small to perform subgroup analyses in 
patients with post-inflammatory IBS and in those with a history of abuse. However, 
the relationship between any kind of abdominal trauma and symptom severity in IBS 
is interesting and deserves further investigation.
Age and gender were expected to affect IBS symptomatology through vigilance 
(higher in older female patients)39 and ANS function (impaired in the elderly)38. 
Although the associations with ANS function and vigilance were all significant, age 
and gender were not related to IBS symptom severity via these paths since no sig-
nificant path coefficients were found from BRS to IBS symptoms and from vigilance 
to IBS symptoms. Several mechanisms have been proposed regarding the female 
predominance in IBS patients, including gender differences in visceral sensitivity, 
CNS pain processing, gastrointestinal transit time, and specific effects of estrogen 
and progesterone on gut function25. The link with the observed sex differences yet 
remains to be clarified. Decreased prevalence of functional bowel disorders in older 
patients has been suggested but, again, very little research addressed this topic and 
the effect of age on IBS remains largely unknown.
A possible limitation of our study is the adjustment we made to the cognitive-
behavioral section in the biobehavioral model proposed by Naliboff and colleagues. 
The original model suggests that IBS symptoms successively modify illness behavior, 
environmental responses, health beliefs, vigilance, and visceral motor and sensory 
function, eventually leading back to IBS symptoms. The model also predicts a di-
rect effect of IBS symptoms on health beliefs and vice versa. As explained in the 
Introduction, we were coerced to perform a path analysis rather than a structural 
equation model analysis (including latent variables) due to the ratio between the 
number of observed variables and the number of patients. In addition, our data 
were from a cross-sectional design, not a longitudinal design. By eliminating the 
abovementioned feedback loop, we simplified the model to be able to test its valid-
ity, but at the same time denied some of the interactions that may be important in 
the pathophysiology of IBS. Larger patient samples and a longitudinal design are 
required to overcome this limitation. Another possible limitation is that ‘arousal’ and 
‘environmental responses’ were not incorporated in the working model. These were 
omitted because no accurate measures were available to quantify these domains. 
Finally, visceromotor activity and viscerosensory activity were operationalized as 
‘visceral pain’ because verification of the proposed interaction would require a much 
larger sample size and more complex statistical calculations that would exceed the 
aim of this study.
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In conclusion, the biobehavioral model that was proposed by Naliboff and col-
leagues to improve our understanding of the pathophysiology of irritable bowel 
syndrome could not be validated in the present study. Although the association 
between visceral hypersensitivity and IBS symptom severity was undoubtedly pres-
ent, a relationship between ANS function and IBS symptoms could not be confirmed. 
Cognitive-behavioral aspects are important in the clinical expression of IBS, with 
illness behavior playing an intermediate or modulating and not an autonomic role. 
Internal and/or external stimuli seem to affect IBS symptoms by modulating illness 
behavior rather than ANS function or visceral sensitivity. Future longitudinal studies 
in larger patient samples are required to further investigate the mechanisms involved 
in the pathophysiology of IBS.
Computational Note
The descriptive analyses and linear regression analyses were performed with SPSS, 
version 11.5.  The missing imputation and the path model analyses were performed 
with EQS, version 6.1. For each path analysis, we used the option METHOD=ML, 
ROBUST.
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141Summary and discussion
Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by re-
current episodes of abdominal pain or discomfort accompanied by disturbed bowel 
habits. It is among the most frequently occurring functional bowel syndromes, with 
a prevalence ranging from 5 to approximately 20%. Diagnosis is made according 
to the Rome criteria. Despite the growing body of literature, the pathophysiology 
of IBS remains poorly understood. A variety of mechanisms have been proposed 
in symptom generation, including enhanced visceral sensitivity, disturbed intestinal 
motility, autonomic dysfunction, mucosal inflammation, altered immune activity, 
altered processing of afferent sensory information, and psychological disturbances. 
These alterations probably reflect dysfunction at different levels of the brain-gut axis, 
a conceptual framework which has recently emerged in an attempt to improve our 
understanding of the etiology, pathogenesis and clinical expression of IBS. The stud-
ies presented in this thesis highlight different aspects of the brain-gut axis in order to 
gain further insight in the pathophysiological mechanisms underlying IBS.
In Chapter 2, we studied involvement of baroreflex sensitivity (BRS), a measure 
of autonomic (dys)function, in IBS patients and healthy controls under baseline 
conditions and during a gastrointestinal stressor, i.e. rectal balloon distension. As 
BRS not only modulates sympathetic and parasympathetic autonomic outflow, but 
also affects cortical arousal and somatic and visceral pain perception, it might play a 
role in the pathophysiology of IBS. A previous study in rats demonstrated increased 
sympathetic outflow and decreased BRS during electrical stimulation of abdominal 
vagal afferents1. In contrast, we found an increase in BRS under mild rectal stimu-
lation in healthy subjects and in IBS patients, which persisted in controls during 
intense stimulation, whereas BRS returned to baseline in patients. The interpretation 
of these contrasting results is unclear, but the differences may be related to the use 
of anaesthesia in these rats1, which affects cortical perception and depresses the arte-
rial baroreflex. More importantly, we demonstrated that resting BRS is significantly 
larger in IBS patients compared to healthy subjects. This is opposite to our assump-
tion that resting BRS is lower in IBS (as is the case in most chronic diseases2,3), 
which renders the hypothesis that IBS patients are hypersensitive due to diminished 
baroflex function unlikely. In contrast, a recent study demonstrated decreased BRS 
in IBS patients compared to controls, both at baseline and during ramp en phasic 
rectal balloon distension4. Differences in balloon distension protocol may, at least in 
part, account for this discrepancy. Our study does not provide information on the 
basis of which (the difference between) these results can be explained. One theory 
is that the frequently experienced viscerosensory stimuli in IBS, such as abdominal 
pain, may entail a training-effect, possibly materialized in chronic elevated substance 
P concentrations at the level of the nucleus tracti solitarii (NTS)5,6. Such a training-
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mechanism can only be further investigated in animal models of visceral afferent 
stimulation. Alternatively, it may reflect an intrinsic autonomic characteristic in which 
IBS patients differ from healthy individuals, which may occur at the NTS level, as has 
previously been shown for the oesophagus7. It is tempting to interpret the enhanced 
baseline baroreflex response in patients as an anticipatory phenomenon and to ex-
pect benefits from that anticipation in the form of inhibition of cortical arousal and 
visceral pain perception during irritating stimuli such as abdominal pain. However, 
our finding that no differences in BRS values exist between IBS patients and control 
subjects during rectal distension makes such a hypothesis unlikely. Whether these 
autonomic changes are either a consequence of IBS or play a role in the pathophysi-
ology should be the focus of future investigations.
Several gut peptides are involved in the regulation of gastrointestinal motor and 
sensory function. We studied plasma levels of gut peptides released from the upper 
(cholecystokinin (CCK) and motilin) and lower (peptide YY, PYY) small intestine 
under fasting and postprandial conditions in IBS patients and controls, the results 
of which have been presented in Chapter 3. Both fasting plasma CCK levels and 
the incremental postprandial CCK response were elevated in IBS patients compared 
to controls. These results support previous studies in IBS showing disturbed CCK 
release and altered organ sensitivity8, excessive intestinal motor activity9 and re-
duced pain thresholds10 during infusion of CCK. Furthermore, neither fasting nor 
postprandial CCK levels were significantly different between patients who were clas-
sified as either hypersensitive or normosensitive to rectal balloon distension, which 
renders a contribution of increased CCK secretion to the pathogenesis of enhanced 
visceral perception less likely. However, CCK infusion has been shown to aggravate 
symptom severity in IBS patients11. It is therefore possible that CCK release after 
a meal is involved in the exaggerated postprandial colonic motor response that 
has been demonstrated in IBS patients12. Although postprandial CCK concentrations 
were merely twofold increased in IBS compared with controls, the combination with 
increased end-organ sensitivity may be responsible for postprandial symptom aggra-
vation in IBS. Against the background of the female predominance in IBS, another 
interesting finding was that the elevated fasting and postprandial plasma CCK levels 
were almost completely attributable to female IBS patients. Differences in the effect 
of CCK on gastrointestinal motility between males and females have been reported 
(for instance increased sphincter of Oddi motility during CCK infusion in female 
compared to male dogs)13, but the interpretation of this finding remains unclear. 
Fasting and postprandial motilin levels did not differ between patients and controls, 
which is supported by the literature. Remarkably, fasting motilin levels were signifi-
cantly elevated in patients with a diarrhoea predominant bowel habit compared to 
other subgroups. This may be clinically relevant as motilin stimulates human colonic 
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motility14 and may therefore play a role in the accelerated colonic transit that has 
been demonstrated in patients with diarrhoea15. Overall, no differences were found 
in fasting and postprandial PYY-levels, which is in line with previous data. Our 
observation that patients who were hypersensitive to rectal balloon distension have 
a greater postprandial PYY response, together with data showing increased numbers 
of PYY-containing enteroendocrine cells in rectal biopsy specimens from patients 
with post-infectious IBS16, may imply a role for this hormone in the development of 
post-infectious visceral hypersensitivity and/or IBS.
With increasing evidence to suggest a role of mucosal inflammation and immune 
system alterations in the pathophysiology of IBS, we studied genetically determined 
immune activity by comparing the prevalence of gene promoter single nucleotide 
polymorphisms (SNPs) of interleukin 10 (IL-10, anti-inflammatory cytokine) and tu-
mor necrosis factor alpha (TNF-α, pro-inflammatory cytokine) between IBS patients 
and controls. In Chapter 4, we demonstrated that the high producer TNF-α geno-
type is more prevalent in IBS patients compared to healthy controls, particularly the 
heterozygous genotype which is associated with a high TNF-α production phenotype 
(41% versus 26%). The previously demonstrated fivefold increase in TNF-α producing 
intraepithelial activated macrophages in patients with post-infectious IBS16, together 
with the potency of enteric pathogens such as Campylobacter jejuni, Salmonella and 
Shigella to stimulate macrophage TNF-α production17, supports a role of this cytokine 
in persisting bowel symptoms in these patients after infection. Low-producer geno-
type frequencies for IL-10 were similar between patients and controls. The combined 
high-producer TNF-α and low-producer IL-10 genotype (i.e., ‘high risk profile’ for 
inflammation) was three times more prevalent in patients compared to controls but 
occurred in only 9% of cases. This implies that other mechanisms and/or cytokines 
are also involved. Yet, this genotype combination tended to occur more often in pa-
tients with a diarrhoea predominant bowel habit compared to the constipation and 
alternating types (20% versus 4% and 3%, respectively). This is supported by a recent 
study showing enhanced baseline TNF-α and Escherichia coli lipopolysaccharide-
induced TNF-α and IL-6 levels in diarrhoea predominant IBS-patients reporting more 
than 3 bowel movements per day, urgency, watery stools, and pain associated with 
diarrhea18. While statistical significance was not reached, these data indicate that IBS 
subgroups may exhibit different cytokine producer genotypes that might be involved 
in disease expression.
Motor disturbances of the gut have been demonstrated in IBS, but the role of this 
abnormality in the pathogenesis of IBS and particularly in postprandial symptom 
deterioration has not been established. With the recent characterization of a rectoco-
lonic inhibitory reflex in healthy individuals, the study presented in Chapter 5 was 
performed to investigate this phenomenon in IBS. We found that rectal pain dur-
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ing balloon distension after a standard high-caloric meal was increased in patients 
compared to controls. Rectal distension inhibited colonic motor activity (measured 
by tone and phasic volume events using barostat) in an intensity-dependent manner 
in both IBS patients and controls. Most interestingly, the magnitude of this response 
was comparable between patients and controls under fasting conditions, but was 
significantly impaired in patients versus controls after a meal, with more postprandial 
phasic motor activity occurring in patients. A possible explanation for this finding is 
that exaggerated postprandial colonic motor activity impairs the ability of the colon 
to relax and thereby attenuates rectocolonic reflexes in IBS patients after a meal. The 
role of the (impaired) rectocolonic inhibitory reflex in the pathophysiology of IBS 
awaits further elucidation. Altered reflexes at other locations in the gastrointestinal 
tract have already been demonstrated in patients with functional bowel disorders. 
For instance, impaired reflex fundic relaxation following intestinal administration of 
nutrients has been shown in patients with functional dyspepsia19. Our finding that 
the rectocolonic reflex is impaired in IBS after a meal, together with the increased 
rectal pain during balloon distension in IBS, is consistent with the hypothesis of a 
generalized disturbance of postprandial colonic sensori-motor functions in IBS. 
Visceral hypersensitivity is one of the few reproducible phenomena in IBS and 
has been put forward as a biological marker. Processing of afferent visceral infor-
mation and emotional pain management both occur in similar brain regions, but 
little is known about the relationship between psychological variables and visceral 
hypersensitivity. Chapter 6 explored the prevalence of rectal hypersensitivity, levels 
of psychological distress and symptom severity in IBS. In addition, we aimed to 
address which demographical, clinical and psychological variables predict the oc-
currence of visceral hypersensitivity in IBS. We found that rectal compliance and 
pain thresholds are reduced and that the intensity of pain perception but not urge is 
increased in IBS patients when compared to healthy controls. The latter is consistent 
with previous reports demonstrating decreased perception thresholds in IBS only for 
noxious stimuli, and not for stool20. Furthermore, visceral hypersensitivity (defined 
by pain perception threshold ≥ 2 standard deviations below the mean threshold 
in controls) was present in one third of patients. This finding is remarkable, since 
some report up to 95% percent of IBS patients being hypersensitive to balloon 
distension20. The difference is probably due to the use of different parameters to 
define visceral hypersensitivity (for instance, inclusion of intensity of sensations and 
altered viscerosomatic referral in the definition20 besides reduced perception thresh-
olds). Logistic regression analysis showed that only symptom severity predicts the 
occurrence of visceral hypersensitivity and that no correlation exists with any of 
the investigated psychological and demographical characteristics. A recent study in 
109 adult IBS patients also demonstrated a significant correlation between symptom 
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severity and hypersensitivity to rectal balloon distension21. In contrast, another recent 
study in children with IBS and functional abdominal pain did not find an association 
between symptom severity and rectal pain perception thresholds22. Taken together, 
these data challenge the view that visceral hyperalgesia is a biological marker of 
IBS, since hypersensitivity may be absent in Rome II positive patients with mild 
symptoms. They also show that psychological characteristics such as anxiety, so-
matization, and neuroticism do not correlate with sensory thresholds. In particular, 
neither vigilance nor dysfunctional cognitions were different between hypersensitive 
and normosensitive patients, suggesting that symptom perception and management 
do not differ between these groups. Yet, these findings do not exclude a common 
neuropsychological basis in the clinical expression of IBS because several studies 
show that psychological distress is more prevalent among patients who seek health 
care23. Therefore, the role of psychological factors in IBS symptom presentation 
remains an interesting subject of investigation.
Pharmacotherapy for successful treatment of IBS is often disappointing, but cu-
mulative evidence suggests efficacy of psychological interventions such as cognitive 
behavioural therapy, dynamic psychotherapy and hypnotherapy in treating IBS. Most 
of these interventions incorporate a relaxation technique. In Chapter 7 we pre-
sented the results of a randomized controlled trial to determine short and long-term 
efficacy of relaxation training (RT), a brief psychological group intervention, when 
added to standard medical care, on symptom severity and psychological wellbeing 
in IBS patients. We found that RT leads to significant symptom improvement up to 
12 months after treatment, with a 34% reduction in IBS composite symptom score 
in the RT group compared to only 12% in patients receiving standard medical care. 
Quality of life (general health, health change) also improved significantly more in 
patients treated with RT compared to those receiving standard treatment. According 
to the Jacobson and Truax criteria for clinically significant symptom improvement, 
12 RT-treated patients (23%) were improved at 12 months after treatment, compared 
to 1 patient (3%) who received standard medical care. These results are at least 
similar, if not better, when compared to the beneficial effects of other psychological 
interventions24,25. Although treatment duration is short (4 weeks), consolidation of 
symptom improvement probably lies in routine use of relaxation techniques in daily 
life. When embedded in a clear rationale, this provides patients with a useful tool to 
cope with their symptoms and establishes long-term symptom reduction.
One of the first attempts to conceptualize the multifactorial pathogenesis of IBS 
comes from Naliboff and colleagues in 1998. They proposed a biobehavioral model 
which integrates the central nervous system, visceral sensory and motor function-
ing, and cognitive-behavioral systems into one comprehensive working model. In 
Chapter 8, we tested the validity of an operationalized version of this model using 
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a path analysis method based on Structural Equation Modeling (SEM). This method 
allows calculation of reciprocal and chronological relationships between model vari-
ables. Initial analysis indicated poor model fit, rejecting the validity of this model 
when applied to our patient population. In particular, ANS functioning (represented 
by BRS) was not associated with IBS symptom severity. In view of the convincing 
evidence showing ANS alterations in IBS patients, it is probable that autonomic 
dysfunction takes place through different mechanisms than those proposed in the 
working model. Our finding that ANS functioning was significantly correlated to (hy-
per)vigilance without affecting IBS symptom severity is supported by a recent study 
showing that repeated exposure to aversive visceral stimuli in IBS patients leads to 
habituation of visceral perception, while central processing of anticipation of visceral 
pain (i.e., vigilance) remains activated26. Further evaluation of the model confirmed 
that visceral pain during rectal balloon distension is related to IBS symptoms (which 
is consistent with the results presented in Chapter 6), but no association with a 
history of ‘abdominal trauma’ (sexual or physical abuse, inflammatory processes), 
autonomic dysfunction, or vigilance was found. We also hypothesized that illness be-
havior influences cognitions, which in turn modulate symptom severity. The results 
showed that a better fit was achieved when illness behavior was positioned in the 
model as a mediator between cognitions and IBS symptoms, suggesting that dysfunc-
tional cognitions do not affect symptom severity by themselves but are modulated by 
a patient’s approach to his or her symptoms (illness behavior). Another interesting 
finding was that the well-known association between a history of ‘abdominal trauma’ 
and increased IBS symptom severity does not involve visceral hyperalgesia, but is 
also mediated by illness behavior. These data not only suggest a central role for ill-
ness behavior in the pathyphysiology of IBS, but also highlight behavioral interven-
tions such as relaxation training as potentially beneficial treatment options.
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Irritable Bowel Syndrome (IBS; ook Prikkelbaar Darm Syndroom, PDS) is een 
functionele darmaandoening die gekenmerkt wordt door episodes van buikpijn of 
een onaangenaam gevoel in de buik die gepaard gaan met veranderingen in het 
defaecatiepatroon. PDS behoort tot de meest frequent voorkomende functionele 
maag-darmaandoeningen en heeft een prevalentie van 5 tot 20 %. De diagnose 
wordt gesteld met behulp van de Rome criteria. Ondanks het toenemende aantal 
wetenschappelijke publicaties blijft de pathofysiologie van PDS onduidelijk. Ver-
schillende mechanismen kunnen mogelijk een rol spelen bij het ontstaan van symp-
tomen, zoals toegenomen viscerale gevoeligheid, verstoorde maagdarmmotoriek, 
stoornissen in het autonome zenuwstelsel, ontsteking van de mucosa, veranderde 
activiteit van het immuunsysteem, gestoorde verwerking van afferente sensorische 
informatie, en psychologische problematiek. Waarschijnlijk zijn deze veranderingen 
representatief voor afwijkingen op verschillende niveaus van de hersen-darm-as. De 
hersen-darm-as is een model dat gebruikt wordt om de etiologie, pathogenese en 
klinische expressie van PDS beter te begrijpen. De studies die beschreven staan in 
dit proefschrift belichten verschillende aspecten van de hersen-darm-as en hebben 
als doel een beter inzicht te verkrijgen in de pathofysiologische mechanismen die 
aan PDS ten grondslag liggen.
In Hoofdstuk 2 onderzochten we de baroreflex sensitiviteit (BRS), een maat voor 
het functioneren van het autonome zenuwstelsel, bij IBS patiënten en gezonde vrij-
willigers tijdens rust en gedurende een ‘gastro-intestinale stressor’, namelijk ballon-
distensie van het rectum. Aangezien BRS niet alleen de activiteit van het sympatische 
en parasympatische deel van het autonome zenuwstelsel moduleert, maar ook op 
hersenniveau corticale alertheid en somatische en viscerale pijnperceptie beïnvloedt, 
zou het een rol kunnen spelen in de pathofysiologie van PDS. Een studie in ratten 
toonde toegenomen sympaticusactivatie en afgenomen BRS aan tijdens elektrische 
stimulatie van afferente vezels afkomstig uit de abdominale nervus vagus. Wij von-
den echter een toename in BRS tijdens een milde viscerale prikkel (rectale ballon-
distensie), welke tijdens een intensivering van deze prikkel aanhield bij gezonde 
vrijwilligers maar afnam tot basale waarden bij PDS-patiënten. De interpretatie van 
deze tegenstrijdige resultaten is complex, maar de verschillen zijn mogelijk het ge-
volg van het gebruik van anaesthetica bij de rattenpopulatie omdat deze middelen 
de corticale perceptie beïnvloeden en de arteriële baroreflex onderdrukken. Een van 
onze belangrijkste bevindingen was dat BRS tijdens de rustfase significant groter is 
bij PDS-patiënten in vergelijking met gezonden. Dit is in strijd met onze aanname 
dat BRS tijdens rust lager is, zoals het geval is bij de meeste chronische ziekten. 
De hypothese dat PDS-patiënten visceraal overgevoelig zijn ten gevolge van een 
afgenomen functie van de BRS is daarom onwaarschijnlijk. Onze studie geeft geen 
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informatie op basis waarvan deze bevindingen verklaard kunnen worden. Eén the-
orie is dat het frequent optreden van viscerale stimuli bij PDS, zoals buikpijn, een 
trainingseffect behelst, wat op het niveau van de nucleus tracti solitarii (NTS) een 
chronisch toegenomen concentratie substance P tot gevolg heeft. Zo’n trainingseffect 
kan alleen onderzocht worden in diermodellen met stimulatie van afferent viscerale 
vezels. Anderzijds zou het ook een intrinsiek kenmerk van het autonome zenuw-
stelsel kunnen zijn waarin PDS-patiënten afwijken van gezonden. Mogelijk betreft 
ook dit een verschil op het niveau van de NTS, zoals reeds is aangetoond voor de 
oesofagus. Het is verleidelijk om de toegenomen BRS tijdens rust bij patiënten te in-
terpreteren als een vorm van anticipatie en om hiervan een voordeel te verwachten 
in de vorm van inhibitie van zowel corticale alertheid als somatische en viscerale 
pijnperceptie tijdens een buikpijnepisode. Echter, onze bevinding dat de hoogte 
van BRS tijdens rectale ballondistensies niet verschilt tussen patiënten en gezonden 
maakt een dergelijke hypothese niet aannemelijk. Nader onderzoek moet uitwijzen 
of deze autonome veranderingen een rol spelen in de pathogenese van PDS of 
hiervan juist het gevolg zijn.
Verschillende maagdarmhormonen zijn betrokken bij de regulatie van de moto-
riek en sensibiliteit van de tractus digestivus. Wij onderzochten bij PDS-patiënten 
en gezonde controles plasmaconcentraties van hormonen die door de proximale 
(cholecystokinine (CCK) en motiline) en de distale dunne darm (peptide YY, PYY) 
worden afgescheiden, zowel in de nuchtere fase als na een maaltijd. De resultaten 
van deze studie staan beschreven in Hoofdstuk 3. Plasmaconcentraties CCK waren 
toegenomen in patiënten ten opzichte van controles, zowel tijdens de nuchtere als 
de postprandiale fase. Deze bevinding ondersteunt eerdere studies waarin reeds een 
verstoorde CCK afscheiding, veranderde orgaan sensitiviteit, buitensporige intesti-
nale motoriek en afgenomen pijndrempel bij PDS-patiënten werd aangetoond. Wij 
vonden echter  geen verschillen in nuchtere of postprandiale plasmaconcentraties 
CCK tussen de groep patiënten die hypersensitief was voor rectale ballondistensie en 
de groep die normosensitief was. Het lijkt derhalve op basis van deze feiten minder 
waarschijnlijk dat CCK een belangrijke rol speelt bij de pathogenese van toegeno-
men viscerale perceptie. Intraveneuze infusie van CCK verergert echter wel symp-
tomen bij PDS-patiënten. Het is dus mogelijk dat toename van de CCK-secretie na 
een maaltijd van belang is bij de excessieve motorische respons van het colon die al 
is aangetoond bij deze patiënten. Hoewel de plasmaconcentratie van CCK slechts 2 
maal verhoogd was in de patiëntengroep in vergelijking met controles is mogelijk de 
combinatie met toegenomen eindorgaan gevoeligheid voor CCK mede verantwoor-
delijk voor toename van de klachten na een maaltijd. CCK wordt gesecerneerd van-
uit enteroendocriene cellen. Deze cellen zijn belangrijke nutrient- en chemosensoren 
van de darm. Het viel op dat de verhoogde nuchtere en postprandiale plasmacon-
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centratie CCK voornamelijk viel toe te schrijven aan vrouwen. Dit is een interessante 
bevinding gezien het gegeven dat ongeveer tweederde van de PDS-patiënten vrouw 
is. Geslachtsafhankelijke verschillen in het effect van CCK op maagdarmmotoriek 
zijn weliswaar eerder beschreven (bijvoorbeeld toegenomen sfincter van Oddi mo-
toriek tijdens CCK-infusie in vrouwelijke honden vergeleken met mannelijke), maar 
het is niet duidelijk hoe deze bevindingen geïnterpreteerd moeten worden. Nuchtere 
en postprandiale plasmaconcentraties motiline verschilden niet tussen PDS-patiënten 
en controles, wat vanuit de literatuur al min of meer bekend is. Opvallend was wel 
dat de nuchtere plasmaconcentratie motiline significant was toegenomen bij patiën-
ten met overwegend diarreeklachten in vergelijking met patiënten met obstipatie of 
een wisselend ontlastingspatroon. De klinische relevantie van deze bevinding ligt 
mogelijk in het gegeven dat motiline de colonmotoriek stimuleert en dus een rol 
zou kunnen spelen bij de versnelde colonpassagetijd bij patiënten met diarree. Over-
eenkomstig de literatuur werden geen verschillen gevonden in plasmaconcentraties 
PYY tussen PDS-patiënten en gezonde controles. Patiënten die hypersensitief waren 
voor rectale ballondistensie hadden echter wel een toegenomen postprandiale PYY-
afgifte. Dit, samen met aanwijzingen voor toegenomen aantallen PYY-bevattende 
enteroendocriene cellen in rectumbiopten van patiënten met postinfectieuze PDS, 
zou kunnen wijzen op een rol van dit hormoon in het ontwikkelen van postinfecti-
euze viscerale hypersensitiviteit en/of PDS.
Er zijn steeds meer aanwijzingen dat mucosale ontsteking en veranderingen in het 
immuunsysteem bijdragen aan de pathofysiologie van PDS. Daarom onderzochten 
wij bij PDS-patiënten en gezonde controles genetisch bepaalde immuunactiviteit 
door de prevalentie van genpromoter ‘single nucleotide polymorphsims’ (SNP’s) van 
interleukine 10 (IL-10, anti-inflammatoir cytokine) en tumor necrosis factor alpha 
(TNF-α, pro-inflammatoir cytokine) tussen deze groepen te vergelijken. In Hoofd-
stuk 4 laten we zien dat het ‘high producer’ genotype van TNF-α vaker voorkomt 
bij PDS-patiënten dan bij controles, voornamelijk het heterozygote genotype dat 
codeert voor een fenotype waarbij veel TNF-α wordt geproduceerd (41 versus 26%). 
Eerder onderzoek toonde al aan dat het aantal TNF-α producerende intraepitheliale 
geactiveerde macrofagen bij patiënten met postinfectieuze PDS vijf maal hoger ligt 
dan in de gezonde populatie. Samen met het gegeven dat darmpathogenen als 
Campylobacter jejuni, Salmonella en Shigella in staat zijn om TNF-α productie door 
macrofagen te stimuleren, vormt dit mogelijk een verklaring voor de aanhoudende 
klachten die sommige van deze patiënten hebben. De prevalentie van het ‘low pro-
ducer’ genotype van IL-10 verschilde niet tussen patiënten en controles. Het gecom-
bineerde ‘high producer’ TNF-α genotype en ‘low producer’ IL-10 genotype kwam 3 
keer vaker voor bij patiënten dan bij controles, maar slechts in 9% van de gevallen. 
Dit suggereert dat andere mechanismen en/of cytokines mede-verantwoordelijk zijn 
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bij de pathogenese. Het was wel opvallend dat deze combinatie van genotypes veel 
vaker voorkwam bij PDS-patiënten die voornamelijk diarreeklachten hadden dan 
bij patiënten met obstipatie of een wisselend ontlastingspatroon (20% versus 4%). 
Hoewel dit verschil niet statistisch significant was, is het mogelijk dat verschillen 
in cytokine producer genotypes tussen PDS subgroepen van belang zijn bij het tot 
uiting komen van ziekteverschijnselen.
Verstoorde darmmotoriek is een bekend gegeven bij PDS, maar de rol hiervan in 
de pathogenese van PDS, en met name postprandiale klachtentoename, staat nog 
niet vast. Omdat recent onderzoek de aanwezigheid van een rectocolische inhi-
bitiereflex heeft aangetoond, verrichtten wij een onderzoek naar dit fenomeen in 
PDS-patiënten. De resultaten beschreven in Hoofdstuk 5 laten zien dat pijn tijdens 
ballondistensie van het rectum na een maaltijd meer aanwezig was bij patiënten dan 
bij controles. Distensie van het rectum inhibeerde de colonmotoriek (gemeten door 
afgenomen tonus en fasische contracties met behulp van een barostat) bij patiënten 
en controles op intensiteitsafhankelijke wijze. De meest interessante bevinding was 
dat de omvang van deze inhibitiereflex vergelijkbaar was tussen beide groepen in 
de nuchtere fase, maar in de postprandiale fase significant minder uitgesproken 
was bij patiënten dan bij controles, waarbij vooral het aantal fasische contracties bij 
patiënten was toegenomen. Dit kan mogelijk verklaard worden doordat excessieve 
postprandiale colonmotoriek bij deze patiënten het vermogen van het colon om te 
relaxeren beperkt en op die manier de rectocolische inhibitiereflex tegenwerkt. De 
rol van deze bevindingen bij de pathogenese van PDS dient nader onderzocht te 
worden. Verstoorde reflexen op andere plaatsen in de tractus digestivus zijn reeds 
aangetoond bij patiënten met diverse functionele maagdarmaandoeningen, zoals een 
afgenomen fundusrelaxatie tijdens het toedienen van voeding in de dunne darm bij 
patiënten met functionele dyspepsie. Zowel de gecompromitteerde postprandiale 
rectocolische reflex als de toegenomen pijnperceptie tijdens ballondistensie van het 
rectum bij PDS-patiënten ondersteunen de hypothese dat bij patiënten met PDS 
een gegeneraliseerde postprandiale verstoring van colonmotoriek en –sensibiliteit 
bestaat.
Viscerale hypersensitiviteit is een van de weinige reproduceerbare fenomenen bij 
PDS en door sommige auteurs is zelfs gesuggereerd om dit als biomarker voor PDS 
te gebruiken. Het verwerken van afferente viscerale informatie en verwerking van 
pijn op emotioneel niveau gebeurt beiden in dezelfde gebieden van de hersenen. 
Er is echter weinig bekend over de relatie tussen viscerale hypersensitiviteit en 
psychologische variabelen. In Hoofdstuk 6 onderzochten we bij PDS-patiënten de 
prevalentie van viscerale hypersensitiviteit, de ernst van symptomen, en het voorko-
men van psychopathologie. Verder analyseerden we welke demografische, klinische 
en psychologische karakteristieken het optreden van viscerale hypersensitiviteit 
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voorspellen. Rectale compliantie en pijndrempels tijdens rectale ballondistensie wa-
ren afgenomen bij patiënten in vergelijking met controles. Ook de intensiteit van 
pijnperceptie was toegenomen, maar perceptie van aandrang was hetzelfde in beide 
groepen. Deze laatste bevinding komt overeen met gegevens uit de literatuur die la-
ten zien dat perceptiedrempels bij PDS-patiënten alleen verlaagd zijn voor noxische 
prikkels, en niet voor fysiologische. Viscerale hypersensitiviteit, gedefinieerd als een 
pijndrempel ≥ 2 standaarddeviaties onder de gemiddelde pijndrempel gemeten bij 
gezonde controles, was aanwezig bij 33% van de patiënten. Dit is een opmerkelijke 
bevinding, omdat sommige studies vinden dat 95% van de PDS-patiënten hyper-
sensitief is voor ballondistensie. Dit verschil wordt waarschijnlijk veroorzaakt door 
het hanteren van andere parameters om viscerale hypersensitiviteit te definiëren 
(bijvoorbeeld door niet alleen een afgenomen pijndrempel maar ook toename in 
intensiteit van perceptie en een veranderd viscerosomatisch perceptiepatroon tij-
dens balloondistensie in de definitie van hypersensitiviteit te includeren). Na een 
logistische regressie-analyse werd duidelijk dat alleen de ernst van de klachten het 
optreden van viscerale hypersensitiviteit voorspelt en dat er geen relatie bestaat tus-
sen viscerale hypersensitiviteit en demografische of psychologische factoren. Deze 
gegevens plaatsen vraagtekens bij de opvatting dat viscerale hypersensitiviteit een 
biologische marker is voor PDS, omdat het afwezig kan zijn bij patiënten met milde 
symptomen die wel voldoen aan de Rome II criteria. Verder blijkt uit onze resulta-
ten dat psychologische karakteristieken, zoals angst en somatisering, niet correleren 
met perceptiedrempels voor aandrang en pijn. Met name vigilantie en dysfuncti-
onele cognities waren niet verschillend tussen patiënten met en zonder viscerale 
hypersensitiviteit, wat suggereert dat perceptie en verwerking van symptomen niet 
verschilt tussen deze groepen. Een onderliggende neuropsychologische basis voor 
de klinische uitingsvorm van PDS kan op basis hiervan echter niet worden uitgeslo-
ten omdat meerdere onderzoeken aantonen dat psychologische problemen vaker 
voorkomen bij patiënten die medische hulp zoeken. De betekenis van psychologi-
sche factoren bij het manifest worden van PDS-symptomen blijft dus een boeiend 
onderzoeksterrein.
Medicamenteuze behandeling van PDS-symptomen is vaak teleurstellend. Steeds 
meer onderzoeken laten echter zien dat psychologische interventies, zoals cognitieve 
gedragstherapie, dynamische psychotherapie en hypnotherapie, succesvol kunnen 
zijn bij de behandeling van PDS. Relaxatietechnieken maken onderdeel uit van het 
merendeel van deze behandelingen. Hoofdstuk 7 beschrijft een gerandomiseerde, 
gecontroleerde studie naar de korte en lange termijn effectiviteit van relaxatietraining 
(RT), een korte psychologische groepsinterventie, toegevoegd aan standaardbehan-
deling, op klachten en het psychologisch welzijn van PDS-patiënten. De resultaten 
van deze studie laten zien dat RT een significante klachtenverbetering oplevert tot 
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tenminste 12 maanden na de behandeling, met 34% afname in symptoomscore in de 
groep die RT kreeg tegen slechts 12% in de groep met standaardbehandeling. Kwa-
liteit van leven (algeheel welzijn, verandering in algehele gezondheid) verbeterde 
ook significant meer in de met RT behandelde patiëntengroep versus de groep die 
standaardbehandeling kreeg. Volgens de Jacobson en Truax criteria, die klinisch sig-
nificante klachtenverbetering vaststellen, waren op 12 maanden na de behandeling 
12 patiënten in de RT groep (23%) significant verbeterd en 1 patiënt (3%) in de groep 
met standaardbehandeling. Deze resultaten zijn tenminste vergelijkbaar met, zo niet 
beter dan die van andere psychologische interventies. Hoewel de behandeling maar 
kort duurt (4 weken), ligt de verklaring voor het voortduren van deze klachtenverbe-
tering waarschijnlijk in het gegeven dat patiënten wordt aangeleerd om de relaxatie-
technieken routinematig in het dagelijks leven toe te passen. Omdat relaxatietraining 
is gebaseerd op een heldere rationale geeft dit patiënten een hulpmiddel om met 
hun klachten om te gaan en leidt het tot langdurige klachtenverbetering.
Eén van de eerste pogingen om de multifactoriële pathogenese van PDS door 
middel van een model inzichtelijk te maken, werd gedaan door Naliboff en collega’s 
in 1998. Zij presenteerden een conceptmodel dat het centrale zenuwstelsel, de visce-
rale sensoriek en motoriek, en cognitieve gedragsaspecten in één model integreert. 
In Hoofdstuk 8 wordt de validiteit van een aangepaste, geoperationaliseerde versie 
van dit model getest door middel van een padanalyse die gebaseerd is op Structu-
ral Equation Modeling (SEM). Deze methode maakt het mogelijk om reciproke en 
chronologische verbanden tussen modelvariabelen te berekenen. De eerste analyse 
toonde een matige ‘fit’, waarmee de validiteit van dit model, als het wordt toegepast 
op onze onderzoekspopulatie, niet kon worden aangetoond. Opvallend was dat de 
functie van het autonome zenuwstelsel niet was gecorreleerd met de ernst van de 
klachten. Er is echter zodanig overtuigend bewijs in de literatuur voor een belangrij-
ke rol van autonome dysfunctie bij PDS, dat de meest waarschijnlijke verklaring voor 
deze discrepantie is dat autonome veranderingen via andere paden een rol spelen 
dan in het model wordt gesuggereerd. Tevens vonden we dat autonome dysfunctie 
wel was gecorreleerd met verhoogde waakzaamheid (hypervigilantie) maar niet met 
ernst van de klachten. Dit wordt ondersteund door een recente studie die laat zien 
dat herhaaldelijke blootstelling aan viscerale pijnprikkels leidt tot gewenning wat 
betreft de perceptie van deze prikkels, maar dat de anticipatie op onaangename 
stimuli in het centrale zenuwstelsel actief blijft. Verder werd bij de modelanalyse 
de eerder gevonden relatie tussen pijn tijdens rectale ballondistensie en ernst van 
PDS-klachten bevestigd (Hoofdstuk 6), maar werd geen verband gevonden  tussen 
viscerale hypersensitiviteit en een ‘buiktrauma’ in de voorgeschiedenis (sexueel of 
fysiek misbruik, inflammatoire processen), autonome dysfunctie of verhoogde waak-
zaamheid. We veronderstelden ook dat ziektegedrag cognities beinvloedt, die op 
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hun beurt de ernst van de klachten moduleren. De resultaten tonen dat een betere 
‘fit’ werd verkregen wanneer ziektegedrag als modulerende factor tussen cognities 
en PDS-symptomen in het model werd geplaatst, wat suggereert dat dysfunctionele 
cognities zelf de ernst van de klachten niet beïnvloeden, maar dat dit wordt bepaald 
door de houding van een patiënt ten opzichte van zijn of haar klachten (ziektege-
drag). Een andere interessante bevinding was dat de vanuit de literatuur bekende 
samenhang tussen een ‘buiktrauma’ in het verleden en de ernst van PDS-klachten 
niet via toegenomen viscerale hypersensitiviteit verloopt, maar dat deze relatie ook 
wordt bepaald door ziektegedrag. Deze gegevens suggereren niet alleen dat ziekte-
gedrag een centrale rol speelt in de pathofysiologie van PDS, maar benadrukken ook 
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